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Abstract
Bordetella pertussis is the causative agent of whooping cough, a contagious
childhood respiratory disease. Increasing public concern over the safety of
current whole-cell vaccines has led to decreased immunisation rates and a
subsequent increase in the incidence of the disease. The preparation of safer
vaccines is at present concentrated on the production of detoxified virulence
factors such as pertussis toxin (PT), filamentous haemagglutinin

(FHA),

pertactin and serotype specific fimbriae for inclusion in acellular vaccine
preparations. This study analyses the expression of several of these antigens
in different genetic backgrounds.

A permanently avirulent Bordetella bronchiseptica strain was previously
engineered to constitutively produce P T (Walker et al., 1991). A n in vivo
cloning technique, based on

the principles of conjugal

mating

and

c h r o m o s o m e transfer w a s employed to transfer the P T expression locus of
this strain to virulent and avirulent strains of B. bronchiseptica. This
transfer w a s confirmed by Southern hybridisation.

An

analysis of P T

secretion in isogenic virulent and avirulent strains of B. bronchiseptica
revealed that the P T produced w a s cell-associated, and not secreted to the
growth m e d i u m . This evidence further suggests that B. bronchiseptica does
not possess functional P T secretion (ptl) genes. Therefore, to achieve a P T
expression and secretion system suitable for vaccine purposes in Bordetella
bronchiseptica, functional ptl genes of B. pertussis are also required.

The use of "natural mutants" of Bordetella pertussis overexpressing
immunogenic

proteins as whooping cough vaccine strains m a y have a

higher level of public acceptance than both the traditional whole cell
preparation and the genetically engineered recombinant acellular vaccines
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currently under formulation. Mutants naturally overexpressing various
candidate vaccine components have been created by Commonwealth Serum
Laboratories (CSL Ltd.) via continuous subculture. These three strains (CSL
127S, CSL 137S and CSL 1237S) were genetically characterised by amplifying
relevant regions of the genome, cloning these fragments into plasmid
vectors and performing D N A sequencing analyses. B. pertussis CSL 137S,
producing large amounts of type 3 fimbriae was found to possess an extra
cytosine residue in the "fimbrial C stretch" of the promoter when compared
to its parental strain. B. pertussis CSL 127S, which overexpresses type 2
fimbriae as well as F H A also has an altered C stretch. It contains one less
cytosine than its parental strain. The upregulation in F H A could not be
explained in terms of promoter differences. W h e n the parental strain and
CSL 127S were compared, the promoter regions of the F H A gene and the
FHA/fimbrial accessory gene cluster were genetically identical. The third
candidate vaccine strain (CSL 1237S) presented a more puzzling expression
pattern. A moderate increase in the expression of most virulence factors
analysed compared to its parental strain suggested a possible favourable
mutation in the BvgAS promoter region. This however was not the case,
with no differences being observed at any of the promoters analysed.

The two strategies for vaccine antigen expression investigated here ma
eventually lead to the production of readily manufactured and therefore
more affordable whooping cough vaccine preparations.

1

Chapter O n e

Literature Review

1.1 Bordetella pertussis - A General Perspective
1.1.1 Whooping Cough

Pertussis, or whooping cough is a highly contagious disease of the human
respiratory tract which is particularly severe in infants. The disease is
characterised by bronchopneumonia, paroxysmal coughing

and the

distinctive "whooping" intake of air, and if left untreated can lead to
neurologic damage or death. This is especially pertinent in developing
countries where appropriate medical assistance is often unavailable and
disease progression is unimpeded by the lack of suitable antimicrobials.
The readily transmissible nature and severity of the disease in these
countries has seen worldwide deaths from whooping cough increase to
over 350 000 per year (Strebel et al., 1994). This serious disease is caused by
the obligate h u m a n pathogen, Bordetella pertussis, a Gram-negative
coccobacillus originally isolated in 1906 by Bordet and Gengou.

The normal course of infection begins with the bacteria entering the host
via the airways, contained within airborne droplets derived from the
cough of an infected individual. The pathogens proceed d o w n the
respiratory tract, adhering to ciliated epithelial cells in the trachea and
nasopharynx. Once attachment is initiated, the bacteria begin to replicate
and colonise adjacent areas. Toxins secreted by the microorganism
damage the epithelial lining, resulting in the loss of ciliated cells which
induces the characteristic coughing. These toxins also allow the bacterium
to evade the host i m m u n e

response by interfering with clearance

mechanisms. Halting ciliary function, short circuiting host G protein
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signalling

apparatus

and

inhibiting

immune

cell

function

by

upregulating c A M P levels are all examples of the strategies employed by
the various toxins of Bordetella pertussis.

The incidence of whooping cough has been greatly reduced since the
advent of pertussis vaccines in the 1940's. These "whole cell" vaccines
consist simply of chemically or heat-killed Bordetella pertussis cells.
These vaccines, as part of the Diphtheria, Tetanus, Pertussis (DTP)
immunisation

regime proved extremely effective at preventing

the

symptoms of whooping cough. Unfortunately, a loose association with
rare neurologic complications and deaths has lead to a decline in public
confidence, a subsequent reduction in immunisation

rates, and

an

inevitable worldwide increase in the incidence of the disease. The other
constituents of the D T P vaccine are purified, inactivated diphtheria and
tetanus "toxoids". These single component vaccines have attained a
comparatively less controversial reputation, and there is currently m u c h
research being carried out in an attempt to bring the pertussis component
into line with the less reactogenic constituents of the vaccine.

1.1.2 The Genus Bordetella

Historically, the bacteria currently classified within this Genus have had
very dynamic and controversial taxonomic existence, not always being
classified together. It was Lopez (1952) w h o proposed that a n e w group,
the Genus Bordetella be created to house the then three species, B.
pertussis, Bordetella parapertussis and Bordetella bronchiseptica. M o r e
recent

molecular

evidence, including

DNA

sequencing

analysis,

multilocus enzyme electrophoresis and R F L P typing has justified the
grouping of these three species into the same genus (Table 1.1) (Arico et
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al., 1987; van der Zee et al., 1997). B. pertussis is exquisitely tuned to a
single environment and will only infect humans. B. parapertussis causes
a milder "pertussis-like" disease state in humans and has also been found
associated with ovine respiratory infections (Cullinane et al., 1987). Most
other m a m m a l s

can be colonised by B. bronchiseptica, and m a n y

commercially important diseases are caused by this versatile organism
(Goodnow, 1980). The most notable being an association with atrophic
rhinitis in swine which costs the meat industry considerable profits and
kennel cough in dogs (Switzer, 1956; T h o m p s o n et al., 1976). The bird
pathogen Bordetella avium, a later addition to the genus (Table 1.1),
causes turkey coryza and other respiratory diseases of foul (Kersters et al.,
1984).

Table 1.1 The four most studied members of the Genus Bordetella comparing
characteristic proteins produced by each species. Modified from Gross et al., 1989; Parton,
1996.

B. pertussis B. parapertussis B. bronchiseptica B. avium
Pertussis Toxin
+
+
+
Adenylate Cyclase

FHA
Fimbriae
Pertactin
Tracheal Cytotoxin
Lipopolysaccharide
Dermonecrotic Toxin

Flagella
Urease

+
+
+
+
+
+

+
+
+
+
+
+

-

-

+/-

-

+
+
+
+
+
+
+
+
+

-

+
+
+
+
+
+
-

M o r e recently, a number of n e w members have been proposed. Bordetella
hinzii is the n a m e assigned to a novel species recently isolated from a
bacteremic individual with H I V / A I D S (Cookson et al, 1994). Associated
with h u m a n septicemia, another species, designated Bordetella holmesii
has been identified (Weyant et al., 1995). The n a m e Bordetella trematum
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has recently been proposed for a novel species isolated from

human

w o u n d s and ear infections ( V a n d a m m e et al., 1996). Although none of
these n e w species were associated with respiratory tract infections they
display characteristics indicative of the Genus. Since its initial discovery,
Bordetella hinzii has been isolated from the respiratory tract of infected
poultry ( V a n d a m m e et at., 1995).

1.2 Genetic Control of Virulence - Turn On's an
Turn Off s
Pathogenic bacterium colonise and multiply by exploiting their
environment to the fullest extent. Bordetella pertussis accomplishes this
aim with prodigious efficiency. The method of achieving this is for the
bacterium to have some level of control over the production of the
specific factors which enable it to infect its host. There is a very
coevolutionary link between the exceedingly strict regulation of the
virulence determinants of B. pertussis and the highly evolved interaction
it possesses with the h u m a n respiratory tract.

1.2.1 Bordetella Virulence Gene Regulation System

It was realised many years ago that Bordetella pertussis existed in more
than one phase (Leslie and Gardner, 1931). "Phase variation" occurs w h e n
spontaneous mutations during D N A replication give rise to avirulent
variants. This process is generally irreversible and occurs at a frequency of
one in a thousand to one in a million cells. This produces phase-locked
avirulent bacteria which do not have the ability to invade and colonise
the host. However, if w h e n culturing wild type Bordetella pertussis, the
growth conditions are altered, the bacteria undergo a totally reversible
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conversion to one of principally two states, called X and C modes (Lacey,
1960). Termed

"antigenic modulation", this phenomenon,

may

be

important in the survival of this microorganism. This landmark study
also recognised a third state (I mode), a phase of growth intermediate
between X and C modes, and "an infinitude of other antigenic states".

Research since has dealt almost entirely with the two extreme mode
growth, virulent (X) and avirulent (C) phases. N e w research on the
related species B. bronchiseptica has given us new insight into the
intricacies of antigenic modulation. Due to the expression of a set of genes
under modulating growth conditions which are easily monitored, B.
bronchiseptica may be used as a model for other members of the Genus.
A n intermediate phase B. bronchiseptica mutant similar to Lacey's I
mode,

has

recently

been

isolated

which

expresses

phenotypes

characteristic of both virulent and avirulent states (Cotter and Miller,
1997).

The members of the Genus Bordetella share a genetic locus which
encodes a type of biological "switch" enabling these species to oscillate
principally between two very different phenotypic states depending on
whether they are inside a suitable host or in the outside environment.
Species of Bordetella encounter vast differences between these two
environmental

extremes. For

a pathogenic

bacterium

which

has

coevolved with its host to live in a specific niche, the environment
outside a host is extremely harsh. The drying atmosphere and fluctuating
temperatures make it a very inhospitable place. Under these conditions,
the Bordetellae switch to avirulent phase. Proteins required for host
invasion are not produced, instead, a set of genes which allow the
organism to best deal with such difficult conditions are expressed. There
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is considerable energy saved in not producing virulence factors, a point
substantiated in the laboratory by the considerable difference in growth
rates between virulent and avirulent organisms. The w a r m , moist,
surroundings of the h u m a n respiratory tract is a more obliging place for
the bacterium to thrive. In these physically favourable conditions, a
different subset of genes are expressed. The genes for a number of
adhesins, such as filamentous haemagglutinin (FHA), serotype specific
fimbriae, and a 69 kDa outer membrane protein k n o w n as pertactin are
expressed, as are the genes encoding more harmful products involved in
evasion of the host i m m u n e system, pertussis toxin, adenylate cyclase
toxin/haemolysin and dermonecrotic toxin.

In the laboratory, the virulence control switch can be manipulated to
bring Bordetella species into avirulent phase by the addition of sulfate
ions or nicotinic acid to the culture medium, or by reducing the culture
temperature from 37°C to 25°C.

The expression of virulence factors in Bordetella species is coordinately
regulated by what was originally termed the vir locus (Weiss and Falkow,
1984) and is n o w k n o w n as the Bordetella virulence gene locus (bvg)
locus. This gene locus encodes two proteins which enable the bacterium
to "sense" the prevailing environmental conditions, and then "act"
accordingly by controlling the expression of specific genes and gene loci.
The sensor protein is k n o w n as BvgS and the activator, BvgA. Together
they constitute a two-component signal transduction system and m a k e up
part of a signal transduction superfamily (Parkinson and Kofoid, 1992).
This type of system is utilised by m a n y prokaryotes, and recently described
in some eukaryotes (Choi and Greenberg, 1991; Parkinson and Kofoid,
1992; Chang et al, 1993, Ota and Varshavsky, 1993) in response to m a n y
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different environmental stimuli.

The genes encoding BvgA and BvgS are contained within an operon
(Arico et ah, 1989). The original sequencing data unfortunately contained
mistakes, confusing the exact arrangement of the operon (Figure 1.1). T h e
discovery and sequencing of a third gene, bvgR has confirmed the true
operon structure (Merkel et al, 1998a). While bvgA

and bvgS are

transcriptionally linked, bvgR is transcribed separately from the opposing
D N A strand (Figure 1.1).

bvgA bvgS bvgR

TZM

=i

i=m

Figure 1.1 Schematic representation of the operon structure of the Bordetella
virulence gene regulation system. Genes encoding BvgA, BvgS and B v g R (open boxes) and
promoter regions (filled arrows) are indicated. The genes for bvgA

and bvgS

are

transcriptionally linked. bvgR is transcribed separately in the opposite direction.

Transcription of bvg AS is controlled by three self regulated promoters,
P3 and P4 and one bvg independent promoter, P2 (Figure 1.2) (Roy et al.,
1990; Scarlato et al., 1990). Transcription from P2 is constitutive, thereby
maintaining low level production of intracellular B v g A S proteins. W h i l e
P2, P2 and P3 are all involved in the transcription of bvgAS, P4 produces
an anti-sense R N A strand complimentary to transcripts expressed from
the other three promoters. The exact in vivo function of this promoter
remains a mystery, however it m a y be involved with stabilisation of the
sense transcripts via the prevention of secondary structure formation.
Hybridisation between m R N A

from P? and P4 m a y lead to a m o r e

efficient interaction with ribosomes (Scarlato et al., 1990).
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The gene encoding F H A is transcribed from a region just upstream of

these four promoters (Scarlato et al., 1990) at P^fl (Figure 1.2). There ha
since been discovered a bag-independent FHA promoter, P^fl* which
expresses low levels of the FHA precursor protein, FhaB (Steffen et al.,
1996; Boucher et al, 1997).

fl1"* Pflm Pfha* n bv8A
<=^ - ^ - ^^=>
P3

P2

Pi

Figure 1.2 Promoter organisation of the bvg/fha intergenic region. The bvgA and
fhaB genes (open boxes) are shown. Direction of transcription from each promoter
indicated by arrows. Modified from Scarlato et al, 1990 and Coote, 1991.

1.2.2 BvgA

The transcriptional activator, BvgA, which can directly and indirectly

affect the expression of a number of virulence controlled genes is a 23 kD
cytoplasmic protein. The two domain structure of BvgA (Figure 1.3),
consisting of a receiver at the N-terminus and a C terminal helix-turnhelix (HTH) motif is characteristic of response regulators (Arico et al,
1989; Stibitz and Yang, 1991). It is this HTH module which facilitates
specific DNA sequence binding at the promoters of bag-activated genes
(Boucher et al, 1994). Although not part of the HTH domain, the last 20

amino acid residues are also required for binding, probably by stabilising
the HTH-DNA binding interaction (Boucher et al, 1994; Kahn and Ditta,
1991).
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Reciever HTH

^

=

H
D54

•
168

185

Figure 1.3. Domain structure of the 209 amino acid transcriptional activator BvgA
The receiver domain (open box) is shown, with the phosphorylation site (Aspartic acid,
D 5 4 ) indicated. The C-terminal domain (light shading) incorporating the helix-turn-helix
domain (dark shading; amino acids 168-185) is also shown. Modified from Uhl and Miller,
1995

The binding of DNA by proteins is a common phenomenon within cells,
and the C terminal H T H domain of BvgA shares sequence homology
with a number of different protein families. A s expected, this domain is
homologous to corresponding areas of other response regulators such as
FixJ, U h p A and NarL (Kahn and Ditta, 1991). Other D N A binding proteins
such as LuxR from Vibrio fischeri (Choi and Greenberg, 1992) as well as
the C termini of selected bacterial o factors (Helmann and Chamberlin,
1988) also share homology to this evolutionally well conserved domain.

Direct control over the transcription of a number of bug-activated gene
by B v g A is achieved via binding to specific sequences at target promoter
regions (Roy et al, 1989; Roy and Falkow, 1991). The heptameric sequence
specific B v g A binding site, T T T C C T A or T T T G G T A , first proposed by R o y
and Falkow is present as either direct or inverted repeats upstream of
various bug-regulated genes (Roy and Falkow, 1991). The importance of
these repeats has since been confirmed at a number of virulence activated
promoters by DNase I protection studies (Boucher and Stibitz, 1995;
Karimova et al, 1996; Z u et al, 1996; Marques and Carbonetti, 1997).
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1.2.3 BvgS

In a process that is not yet fully understood, changes in the extracellular
environment trigger a histidine kinase in the transmitter domain of
BvgS to autophosphorylate (Uhl and Miller, 1994). Following a series of
intramolecular

phosphorylation

events, the

phosphoryl

group

is

eventually transferred to B v g A (Uhl and Miller, 1994).

The 135 kDa sensory component of the signal transduction system, BvgS
is often termed an unorthodox sensor protein because of the number of
extra functional domains it contains. The membrane spanning nature of
this protein predicts it possess both periplasmic and transmembrane
domains, and sequence homology

studies confirm

the

absolutely

conserved histidine kinase domain (Arico et al, 1989; Stibitz and Yang,
1991). However, BvgS also contains a linker section and regions usually
reserved for response regulators such as BvgA, a receiver domain and a C
terminal output domain (Figure 1.4) (Arico et al, 1989; Stibitz and Yang,
1991). The deletion of these "extra" domains has been shown to m a k e
BvgS inoperable (Arico et al, 1989; Uhl and Miller, 1994; Beier et al, 1995).

Experiments with BvgS-PhoA fusion proteins have shown the Nterminal region is located in the periplasm (Stibitz and Yang, 1991).
Mutations in the linker region render the bacterium incapable of sensing
the environment providing evidence that this region acts as a molecular
relay between periplasmic and C terminal domains located in the
cytoplasm (Miller et al, 1992; Manetti et al, 1994).
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Figure 1.4 Domain structure of the 1236 amino acid protein BvgS. The 514 aa sensor

domain (single line), the 159 aa linker region (single line), 232 aa transmitter doma

(open box), 131 aa receiver domain (lightly shaded box) and the 126 aa C-terminal o

(heavily shaded box) regions are shown. Phosphorylation sites (Histidine, H72g; Asp

acid, D1023; and Histidine, H1172) are indicated. The short membrane spanning domains
(TM; black boxes) are also depicted. Modified from Uhl and Miller, 1996a

The transmitter region of BvgS is necessary and sufficient for
autophosphorylation (Uhl and Miller, 1994) however transfer of this
phosphoryl group to the C-terminal (output) domain can only be effected
via the receiver domain (Uhl and Miller 1996a). Not only does the
receiver domain positively regulate the phosphotransfer to the C
terminal output domain, it also has the ability to reverse this transfer,
thereby rephosphorylating itself and postponing BvgA activation (Figure
1.5). It can also totally dephosphorylate BvgS from the receiver itself,
thereby completely halting the activation of BvgA (Figure 1.5) (Uhl and
Miller 1996a). It is the output domain (particularly Hisn72) of the C
terminal which is responsible for the phosphorylation of BvgA (Uhl and
Miller 1996b).
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Figure 1.5 The BvgS-BvgA phosphorylation cascade model. The sensor domain
receives an environmental signal that causes the autophosphorylation of the histidine
(H72g) residue of the transmitter domain (open box). The phosphoryl group is then
transferred to an aspartic acid residue(D1023) of the receiver domain (lightly shaded box).
The phosphoryl group can then be relayed to the histidine (H 1172 ) residue of the Cterminal output (heavily shaded box), or can react with water to dephosphorylate the
BvgS molecule. The output domain then donates the phosphoryl group to BvgA, leading to
the transcriptional initiation of virulence genes. The short membrane spanning domains
(TM; black boxes) are also depicted. Modified from Cotter and Miller, 1997.
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1.2.4 BvgR

While BvgA exercises direct control over the expression of fri?g--activate
genes by binding to promoter sequences, control over virulence repressed
genes (org's) is indirect, implicating a Bvg activated repressor protein. The
gene which controls repression of the bvg repressed genes has been
identified

and

termed

bvgR

(Merkel

characterisation, including D N A

and

Stibitz, 1995). Further

sequence analysis has since been

performed (Merkel et al, 1998), revealing mistakes in the previously
published bvg operon sequence (Arico et al, 1989) which m a y have
delayed the discovery of this gene.

The DNA sequence of the 5' end of each of the five bvg repressed genes
(vrg6, vrgl8, vrg24, vrg53 and vrg73) has brought to light a conserved
consensus sequence element present in the coding region of four of these
genes (Beattie et al, 1990; Beattie et al, 1993). Using a southwestern
analysis at vrg6, this sequence was recognised by the irg-repressor (BvgR)
a 34 k D a protein (Beattie et al, 1993). Although unusually situated in the
coding sequence, homology of the 32 base pair conserved BvgR binding
site a m o n g bvg repressed genes is restricted to the D N A level. N o n e of
the native promoter regions of any of the bvg repressed genes seem
necessary for modulative repression to occur (Beattie et al, 1993).

The bvgR gene lies downstream of and adjacent to bvgAS (Merkel and
Stibitz, 1995). Further characterisation led to the identification of the exact
location of the bvgR gene (Fig 1.1) (Merkel et al, 1998a). Transcribed from
its o w n B v g A regulated promoter, bvgR lies 43 base pairs downstream of
bvgS and is read in the opposite direction. Transcriptional analysis has
s h o w n that this open reading frame produces a predicted protein of 32
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kDa, close to the molecular weight (34 kDa) obtained by Beattie and
associates (Merkel et al, 1998a).

The new corrected sequence analysis also allowed bvgR to be placed in a
gene family in which none of the members have been assigned a
function. Although there are n o w 19 homologous genes in this family,
bvgR is the only one for which a role has been elucidated (Merkel et al,
1998a). A follow up study showed that mutants lacking bvgR are less
efficient than the wild type in the mouse aerosol challenge model,
demonstrating that BvgR regulation of the bug-repressed genes makes a
significant contribution to infection in mice (Merkel et al, 1998b).

1.2.5 Transcriptional Regulation by BvgA

As the final part of an intricate phosphorelay process, BvgS
phosphorylates

BvgA.

When

compared

to its unphosphorylated

counterpart, this activated "BvgA~P" has a far greater affinity for
virulence factor promoter B v g A binding sites (Boucher et al, 1994;
Boucher and Stibitz, 1995; Karimova et al, 1996; Steffen et al, 1996).
Indeed, B v g A must be phosphorylated for bvg activated promoters to
become fully operational in in vitro transcription assays (Steffen et al,
1996; Boucher et al, 1997). Although B v g A independent transcription of
the fhaB

gene has been observed, expression from this alternative

promoter, Pfha* only occurs at low levels (Steffen et al, 1996; Boucher et
al, 1997).

It was theorised that the positioning of BvgA~P at a promoter region may
induce B v g A oligomerisation (Scarlato et al, 1990) and raise the affinity of
the response regulator for the target D N A (Boucher et al, 1994). Recent
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research has demonstrated that BvgA~P binds cooperatively to bvgactivated promoters, forming multimers along the promoter template
(Boucher and Stibitz, 1995; Karimova et al, 1996; Z u et al, 1996; Boucher
et al, 1997). Initially, high affinity binding occurs far upstream from the
transcriptional start site, then weaker sites are progressively bound until
the site adjacent to the R N A polymerase recognition sequence is reached.

1.2.6 Involvement with RNA Polymerase

When bound to the promoter DNA at the correct start site, RNA
polymerase catalyses the initiation of transcription. This complex enzyme
is composed of four types of subunit, cc, p, (3', and a. The a subunit is
generally the portion of R N A polymerase that interacts with transcription
factors at positively regulated prokaryotic promoters (Ishihama, 1992;
Busby and Ebright, 1994). The o subunit is involved

in promoter

recognition, interaction with transcriptional activators, D N A unwinding
and setting up initiation complex (Ishihama, 1993). M u c h research into
the important roles played by these two R N A

polymerase subunits is

currently underway.

The a and major o factor of B. pertussis have both been cloned and
characterised (Carbonetti et al, 1994; Steffen et al, 1997). The major o
factor of B. pertussis is larger than the E. coli a70 and has been designated
o80 (Steffen et al, 1997). The B. pertussis R N A polymerase a 80 subunit
confers enhanced expression of fhaB in E. coli (Steffen et al, 1997). The
authors suggest that the role played by a80 may be in positioning the R N A
polymerase/BvgA«P complex at the correct site along the promoter
template. By interacting directly with BvgA«P, the R N A

polymerase o

subunit is provided with an interface point through which it can initiate
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transcription (Steffen et al, 1997).

Studies on response regulator molecules related to BvgA such as LuxR
from Vibrio fischeri and U h p A from Escherichia coli have demonstrated
that while still able to bind target D N A , transcription from promoters
regulated by these proteins is severely hindered by C terminal deletions
(Choi and

Greenberg, 1991; Webber

and

Kadner, 1995). Similar

experiments carried out on B v g A have shown that a deletion of as little
as two amino acids resulted in an avirulent phenotype (Stibitz, 1998).
W h e n this truncated bvg gene was presented on a plasmid (in trans), in
otherwise wild type B. pertussis strains, a massive inhibition of growth
was observed (Stibitz, 1998). Mutations found to remedy the slowed
growth were traced to the a subunit of R N A
suggesting that an interaction between R N A
terminal of B v g A

polymerase, further

polymerase and the C

is required for the transcriptional activation of

virulence associated genes in B. pertussis (Stibitz, 1998).

In the absence of BvgA~P, RNA polymerase binds upstream of the in
vivo transcription start sites of the Pfha promoter leading to low level
expression from the B v g A independent promoter, Pfha* (Steffen et al,
1996; Boucher et al, 1997). However the addition of B v g A ~ P allows
transcription to be initiated at the normal in vivo site. This is further
evidence that B v g A acts upon frpg-activated promoters by correctly
positioning R N A

polymerase for transcription (Steffen et al, 1996;

Boucher et al, 1997).

Recent DNase I protection assays at bag-activated promoters suggest that
the promoter D N A flexes to loop around the B v g A ~ P - R N A polymerase
complex (Boucher and Stibitz, 1995; Boucher et al, 1997; Z u et al, 1996).
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This m a y increase the binding affinity of the weak secondary B v g A « P and
the R N A polymerase and stabilise the entire transcriptional machinery
(Boucher et al, 1997).

1.2.7 Differential Activation of Virulence Factors

Expression of bug-activated genes has been shown to proceed in two
stages, (Scarlato et al, 1991; Scarlato and Rappuoli, 1991). This differential
activation of "early" and "late" promoters allows the bacterium to
produce adhesin molecules soon after entering the host, while the
"second w a v e " bug-activated genes are not expressed until attachment is
achieved.

The activation of PT requires the presence of a threshold concentration of
B v g A ~ P (Scarlato et al, 1991). There is actually a ten fold higher
concentration of B v g A ~ P required to initiate transcription at the Fptx
promoter than either P^fl or bvg Pi (Zu et al, 1996).

Demonstration of the functional difference between early and late
expressers came w h e n mutations in the C-terminal of B v g A allowed
normal levels of F H A expression while totally abolishing P T expression
(Stibitz, 1994). This region has been proposed as the region of the B v g A
molecule that interacts with R N A polymerase (Stibitz, 1994; Stibitz, 1998).

A mutation leading to an increase in expression of the RNA polymerase
a subunit results in a phenotype lacking the production of P T and
adenylate cyclase toxin/haemolysin, but expressing normal amounts of
F H A (Carbonetti et al, 1994). The authors proposed that m u c h of the
intracellular B v g A became bound to the excess a subunit and while there
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w a s still enough free B v g A to activate the Ffha promoter, the titration w a s
not sufficient to turn on expression of the late promoters.

Binding studies at the Fptx promoter have found an initial high affinity
binding site far upstream of the -35 promoter motif (Boucher and Stibitz,
1995). This region includes a 20 bp direct repeat which

in turn

encompasses heptameric inverted repeats (Boucher and Stibitz, 1995;
Marques and Carbonetti, 1997). Genetic analysis of this region has
demonstrated that it is the heptanucleotide repeats that are crucial for
promoter activation (Marques and Carbonetti, 1997). D u e to the distance
of these repeats from the actual start site, Fptx m a y require B v g A ~ P to
multimerise along the promoter template with weaker sites progressively
bound until the site adjacent to the R N A polymerase recognition
sequence is reached.

A similar analysis has been undertaken at the P^, promoter (Boucher et
al, 1997) at which the binding of B v g A ~ P to an extent mirrors that at the
Fptx promoter. Again a high affinity site is bound initially, including an
inverted repeat region homologous to that at Fptx, however it lies further
downstream than the corresponding element at the Fptx promoter (Zu et
al, 1996; Boucher et al, 1997). These B v g A ~ P binding sites have been
calculated to be 7-8 turns of helix upstream from F^a and bvg F\ and 14
turns upstream from Fptx (Zu et al, 1996). The architecture of the bvg Pi
promoter, another early promoter is very similar to that of P^fl and
interacts with B v g A « P and R N A polymerase in a similar manner (Zu et
al, 1996). Since the expression of P T is temporally linked to that of
adenylate

cyclase

toxin/haemolysin

it is interesting

that the

transcriptional machinery of these two toxins is alike. The Fcya promoter
has been s h o w n to behave in a manner which parallels that of Fptx
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(Karimova et al, 1996).

Differences in BvgA binding sites at the promoters of the two classes of
virulence genes suggest specificity of B v g A ~ R N A polymerase interactions
m a y control differences in transcription at these promoters (Boucher and
Stibitz, 1995; Karimova et al, 1996; Z u et al, 1996; Boucher et al, 1997;
Karimova and Ullmann, 1997).

1.2.8 "Bvgi"

Some of the recent research findings involving the coordinate regulation
by the bvg locus has been performed in the closely related species B.
bronchiseptica. While the bug-repressed genes of B. pertussis are seldom
studied and little is k n o w n about their function, B. bronchiseptica has an
array of important functional bug-repressed genes including motility,
iron scavenging, urease and phosphatase activity which are at least in part
repressed by the bvg locus (Akerley et al, 1992; West et al, 1997; Giardina
et al, 1995; M c Millan et al, 1996; Chhatwal et al, 1997).

Due to this expression of functional genes under modulating growth
conditions, B. bronchiseptica is sometimes used as a model for B.
pertussis. A n intermediate phase B. bronchiseptica mutant has recently
been isolated which expresses phenotypes characteristic of both Bvg+ and
Bvg-

states (Cotter and Miller, 1997). Further

investigation

using

polyclonal antisera from animals infected by the intermediate mutant
revealed that under growth conditions described as semi-modulating, B.
bronchiseptica expressed elevated levels of a novel class of gene products.
The phase locked "Bvgi" mutant has a C to T transition in the bvgS gene
resulting in the threonine at position 733 of wildtype BvgS being altered
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to a methionine. The close proximity of this mutation to the putative
phosphorylation site (His?29) i n the transmitter domain is thought to
affect kinase activity (Cotter and Miller, 1997).

1.2.9 DNA Topology

Another factor theorised to affect transcription is the actual structure of
the D N A itself. The topology of D N A relates to changes in the structure of
supercoiled D N A which is maintained in a constant state of flux by D N A
gyrase and topoisomerase I. Stability and structure of the R N A transcripts,
and the presence of D N A - b o u n d proteins such as histones and histonelike proteins are also involved.

Many genes can be affected by changes in DNA topology, including those
controlled by signal transduction systems (Higgins, 1988; Dorman, 1991).
Histone-like proteins have been implicated in the regulation of virulence
factors in a number of pathogens by changing the local D N A topology in
response to environmental signals, altering the activity of topologysensitive promoters (Dorman, 1991).

With respect to B. pertussis, Scarlato and coworkers (1993) found evidence
to suggest that transcriptional regulation of the pertussis toxin gene m a y
require alterations in the local D N A topology. A far more comprehensive
study has since demonstrated that B. pertussis virulence gene expression
is sensitive to D N A topology related changes (Graeff-Wohlleben et al,
1995). Drugs which inhibit D N A gyrase activity were added to the growth
m e d i u m , and the expression of various virulence factors monitored.
Most of the bug-activated promoters assayed were downregulated in the
presence of such drugs (Graeff-Wohlleben et al, 1995). Although this
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study implicates a role for D N A topology in the regulation of virulence
factors in B. pertussis, the data w a s obtained under in vitro conditions
and the in vivo situation has not yet been elucidated.

1.2.10 Bvg Accessory Factor

The temporally differential regulation employed by BvgAS to control
virulence factor expression in Bordetella pertussis m a y

require the

presence of accessory factors. In E. coli, the activation of either fhaB or
bvgAS merely requires the presence of bvgAS in trans (Stibitz et al, 1988;
Miller et al, 1989; Roy et al, 1989). It w a s thought that this w a s not
sufficient however w h e n trying to express pertussis toxin or adenylate
cyclase toxin (Miller et al, 1989; Roy et al, 1989; Goyard and U l l m a n n ,
1991). W h e n investigating the factors affecting the expression of PT, it w a s
found that the activation of the bvg locus m a y depend on the topology of
the D N A (Scarlato et al, 1993). The authors also alluded to the possibility
that the action of an as yet undiscovered auxiliary protein m a y be
required to activate expression from the ptx promoter (Scarlato et al,
1993). Stibitz (1994) also proposed a model suggesting an accessory protein,
which interacts with the C-terminus of BvgA, m a y be required for cya and
ptx activation (Stibitz, 1994). This protein has been characterised and
termed the Bvg accessory factor (Baf) (DeShazer et al, 1995). These
workers showed that the expression of a ptx-lacZ fusion in E. coli requires
B v g A S and Baf in trans. The expression from Fptx in E. coli has been
demonstrated without the presence of Baf, thereby contradicting the
previous w o r k and questioning the need for Baf (Uhl and Miller, 1995).
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1.3 Virulence Factors of Bordetella pertussis
The set of genes expressed by B. pertussis which allow it to invade and
persist inside the host are termed

virulence

factors or virulence

determinants. These include toxins which enable the bacterium to evade
the host i m m u n e system and adhesins which facilitate attachment to
target host cells. At present the consensus with regard to the strategy for
developing recombinant whooping cough vaccines seems to include a
few purified immunogens in an acellular, component vaccine. M a n y of
the virulence factors of B. pertussis have been considered for this
purpose. Since the direct cause of whooping cough symptoms is attributed
to pertussis toxin, it is widely accepted that this antigen constitute the
main component in any n e w vaccine (Pitman, 1984). Other candidate
antigens include F H A , serotype-specific fimbriae, adenylate cyclase and
pertactin.

1.3.1 Pertussis Toxin

A member of the A-B bacterial toxin superfamily, pertussis toxin (PT) is a
106 kDa, hexameric protein comprising five distinct subunits (Tamura et
al, 1982). P T is an A D P ribosyltransferase (116) with the ability to cause a
plethora of effects on host cells. It is the A protomer or SI subunit which
possesses enzymatic capabilities, catalysing the transfer of the ADP-ribose
moiety of N A D + to a family of G proteins, which are involved in vital
signal transduction pathways within the host cell. This short circuits the
cell signalling machinery of surrounding epithelial and i m m u n e system
cells by breaking d o w n G protein interactions (Katada et al, 1983). The B
oligomer comprises the remaining subunits, S2, S3, S4 and S5 m a k e u p
the B oligomer in the ratio 1:1:2:1 (Tamura et al, 1982). This region of the
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protein facilitates attachment of the toxin to host cells, delivering the
toxic action of the SI subunit (Tamura et al, 1982).

The genes encoding the pertussis toxin subunits are clustered together in
an operon typical of many other bacterial toxins (Figure 1.6). Genetic
analysis has revealed that each subunit is translated separately with an
amino-terminal signal sequence which is cleaved during transport to the
periplasm where the holotoxin is then assembled and secreted (Locht and
Keith, 1986; Nicosia et al, 1986).

Pwt SI S2 S4 S5 S3

Figure 1.6 Schematic diagram of the pertussis toxin operon. The genes coding the PT

subunits S1-S5 are represented by open arrows. Signal sequences are demonstrated as

shaded boxes. The wild type pertussis toxin promoter is shown as a filled arrow. Th
arrows indicate the direction of transcription of the genes.

The major hurdle yet to be overcome in the preparation of acellular,
component vaccines is the inability to obtain purified antigens in large
amounts. The incompatibility of PT gene expression signals with respect
to Escherichia coli make the production of PT in this organism difficult to
achieve (Nicosia et al, 1987; Burnette et al, 1988). There are also problems
associated with obtaining high yields of purified PT from virulent B.
pertussis. These include the slow growth rate, fastidious nutritional
requirements, and the inherent low PT production levels of the
bacterium. There is also the risk that the co-purification of low levels of
other virulence regulated toxins may occur in vaccine preparations. Of
the Bordetella species, only B. pertussis produces PT. A cryptic PT operon
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is present in B. parapertussis and B. bronchiseptica; base pair mutations in
the promoter region leave these operons transcriptionally silent (Arico
and Rappuoli, 1987).

An expression system for pertussis holotoxin has been the goal of a
number of groups, particularly stimulated by the cloning and sequencing
of the P T operon. The SI subunit gene has upstream regions analogous to
E. coli ribosomal binding sites. The remaining subunits, however, contain
novel ribosome binding site sequences upstream of the structural genes,
which bear no resemblance to the E. coli consensus ribosome binding site.
This, and the fact that the P T operon is positively regulated by the bvg
locus, are major reasons w h y pertussis holotoxin is yet to be expressed in
E. coli. Expression of P T subunits has been achieved in E. coli and
Bacillus subtilis (Burnette et al, 1988; Runeburg-Nyman et al, 1987; Saris
et al, 1990). Unfortunately, expression of P T subunits in E. coli caused the
majority of the protein to congregate in inclusion bodies, and not be
secreted into the periplasm (Burnette et al, 1988). The other major
problem with expression of subunits for vaccine purposes is their
inability to assemble into holotoxin in vitro. The individual P T subunits
have been s h o w n to induce antibody responses in immunised mice.
However, these mice were not protected w h e n challenged intracerebrally
with B. pertussis cells (Burnette et al, 1988). The B oligomer has been
assembled in vitro and mice immunised with this preparation were able
to neutralise the toxic effects of P T (Burnette et al, 1992). Simultaneous
expression of all five P T subunits has been achieved in E. coli and
Salmonella typhimurium aroA (Dalla Pozza et al, 1997; Dalla Pozza et al,
1998). While this was initially promising, varying levels of expression
and post translational processing, together with a lack of protection in
orally immunised mice indicates that these strains would not be useful as
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vaccine strains.

Efficient expression of pertussis holotoxin, has to date only been achieved
in Bordetella species. The major concern here is that P T production takes
place in only virulent strains of B. pertussis. The copurification of other
toxins and thus contamination of vaccine preparations m a y therefore
occur. Lee and associates have used recombinant plasmids to express P T
in B. parapertussis and B. bronchiseptica (Lee et al, 1989). Yields were
comparable to those of B. pertussis and although the majority of the P T
produced w a s localised in the periplasm, s o m e P T w a s detected in the
culture supernatant. B. parapertussis and B. bronchiseptica have also been
used to produce genetically altered detoxified pertussis toxin (Pizza et al,
1989; Nencioni et al, 1990). Bacterial strains engineered to produce a safe
pertussis "toxoid" are very good candidates for the production of acellular
vaccines. Overexpression and secretion of genetically detoxified pertussis
toxin has been achieved in B. pertussis (Zealey et al, 1992) by using allelic
exchange techniques to introduce multiple copies of a genetically altered
P T operon into the chromosome. Fully inducible production of P T in B.
bronchiseptica has resulted in improved growth rates and P T yields w h e n
compared to B. pertussis (Suarez et al, 1997). Expression of P T w a s
achieved in a permanently avirulent strain of B. bronchiseptica using
mini-transposons to clone a promoterless P T operon in front of a strong
constitutive

B.

bronchiseptica promoter

(Walker

et al,

1991a).

Unfortunately, the toxin w a s not secreted to the growth m e d i u m , m a k i n g
this strain less than suitable as a vaccine expression system. Likely
explanations for this lack of secretion m a y include (i) the secretion of P T
in B. bronchiseptica, as it is in B. pertussis (Weiss et al, 1993), is regulated
by the bvg locus resulting in only virulent strains being capable of P T
secretion, (ii) the strain of B. bronchiseptica used does not possess the
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entire genetic machinery to secrete PT, or (iii) that it does possess P T
secretion genes, but the genes are cryptic or the gene products serve an
alternate function. If the necessary P T secretion genes are intact, the
coordinate regulation by the bvg locus m a y result in only virulent phase
B. bronchiseptica secreting the toxin. W h e n the B. pertussis P T operon
was sequenced (Locht and Keith, 1986; Nicosia et al, 1986), information
for the first 1252 base pairs of the B. pertussis ptl (pertussis toxin
liberation) operon was also obtained. The ptl operon of B. pertussis has
been s h o w n to direct the secretion of P T to the culture supernatant (Weiss
et al, 1993), a finding confirmed in part by Covacci and Rappuoli (1993),
w h o determined that P T secretion was dependent on at least one of these
genes.

The entire B. pertussis ptl operon has recently been cloned and sequenced
(Weiss et al, 1993). There w a s originally thought to be eight open reading
frames (ORFs) present in the operon, designated ptlA-ptlH (Weiss et al,
1993). Evidence for the presence of a ninth gene, ptll, has since been found
(Figure 1.7) (Farizo et al, 1996).

Partial ptl sequence data of B. parapertussis and B. bronchiseptica can be
compared to the equivalent genomic region of B. pertussis (Locht and
Keith, 1986; Nicosia et al, 1986; Weiss et al, 1993). If one focuses on the ptl
region of B. pertussis and B. bronchiseptica encompassing the first 1252
bp, including ptlA, ptlB and the first 624 bp of ptlC (Locht and Keith, 1986;
Nicosia et al, 1986; Weiss et al, 1993), there are 60 base differences in this
region. H o w e v e r

almost all of these are concentrated within

and

immediately upstream of the ptl A gene. It has been postulated that ptl A
of B. pertussis is not actually a trans-acting gene, but a cis-acting promoter
(Weiss et al, 1993). If ptlA is the promoter region, then mutations here
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Pertussis Toxin

Pertussis Toxin Liberation
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Figure 1.7

11

ini \m\

II

\-

Schematic representation of the ptx/ptl operon. Pertussis toxin subunit

genes (open boxes; S1-S5) and pertussis toxin liberation genes (shaded boxes; A-I) are
indicated. The ptx/ptl promoter (filled arrow; P wt ) is also depicted.

may render the bacterium incapable of transcribing the ptl operon. The
homology between B. pertussis and B. bronchiseptica ptlB and ptlC genes
is very high, with only 5 base differences in 924 base pairs. Fusion proteins
expressed in E. coli have been used to raise polyclonal antibodies against
the predicted PtlA, B, C, E, F, G and H proteins (Johnson and Burns, 1994).
Immunoreactive bands in western blots of B. pertussis whole cell extracts
were only detected using polyclonal antibodies against PtlE, F and G. T h e
same antibodies raised against PtlE and F failed to detect immunoreactive
bands in B. bronchiseptica whole cell extracts (Johnson and Burns, 1994).
Replacement of the B. bronchiseptica Fptx promoter with the B. pertussis
Fptx promoter results in detectable expression of PtlF in western blots
(Kotob et al, 1995). This suggested that the ptlA region is not the
promoter of the ptl operon and that Fptx actually drives the transcription
of the complete ptx/ptl region. This w a s confirmed w h e n the 11 kb
m R N A for the entire ptx/ptl operon was isolated from B. pertussis (Baker
et al, 1995). The introduction of the B. pertussis Fptx promoter into B.
bronchiseptica and B. parapertussis via homologous

recombination

results in the expression and secretion of the toxin (Hausman et al, 1996).
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1.3.2 Adenylate Cyclase Toxin/Haemolysin

The adenylate cyclase-haemolysin of Bordetella pertussis is a bifunctional
protein belonging to the R T X (repeat in toxin) family. This assemblage
also includes the m u c h studied a-haemolysin of E. coli, together with
haemolysins and leukotoxins of various pathogenic Gram-negative
bacteria including Pasteurella haemolytica, and Actinobacillus species
(Welch, 1991). Both the adenylate cyclase, and the haemolytic activities
have been s h o w n to be essential for the initiation of B. pertussis infection
(Khelef et al, 1992). Adenylate

cyclase-haemolysin

is a secreted

polypeptide chain consisting of 1706 amino acid residues (Glaser et al,
1988a), with a molecular weight of between 175 and 220 k D a (Rogel et al,
1989; Leusch et al, 1990; Gentile et al, 1990).

The adenylate cyclase activity of this protein is located within the first 400
amino acids at the amino terminal end and is activated by calmodulin
(Glaser et al, 1988a; Ladant et al, 1989). Although the high affinity of
adenylate cyclase toxin/haemoly sin for calmodulin was initially thought
to be involved in the translocation of the toxin into host cells, recent
evidence has proven this to be incorrect (Heveker and Ladant, 1997). T h e
calmodulin is however, crucial for the enzyme once inside the cell, where
it catalyses the formation of ultraphysiologic levels of cyclic A M P (Confer
and Eaton, 1982; Greenlee et al, 1982).

The remaining 1300 residues contains an independently functional
haemolysin (Glaser et al, 1988a; Sakamoto et al, 1992) a m o n g other
structurally and functionally important

domains. The

200 residue

hydrophobic region is inserted into the m e m b r a n e of target host cells as
the initial step of delivery into the eukaryotic cell (Hanski, 1994). T h e
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repeat domain of adenylate cyclase toxin/haemolysin contains 41 repeats
of the glycine and aspartic acid rich regions indicative of the R T X family.
H o m o l o g y with other R T X m e m b e r s suggest that this region is involved
in host cell recognition and calcium binding (Ludwig et al, 1988; B o e h m
et al, 1990). In fact, each repeat motif binds a single calcium ion, leading to
a major conformational change and possibly the translocation of the
catalytic portion of the molecule into host cells (Rose et al, 1995). There is
also a specialised secretion signal domain which interacts with accessory
proteins required for the entry of adenylate cyclase toxin/haemolysin into
host cells (Glaser et al, 1988b).

The gene encoding the adenylate cyclase toxin/haemolysin {cyaA) is
contained within an operon, together with a number of other factors
involved in activating and secreting the toxin (Glaser et al, 1988a) (Figure
1.8).

p
cya

cyaC cyaA cyaB D E

Figure 1.8 Operon Structure of the genes encoding adenylate cyclase
toxin/haemolysin and accessory proteins. The adenylate cyclase gene (lightly shaded box;
cya) and accessory genes (heavily shaded boxes; B, C, E) are indicated. The adenylate
cyclase gene promoter (filled arrow; Fcya) is also depicted. Sizes of promoters indicates
relative levels of transcription. Modified from Goyard et al, 1993.

Secretion will only proceed with the expression of cyaB, cyaD, and cyaE
(Glaser et al, 1988b). The final m e m b e r of the cya operon, cyaC, is required
to activate adenylate cyclase toxin/haemolysin, and is involved in post
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translational modification of the toxin (Barry et al, 1991). This protein
causes the acylation of adenylate cyclase toxin/haemolysin resulting in
the addition of a palmitoyl fatty acid residue to Lys 983 of the polypeptide
chain (Hackett et al, 1994).

Host cell invasion by adenylate cyclase toxin/haemolysin is not effec
via a receptor mediated endocytotic pathway (Gordon et al, 1989), and
instead uses a specialised calcium and temperature dependent entry
system (Hanski, 1994).

The use of a detoxified form of adenylate cyclase toxin/haemolysin in
acellular vaccine preparations has been advocated by a number of groups
(Hewlett et al, 1977; Arcinega et al, 1991; Guiso

et al, 1991).

Immunisation with adenylate cyclase toxin/haemolysin has been shown
to be protective against bacterial colonisation in animal models (Novotny
et al, 1985; Guiso et al, 1989; Guiso et al, 1991). H u m a n s infected with B.
pertussis are known to produce antibodies against adenylate cyclase
toxin/haemolysin to fight the infection (Arcinega et al, 1991). The
interaction between adenylate cyclase toxin/haemolysin and aspects of the
h u m a n immune system is currently the focus of many research groups.
Invasion and survival of B. pertussis into many different immune cells is
n o w well documented

(Saukkonnen et al, 1991; Steed et al, 1991;

Freidman et al, 1992; Masure, 1992). The inhibition of antigen dependent
T cell proliferation by B. pertussis has recently been demonstrated and
necessitates

the

presence

of

adenylate

cyclase

toxin/haemolysin

(Boschwitz et al, 1997).

The role which adenylate cyclase toxin/haemolysin plays in apoptosis
been demonstrated in vitro and in vivo in a number of different cell
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types (Khelef et al, 1993; Khelef and Guiso, 1995; Gueirard et al, 1998). It
has been proposed that this m a y be a method by which Bordetella
pertussis might escape the antibacterial effects of macrophages (Gueirard
et al, 1998). Alternatively, it could be an action facilitated by the i m m u n e
system to remove the bacteria from their possibly safer intracellular niche
and expose it to the rigours of the extracellular environment, patrolled by
killer T cells and antibodies.

1.3.3 Dermonecrotic Toxin

Although known for many years (Bordet and Gengou, 1909), this toxin
has not been as extensively studied as other Bordetella virulence
determinants. This m a y be due in part, to difficulty in the purification
process. Termed heat labile toxin because it becomes inactive at 56°C, it
was given its current n a m e due to its ability to cause necrotic skin lesions
w h e n injected subcutaneously into mice (Iida and Okonogi, 1971; Livey
and Wardlaw, 1984). This injection is lethal w h e n given intravenously.
Dermonecrotic toxins are produced by Bordetella species and are regulated
by the bvg locus (Bordet and Gengou, 1909; Endoh et al, 1986; Endoh et al,
1988; Gentry-Weeks et al, 1988). The toxin is not secreted to the
extracellular environment

and has been localised to the cytoplasm

(Cowell et al, 1979). This and its very low expression levels are probably
the major purification problems. The latest studies agree on a molecular
weight of 140 k D a and contrary to previous reports, a single polypeptide
chain (Horiguchi et al, 1990; Zhang et al, 1991). The gene encoding the B.
pertussis dermonecrotic toxin was sectionally cloned and sequenced
(Walker and Weiss, 1994). The toxin can be placed by homology and
functionality into a family of toxins including the cytotoxic necrotising
factors of E. coli, botulinum C 3 toxin and Pasteurella multocida toxin
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(Hoshijima et al, 1990; Rozengurt et al, 1990; Falbo et al, 1993; Oswald et
al, 1994). All members of this family induce dormant cells to begin D N A
synthesis, leading to either increased cell division or multinuclear cells,
as is the case with dermonecrotic toxin. Although dermonecrotic toxin is
considered

a

virulence

factor, strangely,

mutants

deficient

in

dermonecrotic toxin do not exhibit any differences in virulence in m o u s e
studies (Weiss and Goodwin et al, 1989). The exact role of dermonecrotic
toxin in the pathogenesis of B. pertussis infection is still u n k n o w n ,
however

recent technological

advances

which

have

allowed

the

purification of the toxin and the cloning of its gene m a y allow further
insight into the molecular mechanisms of dermonecrotic toxin to be
obtained.

1.3.4 Tracheal Cytotoxin

Unique among Bordetella virulence factors, tracheal cytotoxin is the only
toxin expressed in both virulent and avirulent growth phases. The major
biological activity endowed by this toxin is the damage to ciliated
respiratory epithelial cells (Cookson et al, 1989a). Tracheal cytotoxin is a
very small molecule and is actually a disaccharide-tetrapeptide derivative
of the cell wall peptidoglycan layer. The structure of this 921 D a
monomeric compound is N - acetylglucosaminyl - 1, 6 - anhydro - N acetylmuramyl - (L) - alanyl - g - (D) - glutamyl - meso - diaminopimelyl(D) - alanine (Cookson et al, 1989b). Both structurally and functionally,
tracheal cytotoxin falls into the muramyl peptide family. Gram-negative
bacteria produce a layer of peptidoglycan, however only Bordetella and
Neisseria release fragments extracellularly, in the form of m u r a m y l
peptides, normally during exponential growth (Sinha and Rosenthal,
1980; Cookson and Goldman, 1987).
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The destruction of cilia and ciliated epithelial cells by tracheal cytotoxin
causes ciliostasis and forces the infected individual to cough persistently
in order to remove m u c u s , a task ordinarily performed by ciliated cells. It
has been demonstrated that the disaccharide moiety of tracheal cytotoxin
is not required for this cytotoxicity (Luker et al, 1993). The lactyl
tetrapeptide portion of the molecule is responsible for its full toxic activity
(Luker et al, 1995). The toxicity conferred by tracheal cytotoxin is indirect,
being caused by the induction of host cells to produce interleukin-1 (Heiss
et al, 1993). This activates host cell nitric oxide synthase leading to high
levels of nitric oxide radicals (Heiss et al, 1994). It is still not certain
whether it is the tracheal cytotoxin or the interleukin-1 which stimulates
nitric oxide synthase. The nitric oxide acts by destroying iron dependent
enzymes, eventually

inhibiting

mitochondrial

function

and

DNA

synthesis in nearby host cells (Heiss et al, 1993). Since Bordetella pertussis
is attached to the ciliated epithelial cells, it is these which undergo the
most damage. Tracheal cytotoxin also has a toxic effect on other cells,
impairing neutrophil function at low concentrations and conferring toxic
activity in larger quantities (Cundell et al, 1994). The production of
tracheal cytotoxin by B. pertussis evolutionary, m a y have been merely as
a by-product or breakdown product of peptidoglycan manufacture,
however it is n o w an integral component in the pathogenesis of B.
pertussis infection.

1.3.5 Filamentous Haemagglutinin

The critical step in Bordetella pertussis infection is attachment of the
pathogen to host cells. The filamentous haemagglutinin ( F H A ) (Figure
1.9) is consistently referred to as the major adhesin of this bacterium. It is
a 220 k D a surface associated protein

secreted to the extracellular
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environment to facilitate adherence to ciliated respiratory epithelial cells,
thereby initiating the pathogenic cycle.

FHA has a filamentous structure, supported by electron microscopy
studies giving the dimensions of the molecule as 2 n m wide and 45-50
n m long (Arai and Sato, 1976; Makhov et al, 1994). A n extensive study by
Makhov and coworkers (1994) has revealed the structure of F H A to be a
polypeptide chain folded into a monomeric hairpin (Figure 1.9). The
hairpin comprises head, shaft and tail regions. Whilst the head contains
the N and C termini, and the tail the important R G D sequence, the shaft
is composed of tandem 19-residue repeat regions Rl (38 cycles) and R2 (13
cycles) which maintain the structural integrity of the molecule.

This protein is unusual in a number of respects. Firstly, the gene for
fhaB has a coding potential of 367 kDa (Delisse-Gathoye et al, 1990;
Domenighini et al, 1990). The precursor protein, FhaB, is later cleaved in

Heparin Binding Domain

Figure 1.9

Diagrammatic

representation

of the

model

of the

mature

FHA

polypeptide, illustrating the hairpin structure and the positioning of repeat regions. The
R G D site implicated in integrin binding is also shown. Modified from Makhov et al., 1994;
Brennan and Shahin, 1996.
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a

complex

post-translational

maturation

process.

Filamentous

haemagglutinin also possesses a n u m b e r of possible binding sites and
functions. A

further interesting point about F H A is the level of

regulation involved in producing and secreting the polypeptide.

Binding Activities
The different domains of F H A (Figure 1.10) encompass various binding
capabilities, including

integrin mediated

attachment

to phagocytes,

lectin-like binding to sulfated sugars found in the extracellular matrix
( E C M ) and epithelial cells, and a carbohydrate recognition domain which
allows attachment to ciliated cells present in the respiratory epithelium.
The main target binding site for B. pertussis is the ciliated epithelium of

Region
required for
export

Protease
sensitive site

Maturation site

TjX - X "

i
Signal
peptide

Figure 1.10

\ i \
A
repeats

M.
i

B
repeats

Proline rich
repeats

II

I m m u n o dominant
region

The domain structure of the precursor molecule, FhaB demonstrates the

complexity of F H A . The precursor must undergo a cleavage at the maturation site to
release the mature protein (black rectangle). The signal peptide (checked box) is shown, as
is the region that exhibits homology to ShlA and H p m A (filled box). Both sets of repeat
regions (A, thick striped boxes; B, thin striped boxes) are indicated. Proline rich repeat
units are designated. The immunodominant region is represented by the lightly shaded
box. There is also a site which is easily degraded by proteases. The R G D site is also
shown. Modified from Locht et al., 1993.
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the respiratory tract (Tuomanen and Weiss, 1985). Attachment to cells in
this region is mediated by the carbohydrate binding capacity of FHA

(Tuomanen et al, 1988; Relman et al, 1989), which has a unique affinity

for glycolipids and ciliated cells (Prasad et al, 1993). This carbohydr
recognition domain was narrowed down to amino acid residues 1141 to

1279 using monoclonal antibodies (Prasad et al, 1993). Recent studies o

this region have enabled high level, soluble expression in E. coli and

further characterisation of this 18 kDa polypeptide, designated fragme
(Liu et al, 1997). Anti-fragment A antibodies were shown to inhibit

binding of B. pertussis to ciliated rabbit cells in the same fashion a

antibodies elicited by whole FHA, raising speculation that with furthe
investigation, the more easily obtained fragment A may replace FHA in
component vaccines against whooping cough (Liu et al, 1997).

The heparin binding activity of FHA may allow B. pertussis to bind to

non-ciliated cells as demonstrated using WiDr cells, HeLa cells, and V

cells (Urisu et al, 1986; Sato et al, 1981) or perhaps facilitate extr
matrix interactions. The lectin-like binding of FHA to heparin and
dextran sulfate was characterised when it was shown that binding to

epithelial cells could be inhibited by the addition of heparin (Menozz
al, 1994). Hannah and associates (1994) extended this research by

revealing that FHA also binds specifically to sulfated, but not unchar
glycolipids and mapped the heparin binding domain to residues 442-863
of the amino terminal end of FHA.

The tail region of FHA includes a binding moiety specific for compleme

receptor type 3 (CR3, aMp2, CDllb/CD18) integrins present on the surfa
of macrophages (Relman et al, 1990). FHA contains an RGD (arginineglycine-aspartic acid) sequence which is present in a number of other
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bacterial adhesins and is a region of attachment in m a n y eukaryotic
integrin binding proteins (Ruoslahti and Pierschbacher, 1986; Hynes,
1982). It has been determined that it is this R G D tripeptide which
facilitates binding to C R 3 (Relman et al, 1990). B. pertussis m a y use this
protein as a dock, which m a y initiate entry into phagocytes without the
associated oxidative burst. It has since been shown that the binding
process involves

the formation of a leukocyte signal transduction

complex which upregulates C R 3 binding activity, suggesting that F H A
could regulate the binding activity of its o w n receptor. This complex is
composed of a receptor protein called leukocyte response integrin (LRI)
and integrin-associated protein (CD47) (Ishibashi et al, 1994). These
authors suggest that the carbohydrate/glycoconjugate binding capacity of
F H A m a y also be involved in the primary stages of the CR3-LRI-CD47
complex formation. This hypothesis was formulated using the example of
leukocyte-endothelial

cell recognition

(Butcher, 1991) whereby

a

transitory state of attachment is mediated by lectins and this w e a k
connection is strengthened by CR3-dependent binding. Hazenbos and
associates found that a macrophage surface fibronectin receptor, very late
antigen-5 (VLA-5) m a y also be involved and proposed that binding and
cross-linking of VLA-5

by B. pertussis activates CR3, facilitating

attachment to F H A (Hazenbos et al, 1993). Further study led to the
finding that VLA-5 was acting as a ligand for the minor fimbrial subunit
F i m D (Hazenbos et al, 1995b). These authors suggest that fimbriae and
F H A m a y act cooperatively to bind to macrophages, leading to uptake and
intracellular survival.

The advantages gained by B. pertussis in binding to "professional
phagocytes" are concerned with evasion of the i m m u n e system and m a y
be threefold. Severing cellular communication links to phagocytic cells by
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obstructing a vital receptor site (CR3, VLA-5 or C4BP) m a y reduce the
impact of the i m m u n e system. Secondly, by attaching to CR3, B. pertussis
has taken the preliminary step in entry and persistence in phagocytes, and
"hand-to-hand combat" using C R 3 as a site from which to deliver
bacterial toxins at close range m a y kill macrophages and neutrophils
more economically (Saukkonen et al, 1991; Steed et al, 1991). Finally, a
recent addition to the B. pertussis versus h u m a n i m m u n e system story is
the finding that F H A binds the serum protein C4BP (Berggard et al, 1997).
This protein is k n o w n as a regulator of complement activation and acts to
inhibit the classical complement pathway, ceasing the formation of the
m e m b r a n e attack complex. Whether B. pertussis is able to utilise this
binding capacity remains unclear, but once again demonstrates the extent
and complexity with which B. pertussis interacts with our

immune

system.

Genetic Regulation and Biogenesis
Being a virulence determinant of Bordetella pertussis, F H A undergoes a
high level of genetic regulation. The bvg locus controls the expression
from fhaB

depending on the prevailing environmental

conditions.

W h e n B. pertussis is in suitable conditions for colonisation, F H A is one
of the first proteins produced, detected in a matter of minutes (Scarlato et
al, 1991). The chromosomal geography of the genes encoding B v g A S and
F H A m a y be a factor in this fast reaction time. They are physically
adjacent, further suggesting direct interaction between B v g A and fhaB.
(Stibitz et al, 1988). Production of F H A

is also dependent on the

expression of at least one accessory protein, FhaC, the gene for which lies
downstream of fhaB in a cluster of accessory genes involved in the export
of both F H A and fimbriae (Figure 1.11) (Locht et al, 1992; Willems et al,
1992). The outer membrane protein FhaC is thought to interact with F H A
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allowing for secretion of the adhesin (Willems et al, 1994). A s the role
played by F H A in the pathogenesis of whooping cough becomes m o r e
clear, more as yet undiscovered factors (Jacob-Dubuisson et al, 1996)
involved in the expression and secretion of F H A m a y be found.

Post Translational Maturation
The D N A

sequence of the structural gene fhaB

was determined

independently by two groups (Delisse-Gathoye et al, 1990; Domenighini
et al, 1990). The gene consists of approximately 10.1 kb and encodes a large
protein of 367 kDa termed FhaB. This precursor must undergo a series of
modifications which are still only partially understood before mature
F H A is secreted to the extracellular environment.

Toward the N-terminus of FhaB lies a domain of approximately 115
residues, bearing homology to regions of the haemolysins of Serratia
marcescens and Proteus mirabilis, and which are required for secretion of
these proteins (Delisse-Gathoye et al, 1990). Secretion of each of these
proteins is also dependent on the presence of a homologous accessory
protein (FhaC in B. pertussis) (Willems et al, 1994). A n FhaC-like outer
membrane protein, H M W B

has since been found in

Haemophilus

influenzae, where its function is also to aid in the export of an adhesin,
HMWA

(Barenkamp and St G e m e , 1994). The precursors of F H A and

HMWB

share an extra region of homology comprising 22 amino acid

residues, followed by a positively charged region and a hydrophobic
segment. This acts as an atypical signal peptide and is cleaved from the
molecule prior to export (Delisse-Gathoye et al, 1990). The C-terminal
third of the precursor protein is also removed leaving mature

FHA

comprising the N-terminal 220 kDa of FhaB. Although not part of the
mature protein, the C-terminal plays an important role in secretion
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(Renauld-Mongenie et al, 1996) possibly as a type of intramolecular
chaperone to stabilise the protein and prevent incorrect folding, allowing
the required secretory interactions to proceed. The latest model of F H A
export put forward by Jacob-Dubuisson et al. (1996), involves the H M W A
homologous N-terminus of FhaB binding to a "pilot" protein which
transports the precursor to the translocase on the inner membrane. T h e
unusual signal peptide is then cleaved as the protein is translocated to the
periplasmic space. The 115 residue, haemolysin-homologous

domain

then interacts with FhaC. A s the N-terminal portion is passing across the
outer membrane, the 150 k D a C-terminal section can be cleaved liberating
mature F H A , which then folds into the rigid hairpin structure (Figure 1.9)
proposed by M a k h o v et al. (1994).

1.3.6 Serotype Specific Fimbriae

Fimbriae, also known as pili and agglutinogens, are long filamentous
protrusions which extend from the bacterial cell surface and facilitate a
variety of binding capabilities. The fimbriae of B. pertussis incorporate
both major and minor subunits. The major subunits form the fimbrial
strand, being grouped into pentameric repeat units, each 13 n m in length
and comprising 2 full helical turns (Steven et al, 1986). This finding has
been supported and extended by more recent research (Heck et al, 1996)
which also obtained an accurate value of 5.7 n m for the diameter of B.
pertussis serotype 3 fimbriae.

Bordetella pertussis produces two distinct types of fimbriae, serotype 2 and
serotype 3 (also called serotype 6). These are constructed using major
subunits, expressed from the fiml and fim3 genes respectively, and minor
fimbrial subunit, encoded by fimD (Willems et al, 1992; Locht et al, 1992).
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Major subunits are stacked to form the long filamentous structure
characteristic of fimbriae and the minor subunit is located at the tip
(Geuijen et al, 1997).

Major Subunits
The major fimbrial subunits which form the structural helices, Fim2 and
Fim3 are small proteins of 22 k D a and 22.5 k D a respectively. The fiml and
fim3 genes which encode these proteins have both been cloned and
sequenced (Livey et al, 1987; Mooi et al, 1990) and exhibit considerable
homology at both the nucleotide and amino acid level. T w o other
pseudogenes related to the major fimbrial subunits have also been found
in Bordetella pertussis, fimX and fimA

(Pedroni et al, 1988; Willems et

al, 1992). The fimX gene encodes for a protein of approximately 20 kDa
which is expressed at very low levels if at all (Riboli et al, 1991). Using
C A T fusion assays, these authors were able to demonstrate transcription
from the fimX promoter in B. bronchiseptica, also showing that it was
bug-regulated. The other silent fimbrial gene, fimA, is located in the
cluster of fimbrial and F H A accessory genes (Figure 1.11) (Willems et al,
1992). This is a region of D N A with sequence homology to fiml, fim3 and
fimX, however the 5' end of the gene corresponding to the N-terminal
region of F i m A is not present in B. pertussis. Recently, it was found that
B. bronchiseptica expresses a fully intact version of F i m A (Boschwitz et
al, 1997). The low level expression of F i m A seen in B. bronchiseptica is
bug-regulated. It has been postulated that the two functional major
fimbrial subunit genes and the pseudogene fimX m a y have arisen via
gene duplication. The discovery of fimA,

its chromosomal

location

within the fimbrial operon, and its viability in B. bronchiseptica suggest
that fimA m a y actually be the original, ancestral major fimbrial subunit
from which fiml and fim3 arose (Willems et al, 1992; Boschwitz et al,
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1997).
fimD
fhaB

Figure 1.11

fimA

fimB

fimC

.

fhaC

Diagrammatic representation of the fim/fha gene cluster. Names are

given above genes. Genes involved in F H A production are shown in shaded boxes and those
involved in fimbrial production are shown in open boxes. Modified from Willems et al,
1994

Since the discovery of the minor subunit and adhesin FimD, the role of
the major subunits in adherence has been somewhat downgraded to
them almost being regarded as merely the scaffolding on which sits the
important adhesin molecule. Recently it has been shown however, that
the major fimbrial subunit has an affinity for sulfated sugars (Geuijen et
al, 1996), an ability shared by the other principal adhesin molecule,
filamentous

haemagglutinin. The association between B. pertussis

fimbriae and derivatives of heparan sulfate is highly dependent on both
the number of sulfate groups present and their placement around the
disaccharide molecule (Geuijen et al, 1996). The localisation of two
heparin binding regions (HI and H 2 ) has since been fully characterised
(Geuijen et al, 1998). These regions share sequence and structural
homology

to each other and to similar heparin binding sites of

fibronectin, a eukaryotic signalling molecule.

The major antigenic domains present on Fim2 and Fim3 fimbriae have
been identified using monoclonal antibodies to screen various synthetic
peptides (Pearce et al, 1994). These epitopes were again confirmed as
highly immunogenic w h e n they were exposed to, and recognised serum
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antibody from, whooping cough infected patients (Williamson

and

Matthews, 1996). A number of these antigenic epitopes in fact correspond
to the recently identified heparin binding domains (Geuijen et al, 1998).

Minor Subunit and Accessory Proteins
The other genes found in the fimbrial cluster (Figure 1.11) are designated
fimB,fimC, and fimD (Willems et al, 1992; Locht et al, 1992). Both these
studies performed homology searches on the proteins predicted by the
newly discovered operon and found similarities to proteins essential for
fimbrial biogenesis in both
pneumonia

Escherichia coli (Pap) and Klebsiella

(Mrk). The genetic organisation of the entire cluster /operon

is very similar to the mrk operon (Allen et al, 1991), perhaps suggesting a
c o m m o n origin. Another similar fimbrial gene cluster has also been
found in Haemophilus influenzae type b (van H a m et al, 1994). A n even
greater level of homology to fimB, fimC and fimD

is demonstrated by

these hif genes. The most interesting aspect of this report was the
inference that the entire cluster represents an ancestral mobile genetic
element and was originally inserted via a transposition event. This was
suggested because, in the regions flanking the cluster, was m a d e the
discovery of repetitive extragenic palindromic (REP) sequences and the
remnants of a duplicated section of the unrelated pur operon. These two
genetic phenomena taken together are indicative of the occurrence of
transposition. Using this as a hypothesis, w e can imply that the ancestral
Bordetella, Haemophilus,

and Klebsiella species m a y have

obtained

fimbrial genes from one another.

The predicted amino acid sequence of FimB is homologous to the PapD
superfamily of periplasmic chaperones (Locht et al, 1992; Willems et al,
1992). A putative signal peptide sequence probably directs the newly
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translated FimB to the periplasm, where the signal sequence is cleaved,
leaving a mature polypeptide of approximately 24 kDa (Locht et al, 1992;
Willems

et al, 1992). Southern

hybridisation of B. pertussis,

B.

parapertussis and B, bronchiseptica disclosed regions homologous to fimB
(Willems et al, 1992) in these closely related species, suggesting that all
three m a y utilise a similar process to escort fimbrial proteins to the cell
surface.

FimC is a protein with predicted homology to many outer membrane
fimbrial accessory proteins, including PapC, M r k C and HifC all of which
are essential for the biogenesis of fimbriae in their respective organisms.
The molecular weight of this predicted protein is approximately 91 kDa
(after signal peptide cleavage) (Locht et al, 1992; Willems et al, 1992).
Based on homology, it was proposed that FimC is probably located in the
outer membrane, involved in fimbrial transportation and anchorage
(Locht et al, 1992; Willems et al, 1992).

Much of the more recent research into the fimbriae of B. pertussis has
concentrated on the minor fimbrial subunit and primary adhesin, FimD.
Lying directly upstream of fimC, the fimD

gene encodes a fimbrial

adhesin protein with a molecular weight of approximately 40 kDa
(Willems et al, 1993). Like its genomic neighbours, fimD

exhibits

homology to genes in the fimbrial clusters of H. influenzae (hifE), K.
pneumoniae (mrkD) and E. coli (fimH) (Klemm and Christiansen, 1987;
Gerlach et al, 1989; Locht et al, 1992; Willems et al, 1992; van H a m et al,
1994). A fimD

homologue is also present in B. parapertussis and B.

bronchiseptica (Willems et al, 1993). In fact, the corresponding gene in B.
bronchiseptica only differs by a single, albeit non-silent base pair change.
There are 20 different amino acids in the FimD polypeptide of B.
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parapertussis resulting from 34 base pair differences.

This sequence data is evidence that FimD is not involved in Bordetella
host specificity and that the similar F i m D adhesins of B. pertussis and B.
bronchiseptica m a y interact with receptors which are highly conserved
between m a m m a l s and humans. The differences present in the F i m D
adhesins of B. pertussis and B. parapertussis m a y create an evolutionary
advantage for both by eliminating binding site competition while sharing
the same host.

Binding studies involving fimbrial mutant strains lacking FimD have
demonstrated that Bordetella pertussis binds to h u m a n monocytes via
F i m D (Hazenbos et al, 1995a). K n o w n to interact with B. pertussis
fimbriae, VLA-5 has since been confirmed as the F i m D receptor on the
surface of monocytes (Hazenbos et al, 1995b). The construction of what
the authors call "true" fimbrial mutants, devoid of both major and minor
fimbrial subunits allowed further investigation (Geuijen et al, 1997). A
mouse colonisation procedure was utilised to show that F i m D plays a
vital role in colonisation. The Fim2"/3"; FimD" mutant colonised the
lungs and trachea of mice significantly less efficiently than wild type,
F H A - mutant, and Fim273"; F i m D + mutant strains (Geuijen et al, 1997).
These researchers also demonstrated the binding of F i m D to the sulfated
sugar heparin, also a possible target molecule for F H A and major fimbrial
subunits (Menozzi et al, 1991; Menozzi et al, 1994; Geuijen et al, 1996).

Genetic Regulation
Like filamentous haemagglutinin, fimbrial expression in B. pertussis is
regulated at a number of levels. A virulence factor employed to enable
the bacteria to attach to host cells, the expression of fimbriae is controlled
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by the bvg locus. The correct processing and secretion of fimbrial subunits
however, requires the expression of a number of accessory genes, which
are located in the fimbrial operon (Figure 1.11). B. pertussis produce two
distinct fimbriae: serotype 2 and serotype 3. S o m e strains (serotype 2,3)
express both simultaneously

(Ashworth et al, 1982). The serotype

expressed depends on the level of transcription of fimbrial major subunit
genes. Alteration of serotype involves switching promoter activation
between the two fimbrial subunit genes in a process termed fimbrial
phase variation (Willems et al, 1990). The genes encoding the major
fimbrial subunits, fiml and fim3 with which the fimbriae are constructed,
have been fully characterised (Livey et al, 1987; Mooi et al, 1990) as have
the homologous but transcriptionally inactive fimX

and fimA

genes

(Pedroni et al, 1988; Locht et al, 1992; Willems et al, 1992). Sequence data
has revealed a high level of homology between all of these genes which
extends into the promoter regions, unveiling some interesting features of
fimbrial promoter architecture (Figure 1.12).

The most noticeable aspect of the fimbrial promoters is the "C stretch", a
long run of cytosine residues which has been implicated in fimbrial phase
variation (Willems et al, 1990). Insertion or deletion of extra cytosine
residues in this C stretch is the source of fimbrial phase variation
(Willems et al, 1990). It is thought that the distance between the putative
-10 box and the activator (BvgA) binding site is vital for transcriptional
activation, and the alteration in the number of C's in the stretch changes
this distance (Willems et al, 1990). The reason for the lack of transcription
from the fimX pseudogene m a y be the short C stretch in the promoter
region.
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CTGTTTCCCACATCGGAATCAGCCCTCCCCCCCCCCCCTAAGACCTAAGATCGTGGCTCCATAA fim2 (W28)
CTGTTTCCCACATCGGAATCAGCCCCCCCCCCCCCCCCTAAGACCTAAGATCGTGGCTCCATAA fim2 (BPSAl)

CAAATTCCCACACAACCATCAGCCCTCCCCCCCCCC-GGACCTGATATTCTGATGCCGACGCCA fim3 (W28)
CAAATTCCCACACAACCATCAG^^^CCCCCCCCCC-GGACCTGATATTCTGATGCCGACGCCA fim3 (BPSAl)

CAAATTCCTACACATCCATCAGCCCCCCC GAGGCGTCTAATAATCTTGCACACA fimX (Tohama)
CAAATTCCTACACATCCATCAGCCCCCCC GAGGCGTCTAATAATCTTGCACACA fimX (BPSAl)

Figure 1.12 Promoter regions of the three fimbrial genes found in B. pertussis. The -10
boxes and putative activator (BvgA) binding sites are indicated in bold. Dashes have been
introduced to increase homology. Differences between strains in the equivalent promoter
regions are underlined. The strain from which each sequence was derived is named in
parentheses. Sequence oifiml (Wellcome 28 strain) is from Livey et al. (1987). Modified
from Willems et al, 1990 and Ribolief al, 1991.

The expression of the minor subunit genes, or accessory genes is also

required for the correct delivery and presentation of B. pertussis fimbri

at the cell surface (Locht et al, 1992; Willems et al, 1992). A mutational
analysis of the fim/fha gene cluster has provided evidence that fimC,
fimD, and fhaC are translationally linked (Willems et al, 1993). These
three genes overlap slightly and there is a putative ribosome binding,

Shine Dalgarno site directly ahead of the first gene of the triplet, fimC
Further evidence to support this is the hairpin loop structure formed by
the mRNA just prior to the end of the fimC gene (Willems et al, 1993).
The translation of fimD may require the complete translation of fimC,
thereby preventing the construction of the hairpin loop and permitting
continuous ribosomal attachment and translation of fimD (Willems et
al, 1993).
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1.3.7 Pertactin

Also known by the aliases p.69 and OMP 69 because of its presumed
molecular weight from electrophoretic mobility in S D S P A G E , pertactin is
actually a 60 k D a outer m e m b r a n e

protein involved

in bacterial

adherence (Makoff et al, 1990; Leininger et al, 1991). Similar molecules
are produced by other members of the genus, p.70 in B. parapertussis (Li et
al, 1990) and p.68 in B. bronchiseptica (Montaraz et al, 1985).

The crystal structure of pertactin has been elucidated, revealing a 16
stranded parallel p-helix with a V-shaped cross section (Emsley et al,
1996).

The

secondary

structure

of

pertactin

contains

two

i m m u n o d o m i n a n t direct repeat regions. The first, (Gly.Gly.Xaa.Xaa.Pro)s
is located directly after the important R G D tripeptide and the other,
(Pro.Gln.Pro)5 thought to be the major immunoprotective epitope, lies
toward the C-terminal end (Charles et al, 1988; Charles et al, 1991).

Pertactin is transcribed from the prn gene, which encodes a 93.5 kDa
polypeptide comprising 910 amino acids (Charles et al, 1988). This
precursor, termed p.93, later undergoes the removal of a 34 amino acid N terminal signal peptide (Makoff et al, 1990) and cleavage of a 30 k D a
polypeptide (p.30) from the C-terminus. Although the precise role of p.30
is unclear, it is detected in outer m e m b r a n e fractions and is likely to be
involved in the export of pertactin to the outer m e m b r a n e (Charles et al,
1994). In a comparison of the prn gene sequences of B. pertussis, B.
parapertussis and B. bronchiseptica, the precursors of the pertactins were
found to be extremely homologous and interestingly, the most highly
conserved region is the C-terminal, suggesting the importance of p.30 to
these organisms (Li et al, 1992).
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The mechanism by which pertactin promotes adherence to eukaryotic
cells is u n k n o w n

and no receptor has been found. The amino acid

sequence revealed an arginine-glycine-aspartic acid ( R G D ; 225-227) motif,
a k n o w n integrin binding moiety present in m a n y bacterial adhesins such
as F H A , and eukaryotic extracellular matrix ( E C M ) proteins including
fibronectin and vitronectin (Relman et al, 1990; Hynes, 1987). It is easy to
assume that this region facilitates binding to m a m m a l i a n cells. Mutants
deficient in pertactin expression adhered 30-40% less well to

CHO

(Chinese hamster ovary) cells and H e L a cells (Leininger et al, 1991).
Synthetic peptides containing R G D derived from pertactin were found to
inhibit pertactin binding to epithelial cells and reduce B. pertussis entry
into H e L a cells (Leininger et al, 1991; Leininger et al, 1992). However, a
recent study has found no role for pertactin as a mediator of invasion
(Everest et al, 1996). These researchers used site-directed mutagenesis
(aspartic acid to glutamic acid) to obtain a pertactin molecule with an R G E
site rather than R G D . Strains expressing the mutation

displayed n o

difference in their ability to promote adhesion to HEp-2 or C H O cells.
Most of the studies performed on this intriguing protein have used either
heterologous bacterial species or mutated B. pertussis strains in the so far
fruitless search for its role in the pathogenesis of disease. It would be
advantageous that the role of pertactin in wild type B. pertussis be
determined, leading to a greater understanding of whooping cough and
the vaccines which prevent it.

Expression of pertactin in wild type B. pertussis is very low, hence
production to high levels for use in vaccines is currently a goal of m a n y
laboratories. M a n y

strategies have

been used to achieve

including expression in E. coli (Makoff et al, 1990); in
typhimurium

this

aim

Salmonella

aro mutants (Strugnell et al, 1992); in the industrial yeast

50

Pichia pastoris (Romanos et al, 1991); in recombinant B. pertussis strains
(Loosmore et al, 1995); and in a baculovirus-based expression system
(Charles et al, 1993).

It has been demonstrated by a number of groups that pertactin is an
immunoprotective antigen, being used in subunit and live oral vaccines
to protect mice from respiratory challenge with virulent B. pertussis
(Shahin et al, 1990; R o m a n o s et al, 1991; Novotny et al, 1991; Strugnell et
al, 1992; Roberts et al, 1993). M a n y h u m a n vaccine trials suggest the
inclusion of pertactin in future preparations is imperative. Although the
role of pertactin in vaccine based immunoprotection

is u n k n o w n ,

preparations including pertactin have attained promising vaccine efficacy
results (Marwick, 1996; Poland, 1996). Recently, the Dutch whole cell
vaccine has come under fire as the incidence of whooping cough rose in
The Netherlands despite high immunisation rates. The cause was traced
to mutations in the B. pertussis strains circulating in the community.
Mutations in the genes encoding pertussis toxin and pertactin were
discovered, indicating the importance of these proteins in eliciting
protective immunity (de Melker et al, 1997; Mooi et al, 1998).

1.3.8 Lipopolysaccharide

The lipopolysaccharide (LPS) molecule of Bordetella pertussis is smaller
than m a n y other bacterial LPS structures and is therefore often referred to
as a lipooligosaccharide (LOS). The role which

LPS plays in the

pathogenesis of B. pertussis infection is unclear, however biological
activities

exhibited

by

B. pertussis LPS

include

antigenic

and

immunomodulating properties ( A m a n o et al, 1990; Watanabe et al,
1990). The most c o m m o n

action associated with LPS is the potent
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endotoxin activity (Chaby and Caroff, 1988).

Present in most Gram negative bacteria, LPS generally comprises lipid A,
core oligosaccharide and a long polysaccharide O antigen. The structure of
LPS molecules expressed at the surface of Bordetella species varies greatly.
The structure of B. pertussis L P S deviates from the n o r m in that it lacks
the O antigen. Bordetella pertussis actually produces two types of LPS,
designated A and B (Peppier, 1984). These molecules possess differing
electrophoretic mobilities due to the presence of an extra trisaccharide
moiety on LPS-A (Caroff et al, 1990). All of the species of Bordetella
express different LPS molecules, which m a y be a factor in the high level
of species specificity demonstrated within this Genus (van den Akker,
1998). Bordetella parapertussis strains isolated from h u m a n s and sheep
display distinct LPS profiles (van den Akker, 1998) adding to the host
specific features of this species (Porter et al, 1995; van der Zee et al, 1996).
The LPS produced by B. bronchiseptica is similar to that of B.
parapertussis, as they both express temperature dependent O antigen (Di
Fabio et al, 1992; van den Akker, 1998). The charged O antigen of B.
bronchiseptica is thought to be the element which confers protection
against antimicrobial peptides since B. pertussis, which lacks O antigen, is
not protected (Baneman et al, 1998). B. bronchiseptica also produces host
specific LPS

molecules, with

isolates from

dogs

having

more

heterogeneous LPS structure than isolates from pigs (van den Akker,
1998). A h u m a n isolate of B. bronchiseptica displays a different L P S profile
than that of a rabbit isolate (Le Blay et al, 1997; Gueirard et al, 1998).
Subsequent isolation of B. bronchiseptica from the same patient over two
years has s h o w n a variation in LPS profiles during the course of infection
(Gueirard et al, 1998).
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Transposon mutagenesis has allowed the identification of a huge gene
cluster encoding LPS biosynthesis in B. pertussis (Allen and Maskell,
1996). M a n y of these genes are similar to polysaccharide and LPS synthesis
genes present in other bacteria, however the B. pertussis LPS operon is
arranged in a unique manner (Allen and Maskell, 1996).

Unfortunately, our knowledge of the Bordetellae LPS remains limited
and further research is necessary before w e are able to define the
involvement of this molecule in both the pathogenesis of diseases caused
by this Genus, and the immunogenicity and adjuvanticity of vaccines
targeted against those diseases.

1.3.9 Tracheal Colonisation Factor

Originally discovered with the aid of a transposon mutated strain which
was deficient in four outer m e m b r a n e proteins (Finn et al, 1991), tracheal
colonisation factor is a b^g-regulated protein, exclusively produced
a m o n g the Bordetellae by B. pertussis. The gene encoding tracheal
colonisation factor, tcfA was first m a p p e d using a TnphoA

insertional

mutation and was termed virulence activated gene #34 (vag 34) (Finn et
al, 1991). The original TnphoA mutants were ten fold less able to colonise
and

persist in the trachea of mice, but were not significantly

disadvantaged in the lungs (Finn and Stevens, 1995). The tcfA gene has
n o w been cloned and sequenced, with the derived amino acid sequence
predicting a 68.6 k D a precursor, the first 39 amino acids of which comprise
a likely signal peptide, leaving a 64.4 kDa protein (Finn and Stevens,
1995). The C-terminal half of tracheal colonisation factor exhibits over
5 0 % homology to the C-terminal of the precursors of the pertactins of
Bordetella species, including the Lys-Arg putative proteolytic cleavage
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site. Another Bordetella protein, the serum resistance factor BrkA also
possesses a C terminal with significant homology to that of tracheal
colonisation factor (Fernandez and Weiss, 1994). The N-terminal half of
tracheal colonisation factor contains 3 R G D motifs and has a surprisingly
high 16.5% proline content, which m a y affect migration in S D S P A G E
gels, perhaps explaining the discrepancy between the predicted 68.6 k D a
protein and the presumed -90 k D a seen in P A G E gels (Finn and Stevens,
1995). This demonstrates another similarity to pertactin and the authors
have hypothesised that the maturation

processes between the two

proteins m a y also share c o m m o n features. Thus, their model of tracheal
colonisation factor secretion involves the precursor molecule (68.6 kDa)
being transported to the periplasm after the cleavage of the typical signal
peptide. The remaining 64.4 k D a precursor is then translocated across the
outer m e m b r a n e , like pertactin, assisted by its o w n C-terminal region.
Cleavage at the Lys-Arg proteolysis site then occurs, liberating the mature
34 k D a tracheal colonisation factor protein. A s a consequence of the
limited research literature on tracheal colonisation factor, the elucidation
of the exact role played by this protein in the pathogenesis of pertussis
will require subsequent scientific scrutiny.

1.4 Whooping Cough Vaccines:
Past Indiscretions, Recent Trials and
Future Directions
Humankind has eternally struggled with the blight of pathogenic
microorganisms. The most successful prophylactic treatment

against

disease to date has been immunisation. The complete eradication of
smallpox w a s achieved

using an extensive

worldwide

vaccination

program and m a n y other diseases have been controlled by immunisation,
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including diphtheria, tetanus, measles, polio, tuberculosis and whooping
cough. Recent data suggests that m a n y of these diseases are reemerging.
A s expected, developing countries have high incidences of these and
m a n y other preventable diseases because the costs of immunisation are
prohibitive. W h o o p i n g cough has returned to the fore in m a n y western
countries recently. Interestingly, this is not because of the cost or the
accessibility of vaccination, but mainly due to a trend in public opinion
that has led to a decrease in immunisation rates.

1.4.1 Whole Cell Vaccines

When Bordetella pertussis was identified as the microbe which caused
whooping cough (Bordet and Gengou, 1906) vaccination against this
scourge became an immediate priority (Evans and Maitland, 1937). Killed
whole B. pertussis cells were found to be protective in a number of
studies and whole cell preparations were manufactured for h u m a n use
quite early this century (1914 in the U S A and 1920 in Australia). These
vaccines were crude, and efficacy and reactogenicity testing was not very
sophisticated so it was not until the 1940's and 1950's that whole cell
pertussis vaccines were routinely used in government

immunisation

programs in these and other countries.

With the advent of such vaccination regimes, the incidence of whooping
cough in western countries decreased dramatically. With a vaccine
efficacy consistently quoted at between 8 0 % and 100%, and immunisation
rates upwards of 8 0 % of the population, the disease was virtually wiped
out in m a n y

countries. This situation remained

unchanged

probably the

1970's w h e n

and

medical

practitioners

the

until
public

(particularly in the United Kingdom) became aware of allegations about
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the vaccine causing brain damage. Vaccine coverage in the U K dropped
almost instantly from 8 0 % to below 3 0 % and whooping cough resumed
the epidemic proportions of pre-immunisation days. Unfortunately this
unconfirmed, media driven hysteria slowly filtered out to the rest of the
western world, reducing worldwide public acceptance of whole cell
pertussis vaccines and causing an increase in the incidence of whooping
cough.

Side effects
The mild side effects k n o w n to be caused by pertussis immunisation can
be categorised into two classes. Local side effects occur at the site of
injection and include erythema, tenderness and swelling. This occurs in
up to 5 0 % of vaccinees (Cherry et al, 1988). Systemic reactions such as
fever, vomiting, diarrhoea and general irritability are also very c o m m o n
(Cherry et al, 1988).

More severe side effects including febrile seizures, atypical high-pitched
crying and persistent screaming occur far less frequently at ~ 3 % (Cody et
al, 1981; Feery et al, 1985). Convulsions and hypotonic-hyporesponsive
episodes have also been associated with pertussis vaccination but only
occur in approximately 0.06% of vaccinees (Harris et al, 1995).

Contrary to popular folklore, whole cell pertussis vaccines do not cause
infantile spasms (Cherry et al, 1989), sudden infant death syndrome (Beal,
1990) or epilepsy (Howson and Fineberg, 1992). Another unfortunate side
effect attributed to these preparations is the alleged association with
encephalopathy and death. These "symptoms" occur so rarely that it is
very difficult to prove that either can be connected to the vaccine. This
has been the topic of m a n y law suits in the U S A and in the U K (reviewed
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in Griffith, 1989). The extreme rarity of these events will ensure that this
conundrum is never fully resolved one w a y or the other.

The current Australian pertussis vaccine is an aluminium phosphate
adsorbed whole cell preparation manufactured by C S L Ltd. This highly
efficacious preparation is usually administered as a component of the
D T P "Triple Antigen®" intramuscular injection given to infants at 2, 4, 6
and 18 months of age as recommended by the National Health and
Medical Research Council. This vaccine can cause mild to moderate side
effects, documented by Feery (1985) as local reaction at the site of injection
(-50%), fever (-20%) and irritable crying (30%). This

benchmark

Australian study has since been confirmed and updated in a study with
531 immunisations (Harris et al, 1995) which documented just a single
hypotonic/hyporesponsive episode and no convulsions or other major
side effects.

1.4.2 Acellular Vaccines

The decline in public confidence and usage of the highly efficacious but
inherently reactogenic whole cell pertussis vaccines, m a d e it imperative
to find a more "user friendly" product which still retained the protective
qualities of the traditional vaccines. Japan was the first country to create
acellular vaccines and introduced
immunisation

them

with

success, into their

program in 1981 (Sato et al, 1984). These original

component vaccines contained formalin detoxified purified pertussis
toxin and demonstrated a decrease in side effects. The Swedish efficacy
trial (Ad H o c Group, 1988) tested the protection conferred by two Japanese
vaccines. The

two

component

(pertussis toxoid and

filamentous

haemagglutinin) vaccine induced a greater level of protection against
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culture confirmed pertussis than the single component (toxoid only)
vaccine (Storsaeter et al, 1990) demonstrating

the advantage

of

multicomponent vaccine preparations.

1.4.3 The Role of Cell Mediated Immunity

One of the major hindrances in developing superior vaccines, is the
limited understanding of the mechanisms involved in either natural
infection based immunity, or that conferred by vaccination. W h i c h
components of the h u m a n i m m u n e system become primed to fight B.
pertussis infection after vaccination? The response elicited by the
i m m u n e system can be divided into two broad sections, cell mediated
(Thl) and humoral (Th2) responses, based upon cytokine release and cell
types activated. Defence against intracellular pathogens is usually
dependent on the activation of a cell mediated Thl response. B. pertussis
has been shown to invade an increasing number of cell types (Ewanovich
et al, 1989; Bromberg et al, 1991; Saukkonen et al, 1991) and is n o w
considered a facultative intracellular pathogen. Intracellular bacteria m a y
be protected from host clearance mechanisms resulting in the infection
persisting. It is therefore astute to assume that cell mediated immunity
(CMI) m a y play some role in eliminating B. pertussis infection, at the
very least by destroying bacteria surviving within phagocytes. Recent
studies have demonstrated the importance of C M I in natural and vaccine
based immunity (Petersen et al, 1992; Redhead et al, 1993). Immunisation
of mice with whole cell vaccine or recovery from natural B. pertussis
infection induces a Thl response, with the activation of C D 4 +

T

lymphocytes secreting interleukin-2 (IL-2) and interferon g a m m a (IFN-y),
whereas immunisation with an acellular vaccine elicits a Th2 response,
with the production of antibodies, and the secretion of IL-5 (Redhead et
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al, 1993). Further illustrating the important role of cytokines, secretion of
IL-12 by macrophages stimulated by infection or whole cell vaccination, in
part due to the presence of lipopolysaccharide, is also involved in the
induction of the Thl response (Mahon et al, 1996). This production of IL12 does not occur after acellular vaccination, however w h e n exogenous
IL-12 is included as an adjuvant with a component vaccine in the murine
respiratory challenge model, the Th2 response switches to a Thl response
and raises the protective efficacy and level of bacterial clearance to that of
whole cell vaccine (Mahon et al, 1996). It has also been demonstrated that
administration of exogenous IL-12 and IFN-y can reduce infection by B.
pertussis by augmenting a Thl response to promote intracellular killing
by activated macrophages and destroy B. pertussis infected phagocytes
(Torre et al, 1996).

The Th2 response elicited after immunisation with an acellular vaccine,
results in delayed bacterial clearance in the murine respiratory challenge
model. In contrast, natural infection or immunisation with killed whole
cells, inducing a Thl response, was associated with rapid clearance
(Redhead et al, 1993; Barnard et al, 1996). Similar studies in h u m a n s
have s h o w n that a mixed Thl/Th2 response is generated (Ryan et al,
1997). Independent studies analysing the C M I responses of children in the
Mainz and R o m e vaccine efficacy trials, revealed that acellular vaccines
induce Thl responses (Zepp et al, 1996; Ausiello et al, 1997) which are
equivalent to responses after natural infection (Zepp et al, 1997).

The differences seen in CMI responses to vaccination of mice and
h u m a n s remains the topic of m u c h debate, and further study is required
to resolve this paradox. The importance of immunisation route and
genetic background of the mice in priming the desired cellular i m m u n e
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response has been highlighted (Barnard et al, 1996), and these may, in
part, explain the differences between the h u m a n and murine responses.

The efficacy of whole cell pertussis vaccines has traditionally been
evaluated

using the Kendrick

murine

intracerebral challenge test

(Kendrick, 1947). This does not mimic the natural infection process at all,
but is an effective measure of the protective capability of a whole cell
vaccine. Acellular vaccines cannot be tested using this method

and

unfortunately vaccine trials have s h o w n no correlation between antibody
responses and vaccine efficacy (Greco et al, 1996; Gustafsson et al, 1996;
Simondon et al, 1997).

Recent research to emerge from studies into the mechanisms of
protective immunity

is the evidence

that the murine

respiratory

challenge test is an excellent model for acellular and whole cell vaccine
efficacy in h u m a n s , and that humoral and cell mediated immunity play
complementary roles in vaccine elicited protection (Mills et al, 1998).
This extensive work, using samples from recent field trials in Italy (Greco
et al, 1996) and Sweden (Gustafsson et al, 1996) has established a highly
significant correlation between protection in the murine respiratory
challenge model and vaccine efficacy in infants. Using knockout mice
deficient in different aspects of the i m m u n e system, Mills and associates
found that both humoral and cell mediated responses are involved in
vaccine based protective immunity. The initial response m a y be antibody
mediated and is involved in restricting the extent of infection and
minimising the damage to epithelial and i m m u n e

cells. Antibodies

directed against the various adhesins and toxin molecules produced by
the bacteria would be most effective at this stage. To achieve complete
bacterial clearance however, also requires the induction of a cell mediated
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i m m u n e response. This two-phase process is consistent with the finding
that antibodies directed against B. pertussis antigens

in

children

immunised with acellular or whole cell vaccines waned dramatically
after immunisation (Zepp et al, 1996; Cassone et al, 1996). The C M I
responses in these children were m u c h longer lasting and in some cases
became more intense, even after antibody titres had fallen to below
detectable limits (Zepp et al, 1996; Cassone et al, 1996). A n

unusual

finding to arise from the latter study was the tentative synergistic link
between humoral and cell mediated immunity. Subjects demonstrating
positive C M I induction exhibited higher antibody titres than those which
failed to elicit a C M I response. This is unusual in that it belies the
dichotomy of the h u m a n i m m u n e response, however it m a y simply be
characteristic of a mixed Thl/Th2 response, or that some children did not
elicit good responses, whether humoral or cell mediated.

1.4.4 Recent Vaccine Trials

The potential shown by the vaccines in Japan and Sweden spurred a
number of vaccine companies in the U S and Europe to establish research
programs aimed at the development of "new generation" vaccines. The
last decade has seen a number of candidate vaccines trialed with quite
varied results (Table 1.1). However the trend lies clearly toward acellular
vaccines, containing at least three components, pertussis toxoid, F H A and
pertactin and possibly also fimbriae. Although trials have demonstrated
that acellular vaccines are less reactogenic than whole cell vaccines, the
complete elimination of adverse reactions seems impossible.

With the advent of large scale trials came a need to uniformly define
pertussis infection. A special W H O

meeting ( W H O , 1991) developed a
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standard pertussis case definition consisting of culture or serologic
confirmation of B. pertussis infection or household contact with positive
individuals, plus 21 days or more

of paroxysmal coughing. This

definition has been used in most of the trials and is a good indicator of
moderate to severe pertussis but does not include milder (culture
confirmed) infection of less than 21 days. For this reason, m a n y
investigators also cite protection data with respect to mild pertussis with
cough for greater than 7 days.

In the Goteborg, Sweden pertussis vaccine study, infants were given
either an A m v a x monocomponent vaccine containing 40 |ig of P T along
with diphtheria and tetanus toxoids (DT) (n=1670), or a D T only vaccine
(n=1665) at 3, 5 and 12 months of age (Trollfors et al, 1995). The protective
efficacy conferred against W H O case definition pertussis was calculated as
71%. Protection against milder pertussis however was significantly lower
at only 53%. The method of P T detoxification in this preparation was
hydrogen peroxide treatment.

A large household contact trial was performed in Mainz, Germany with a
total of 22 503 infants receiving either a three component SmithKline
Beecham

(SKB-3) vaccine, a G e r m a n

(Behring), or a D T

control vaccine

licensed whole
(Schmitt

cell vaccine

et al, 1996). T h e

immunisation schedule was three doses at 3, 4 and 5 months. The efficacy
of the acellular SKB-3 and whole cell vaccines against W H O case defined
pertussis was 8 9 % and 9 7 % respectively.

Concurrently run double blind trials in Stockholm and Rome used
equivalent immunisation schedules (2, 4 and 6 months), the same
Connaught whole cell vaccine, and D T controls. The Italian trial (Greco et
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al, 1996) compared the SKB-3 vaccine (n=4 481) used in the trial in Mainz,
with a three component vaccine produced by Chiron-Biocine (n=4 452).
The latter preparation contains a genetically detoxified form of PT (rPT)
which remains in native form (as distinct from chemically treated PT)
allowing for a reduced dose. The acellular vaccines demonstrated equal
efficacy against W H O defined pertussis, 8 4 % and against milder pertussis,
71%. The efficacy of the SKB-3 vaccine was similar to that observed in the
Mainz trial. The 4 348 vaccinees given the whole cell vaccine showed a
remarkably high incidence of pertussis. The U S licensed Connaught
vaccine afforded only 3 6 % efficacy against typical pertussis and only 2 3 %
against mild disease (Greco et al, 1996). This contrasts markedly with the
Behring vaccine used in the Mainz trial.

The same Connaught whole cell vaccine (n=2 001) was used in the
Swedish trial (Gustafsson et al, 1996), again exhibiting surprisingly low
efficacy, 4 8 % and 4 1 % for typical and mild pertussis respectively. A two
component SmithKline Beecham vaccine (SKB-2), administered to 2 538
subjects was 5 9 % protective against W H O

defined pertussis and 4 2 %

protective against milder pertussis. A five component vaccine produced
by Connaught given to 2 551 infants was 8 5 % and 7 8 % protective against
W H O defined and mild pertussis respectively.

A case-control study performed in Munich, Germany (Liese et al, 1997)
compared a two component Connaught/Biken vaccine (n=12 710) with
the German licensed Behring whole cell vaccine (n=3 200) and

DT

controls (n=2 100). A total of four doses were administered, at 2, 4 and 6
months, with a booster at 15-25 months. This study defined a pertussis
case as any cough of 21 or more days plus a positive culture or household
contact. The acellular and whole cell vaccines achieved efficacies of 8 2 %
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and 96% respectively.

Table 1.1

Site
Goteborg
Mainz
Stockholm

Rome

Munich
Senegal
Erlangen

Sweden

Contents of, and efficacy induced by vaccines in recent trials.

Vaccine *
Contents (|Xg/dose)
Efficacy #
A m v a x (1)
PT(40)
71
SmithKline Beecham (3)
PT(25); FHA(25); PRN(8)
89
Behring
whole cell
97
SmithKline Beecham (2)
PT(25); FHA(25)
59
Connaught-Canada (5) PT(10); FHA(5); PRN(3); FIM(5)
85
Connaught-Canada
whole cell
48
SmithKline Beecham (3)
PT(25); FHA(25); PRN(8)
84
Chiron Biocine (3)
PT(5); FHA(2.5); PRN(2.5)
85
Connaught-Canada
whole cell
36
Connaught US/Biken (2)
PT(23.4); FHA(23.4)
82
Behring
whole cell
96
Pasteur Merieux (2)
PT(25); FHA(25)
85
Pasteur Merieux
whole cell
96
Wyeth-Lederle/Takeda
82
PT(3.5); FHA(35); PRN(2);
FIM(0.8)
(4)
Lederle
whole cell
91
Chiron Biocine (3)
PT(5); FHA(2.5); PRN(2.5)
1.38
Past Mer-Conn (5)
PT(20); FHA(20); PRN(3);
0.85
FIM(5)
Evans (Wellcome)
whole cell
1.0

* Bracketed numbers represent number of vaccine components

# Efficacy values are measured as percentages, except for the final row. These ar

measured as relative risk of protection against pertussis in comparison to the wh
vaccine, which was assigned a risk of 1.0.

The Senegal pertussis trial compared a two component acellular (n=l 847)
and a whole cell vaccine (n=l 772), both produced by Pasteur Merieux
(Simondon et al, 1997). A three dose schedule was adopted, with
immunisations at 2, 4 and 6 months. The absolute efficacy of these
preparations were estimated at 85% and 96% respectively using the WHO
case definition. The protection afforded by both vaccines dropped
markedly to 31% and 55% against the milder protocol case definition
adopted in this study.
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The trial in Erlangen, Germany compared a four component vaccine
from Lederle-Praxis/Takeda to a Lederle whole cell vaccine and a D T
control (Stehr et al, 1998). Subjects were immunised with either the
acellular vaccine (n=4 273) or the whole cell vaccine (n=4 259) at 3, 4.5, 6
and 15-18 months of age, or the D T only combination (n=l 739) at 3, 4.5
and 15-18 months. Specific efficacy against a modified W H O definition of
21+ days of cough with paroxysms, w h o o p or posttussive vomiting was
8 3 % for the acellular vaccine and 9 3 % for the whole cell vaccine. Against
mild pertussis, protection was 7 2 % and 8 3 % respectively. The acellular
vaccine also exhibited moderate efficacy (31%) against B. parapertussis
infection.

In a huge, nationwide trial in Sweden (Olin et al, 1997) over 80 000
infants were immunised

in a randomised trial comparing the two

component SmithKline Beecham D T P vaccine (n=20 465), the three
component

Chiron

Biocine D T P

(n=20 412), the Pasteur-Merieux-

Connaught five component D T P (n=20 491), and a U K licensed whole cell
vaccine from Evans Medical (n=20 467). Apart from the unusually low
efficacy demonstrated by the whole cell vaccine in two recent trials (Greco
et al, 1996; Gustafsson et al, 1996), preliminary results of this latest
Swedish study are consistent with data from previous trials. Specific
efficacy analyses were not performed, however case numbers and relative
risk ( D T w P assigned to 1.0) calculations are available. They demonstrate
that the five component acellular vaccine (relative risk to D T w P : 0.85)
elicited the greatest protection against W H O defined pertussis, followed
closely by the whole cell vaccine (1.0) with the three component acellular
vaccine, with a relative risk of 1.38, affording less protection. Against mild
disease, the relative risk calculations were 1.0, 1.40 and 2.55 for the whole
cell, five component and three component vaccines respectively. T h e
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further analysis of the outcomes of this trial should confirm and extend
our knowledge of vaccines against pertussis.

In a study which assessed adverse events within 72 hours after
vaccination with either whole cell D T P vaccine or two different acellular
vaccines

(Connaught

and

Lederle), the

acellular

vaccines

were

approximately three times less reactogenic (Rosenthal et al, 1996).
However, apart from the Connaught whole cell vaccine, the excellent
efficacy, reduced occurrence of severe side effects and long lasting
protection reported after immunisation with whole cell vaccines reaffirm
that they still constitute a valid alternative to acellular formulations.

1.4.5 Future Vaccine Development

With all the time spent on research into mechanisms of immunity,
efficacy and reactogenicity of vaccines against Bordetella pertussis, the
bacterium itself has evolved and reemerged. Recent data from the
Netherlands reported a dramatic increase in the incidence of pertussis in
that country in 1996, despite high levels of immunisation (de Melker et
al, 1997). M a n y factors might have explained this epidemic, however an
extensive study has traced the problem to B. pertussis itself (Mooi et al,
1998). The population structure of this bacterium in the Netherlands has
changed. The antigenic variation of the protective antigens pertactin and
the SI subunit of pertussis toxin was analysed using circulating clinical
isolates collected over a period of 47 years. Three different variants each of
pertactin and SI were discovered and the presence of these variants s h o w
temporal shifts. Polymorphism in pertactin was found to occur in the
midst of a repeat region (GlyGlyXaaXaaPro)s termed region 1. T h e
mutations in the SI subunit were similarly confined to a small region of
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the polypeptide. The mutations in SI and pertactin are concentrated in
regions defined as T cell and B cell epitopes respectively (Peppoloni et al,
1995; Charles et al, 1991).

The Dutch whole cell pertussis vaccine introduced in the 1950's was
originally a clinical isolate and therefore matched

the circulating

population, and was effective in preventing whooping

cough. T h e

ancestral pertactin molecule (A) remained unchanged until 1981, w h e n
both of the other variants (B and C) emerged. These mutated forms
circulated in the population at low levels until 1989. Fluctuations in the
population structure occurred until the present situation was reached,
with C being the dominant polymorph and A, the form contained within
the whole cell vaccine, only representing 1 0 % of the population. A
similar temporal shift w a s seen in the SI variants with 9 0 % of the present
isolates containing a different SI molecule to that produced by the whole
cell vaccine strain. The temporal trends in both the pertactin and SI
polymorphs, clearly suggest that Bordetella pertussis is under selective
pressure caused by h u m a n immunisation, and is undergoing vaccine
driven evolution. There are major implications of this study, concerned
with the whole cell vaccines currently in use worldwide. This n e w
evidence m a y also explain in part, the poor performance of the U S
Connaught licensed whole cell vaccines in recent trials (Greco et al, 1996;
Gustafsson et al, 1996). The B. pertussis strain used in this Connaught
vaccine m a y be divergent enough from the strains circulating in Sweden
and Italy that they do not confer high levels of protection. The impact o n
acellular vaccines m a y be even greater because by their very nature they
confer a narrower field of protection. In fact some licensed acellular
vaccines contain variants which might only protect 1 0 % of the Dutch
population.
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This evidence reinforces the fact that this organism has probably infected
humans for thousands of years and is exquisitely fine tuned to inhabit the
human respiratory tract. This was achieved via an evolutionary process.
The twentieth century had caught up with this pathogen somewhat, with
the advent of antimicrobials and immunisation, and it was on the way
out. Now it is again evolving and reemerging as a dangerous pathogen.

Together with the attention to vaccine reactogenicity, the induction of
appropriate immune response mechanisms and raising the protective
efficacy of future anti-pertussis vaccines, we must also consider the rapid

evolution of Bordetella pertussis, which we are actually facilitating, in th
development of future whooping cough vaccines.
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Chapter T w o

Materials and Methods

2.1 Bacterial strains, plasmids and media
Recipes for all media and buffers used in this study are listed in Appendix
II. Bacterial strains used in this study are listed in Table 2.1. Escherichia
coli strains were grown on Z agar (Walker and Pemberton, 1988) or in L B
liquid media (Sambrook et al, 1989). Bordetella pertussis and Bordetella
bronchiseptica strains were grown on Bordet Gengou agar supplemented
with 1 0 % defibrinated horse blood. W h e n liquid media was required,
these species were grown in modified SS m e d i u m (Stainer and Scholte,
1970).

Liquid cultures of Bordetella strains assayed for PT secretion were grown
in SS m e d i u m supplemented with 2 % (2,6-Di-0-methyl)-P-cyclodextrin
(M^CD). Bacteria containing plasmids were routinely grown in media
supplemented

with

appropriate

antibiotics, selecting

for plasmid

retention. Antibiotic concentrations used were as follows: ampicillin, 100
|ig/mL; cephalexin, 100 |ig/mL; kanamycin, 50 |ig/mL; nalidixic acid, 50
|ig/mL; rifampicin, 100 |Xg/mL and trimethoprim, 50 |0,g/mL. Agar
containing X-gal (0.004%) and IPTG (40 u M ) was used for blue/white
selection of possible clones. All bacterial strains were grown at 37°C. Plates
were incubated in a Qualtex Solidstat Incubator. Liquid cultures were
aerated by shaking in a BioLine 4610 Shaking Incubator or a Paton 461
Orbital Shaker. Plasmids used in this study are listed in Table 2.2
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Table 2.1

Bacterial strains used in this study

Bacterial Strain

Relevant Characteristics # Reference or Source

Bordetella pertussis
Tohama I

serotype 2 Hly +

CSL 127
CSL 127S
CSL 137
CSL 137S
CSL 1237
CSL 1237S
Bordetella
BB7865

Kasuga et al, 1954

serotype 2 Hly

+

CSL Ltd.

serotype 2 Hly

+

CSL Ltd.

serotype 3 Hly

+

CSL Ltd.

serotype 3 Hly

+

CSL Ltd.

serotype 2, 3 Hly

+

CSL Ltd.

serotype 2, 3 Hly
bronchiseptica

+

CSL Ltd.

BB7866

Monack et al, 1989

Hly+ Smr

Monack et al, 1989

Hly" S m r AbvgS

5376

Fim F H A

5377

Hly" derivative of 5376
Hly"

+

A T C C 10580
A T C C 10580::Tn/usPTl

+

Hly

+

Walker et al, 1991a
This study
Walker et al, 1991a

Hly" Tn/usPT Kan

r

A T C C 10580::Tn/usPTl
(pR751::Tn813)

Hly" Tn/usPT Kan

r

BB7865 Rifr
5376 RiF

This study
RiF Nalr derivative of BB7865
RiF Nal r derivative of BB7866 This study
This study
RiF derivative of 5376

5377 Rifr

RiF derivative of 5377

BB7866 Rifr

Walker et al, 1991a
This study

This study

5376 RiFNaF

Nal derivative of 5376 RiF

This study

5377 RifrNalr

Nalr derivative of 5377 RiF

This study

BB7865 Rif::Tn/usPTl

Tn/usPT Kan r RiF Nalr

This study

BB7866 Rif-Tn/usPTl

Tn/usPT Kan r RiF Nalr
Tn/usPT Kan r RiF Nalr

This study

r

5376 RifNal ::Tn/usPT2
5377 RiFNaF: :Tn/usPn
Escherichia coli
Q358 pR751::TnS13
XLl-Blue M R F ' Kan
INVaF'

r

r

Tn/usPT Kan RiF Nal
Tpr
Kan r competent cells
competent cells

r

This study
This study
Bowen and Pemberton, 1985
Stratagene
^ ^ Invitrogen

# Abbreviations; r, resistant to; Kan, kanamycin; Tp, trimethoprim; Sm, Streptomycin;
Fim, fimbriae production; F H A , filamentous haemagglutinin production; Hly, haemolytic
activity; Tn/usPT, recombinant PT expression locus; AbvgS, non-functional bvgS gene.

Table 2.2

Plasmids used in this study

Plasmid

Relevant Characteristics #

Reference or Source

pCRII / pCR2.1

A m p , Kan ,

Invitrogen

p C R Script

pBluescript based, A m p r
partial ptlH gene in pCRII
fimbrial accessory promoter of
CSL 127S in p C R Script
fimbrial accessory promoter of
CSL 127S in p C R Script
Pftm2 of CSL 127S in pCRII
Pfim2 of CSL 127S in p C R Script
bvg/fha intergenic region of
CSL 127S in p C R Script
Pptx of CSL 127S in pCRII
?fim3 of CSL 127S in pCR2.1
bvg/fha intergenic region of
CSL 127U in p C R Script
bvg/fha intergenic region of
CSL 127U in p C R Script
Pptx of CSL 127U in pCRII
Pptx of CSL 127U in pCR2.1
Pfim2 of CSL 127U in pCRII
Pfiml of CSL 127U in p C R Script
Pfim3 of CSL 127U in pCR2.1
fimbrial accessory promoter of
CSL 127U in p C R Script
fimbrial accessory promoter of
CSL 127U in p C R Script
bvg/fha intergenic region of
CSL 137S in p C R Script
Pptx of CSL 137S in p C R Script
Pptx of CSL 137S in pCRII
Pfim2 of CSL 137S in p C R Script
Pfim3 of CSL 137S in pCR2.1
Pfim3 of CSL 137S in pCR2.1
fimbrial accessory promoter of
CSL 137S in pCR II
bvg/fha intergenic region of
CSL 137U in p C R Script
Pptx of CSL 137U in p C R Script
Pfim2 of CSL 137U in pCRII
Pfim3 of CSL 137U in pCR2.1
Pfim3 of CSL 137U in pCR2.1
fimbrial accessory promoter of
CSL 137U in pCRII
fimbrial accessory promoter of
CSL 137U in pCR Script
bvg/fha intergenic region of
CSL 1237S in pCRII
bvg/fha intergenic region of
CSL 1237S in p C R Script
Pptx of CSL 1237S in p C R Script
Pflm2 of CSL 1237S in p C R Script

Stratagene

pAS5
pAS6
pAS7
pAS8
pAS9
pASlO
pAS12
pAS14
pAS16
pAS17
pAS18
pAS19
pAS20
pAS21
pAS22
pAS24
pAS25
pAS26
pAS28
pAS29
pAS30
pAS32
pAS33
pAS34
pAS36
pAS38
pAS40
pAS42
pAS43
pAS44
pAS45
pAS46
pAS47
pAS48
pAS50

r

r

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
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pAS52
pAS54
pAS56
pAS58
pAS60
pAS62
pAS64
pR751::Tn813
pMW132
pMW127

Pfim3 of CSL 1237S in pCR2.1
fimbrial accessory promoter of
CSL 1237S in pCRII
bvg/fha intergenic region of
CSL 1237U in p C R Script
Pptx of CSL 1237U in p C R Script
Pfim2 of CSL 1237U in pCRII
?fim3 of CSL 1237U in pCR2.1
fimbrial accessory promoter of
CSL 1237U in pCRII

This study
This study

tra+ tnpA+ tnpR'

Bowen and Pemberton, 1985

+

bvg Kan

r

Tn/usPT Kan

This study
This study
This study
This study
This study

Walker et al, 1991a
r

Walker et al, 1991a

# Abbreviations; r, resistant to; A m p , ampicillin; Kan, kanamycin; Tp, trimethoprim;
Tn/usPT, recombinant PT expression locus; tra, conjugative transfer

genes; tnpA,

transposase; and tnpR, resolvase; bvg, expresses functional bvg genes.

2.2 Isolation and purification of DNA
2.2.1 Chromosomal DNA Extraction

Genomic DNA of Bordetella pertussis strains was obtained using the
method of Priefer and associates (1984). Cells were grown to confluence
on Bordet Gengou agar and suspended in 25 m L of 1.0 M NaCl in a sterile
50 m L centrifuge tube. The tube was then shaken on ice for 60 minutes
and centrifuged at 12 000 g for 10 minutes in a Sorvall RC-5 superspeed
centrifuge or a Beckmann J2-MC. The pellet was then washed with 25 m L
of chilled TES buffer and the centrifugation repeated. The supernatant
was discarded and the cells concentrated

in 5 m L

of cold T E

(chromosomal) buffer. Preliminary degradation of bacterial cell walls was
carried out with the addition of lysozyme (chicken egg white, Sigma) in
TE to a final concentration of 0.2 m g / m L , followed by a 15 minute
incubation at room temperature. The addition of S D S to 1 % (w/v)
resulted in solubilisation of cellular membranes and following a brief
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room temperature incubation, a protease solution (Pronase E, Sigma) in
TE was added to a final concentration of 500 u g / m L to induce protein
degradation. The preparation, n o w

extremely viscous, was swirled

intermittently over a three hour period to achieve optimal protein
digestion. Cellular proteins were removed with 5 m L of T E saturated
phenol. Vigorous shaking facilitated transfer of proteins from the
aqueous phase to the phenol phase. Centrifugation at 12 000 g for 10
minutes separated the phases. The aqueous phase was transferred to 1.5
m L microcentrifuge tubes and a further phenol extraction performed.
Trace levels of phenol were removed from the solution by two ether
extractions. The addition of 1 m L of diethyl ether, followed by violent
shaking and centrifugation for 1 minute at 16 000 g allowing the removal
of the organic phase, produces a fraction containing nucleic acids. A
second ether extraction was performed and the nucleic acids were
precipitated by the addition of one tenth volume of 3 M sodium acetate
(pH 7.0) followed by 2.5 volumes of chilled ethanol. The precipitate was
pelleted by centrifugation at 16 000 g for 5 minutes, washed with cold 7 0 %
ethanol and allowed to air dry. The nucleic acids were then dissolved in
an appropriate volume of sterile distilled water containing ribonuclease
A (bovine pancreas, Sigma) at a concentration of 20 |i,g/mL.

2.2.2 Plasmid DNA Extraction

Phenol Extraction
This procedure, modified from Naumovski and Friedberg (1982), was
routinely used for the screening of possible clones by restriction e n z y m e
analysis. Freshly grown cells were removed from selective media using a
sterile loop and resuspended in 0.4 m L of T E buffered sucrose in a sterile
1.5 m L microcentrifuge tube. Lysozyme (chicken egg white, Sigma) was
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added to approximately 1 m g / m L and allowed to breakdown the bacterial
cell walls at room temperature for 30 minutes. A solution containing
Triton X-100 was then added (0.3 m L ) to solubilise cellular membranes.
After incubation at 65°C for 10 minutes, the cell debris was spun d o w n at
16 000 g for 30 minutes. The supernatant was placed into a fresh tube and
0.5 m L of T E saturated phenol added with vigorous shaking. Following
centrifugation at 16 000 g for 15 minutes in an Eppendorf 5415C
centrifuge, the aqueous (upper) layer was placed in a fresh microfuge tube
and 1 m L of diethyl ether added, again with vigorous shaking. The phases
were separated after centrifugation for 1 minute at 16 000 g, and the
organic (upper) layer was discarded. A further ether extraction followed,
ensuring that all trace levels of phenol were removed. The plasmid D N A
was then precipitated, along with cellular R N A , by the addition of 0.1
volume of 3 M sodium acetate and 2.5 volumes of pre-chilled absolute
ethanol. Centrifugation at 16 000 g for a period of 5 minutes yielded a
pellet of nucleic acid which was tnen washed with chilled 7 0 % ethanol,
and allowed to air dry. A total of 50 uX of d H 2 0 was then added, together
with ribonuclease A (bovine pancreas, Sigma) to a final concentration of
100 n g / m L , and incubated for 30 minutes at 37°C to resuspend the pellet
and degrade any R N A contaminating the D N A sample.

QIAprep Spin Plasmid Kit
These 1.5 m L spin columns contain a silica gel which binds plasmid D N A
which is then washed, and eluted with water. The manufacturers
instructions were adhered to w h e n extracting this "sequencing quality"
plasmid D N A . Bacterial cells were grown overnight, then 1.5 m L aliquots
were spun at 16 000 g for 30-60 seconds and the pellet resuspended in 250
\LL of buffer PI. The cells were then subjected to lysis by the addition of
250 uL of buffer P2. Precipitation of cellular debris was achieved by adding
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350 uL of buffer N 3 and centrifugation at 16 000 g for 10 minutes. T h e
impure plasmid preparation was then loaded onto a small Qiaprep
column, spun for 60 seconds to allow the plasmid D N A to bind to the
silica matrix. The bound D N A was then washed with 750 uL of PE buffer.
The column was centrifuged to accelerate washing flow rate and the flow
through liquid was discarded. The spin was then repeated to remove all
traces of P E buffer. The D N A was then eluted by placing 50 uL of d H 2 0 o n
the membrane inside the column. After 1 minute the column was again
centrifuged and the eluant collected in a fresh microfuge tube.

Qiagen midi columns (Tip 100) are larger and rely on gravity, making
them markedly slower than the Spin Preps. However, these were used
w h e n a greater amount of D N A was required, again the manufacturer's
protocol was followed.

Pharmacia Biotech Flexi-Preps
The principle of this kit is similar to the Qiagen spin preps, however the
D N A binding material is a slurry of "Sephaglas"™FP. The bacterial cells
are lysed and the cellular debris precipitated. To the

remaining

supernatant is added a small amount of Sephaglas which reversibly binds
the plasmid D N A . The matrix is then washed, and eluted with water
leaving

a high

quality plasmid

preparation. The

manufacturer's

instructions were followed closely throughout this extraction. Bacterial
cells were grown overnight, then 1.5 m L aliquots were spun at 16 000 g for
30-60 seconds and the pellet fully resuspended in 200 (xL of Solution I. The
cells were then lysed with the addition of 200 pL of Solution II and the
cellular debris precipitated with 200 jiL of Solution EI. After 5 minutes
centrifugation at 16 000 g, the supernatant was removed to a n e w
microfuge tube and 0.7 volumes

of isopropanol added. A

room
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temperature, 1 minute incubation followed by a 5 minute full speed spin
in an Eppendorf 5415C centrifuge, pelleted the plasmid preparation. The
crude D N A pellet was then resuspended in 150 uL of Sephaglas slurry by
vortexing for a minute. The supernatant was separated from the plasmidSephaglas complex by centrifuging at 16 000 g for 15 seconds and
aspirating the supernatant. The complex was then washed with 200 u\L of
Wash buffer and recentrifuged. Again the supernatant was removed and
300 uX of 7 0 % ethanol added. The tube was briefly vortexed, spun and the
ethanol removed. This step was repeated to ensure the removal of all
traces of ethanol and the complex was resuspended in 50 oX of d H 2 0 . The
plasmid D N A

detaches from the matrix, and after 5 minutes

room

temperature incubation, the Sephaglas beads are spun down and the
aqueous plasmid solution is transferred to a fresh microfuge tube.

2.3 Amplification and Cloning of Bordetella
Chromosomal D N A
2.3.1 Polymerase Chain Reaction

Relevant regions of Bordetella pertussis DNA were amplified using the
polymerase chain reaction (PCR). This technique, uses a thermostable
DNA

polymerase to replicate D N A

defined and flanked by specific

oligonucleotide primers. The reaction involves many rounds of strand
separation, primer annealing and strand extension to create copies of the
target D N A . Oligonucleotide primers used in P C R amplifications in this
study are listed in Table 2.3. All P C R procedures were carried out in either
0.1 or 0.5 m L

microcentrifuge

tubes in either

a Perkin

Elmer

GeneAmp9600, or a Hybaid Thermal Reactor. The components of a typical
P C R are described below in Table 2.4.

76

Table 2.3

Name

Oligonucleotide primers used for PCR and D N A sequencing in this study

Oligonucleotide Sequence

b'-CCCGGGATGAGGACTTTGTTGTACAT-3'
5'-GGATCCCCCCTGTACGGTTCGTGTTCAT-3'
y-GAATTCGCCAAGCTGAAGTAGCAGCG-3'
y-GGATCCCGAATTGCCCGAGTGCAACGCAT-3'
y-GATTCACGCTGATGCGCCGGCCCGG-3'
y-GGATCCCCGCGTTGGAAAGGGATTTGCAT-3'
y-GAATTCGACGGCGCCCGCCGAACCGG-3'
y-GGATCCCCAGGGTATGAAAACTTGGACAT-3'
fim 3 3'
5'-G A A T T C T G A A A C C A A C A A A T A G G T A G - 3 '
fim access 5'
5'-GGATCCAGCCGCCGGCGCCAGCGCGCCAT-3'
fim access 3'
5'-TGCAACAAGAACGAAGACGCGGCCGCCCCG-3'
GBF fim3 5'
5'-•TGGCAGTACGGGCGAGGCGGCAAGGATAAG-3'
GBF fim3 3'
5'-ACGCTGATGCGCCGGCCCGGCGCCGCATGG-3'
fim 2 BIG 5'
y--ATGGTGCCGGTGATGACGATGGTGCCGTCG-3'
fim 2 BIG 3'
5'-GGCCAGACCGGTTCGGGCAAGACCACA-3'
PT secrtn 5'
y--TCATGGCGCCGGGAGGCCATCCCGGTA-3'
PT secrtn 3'
5'-GTAAAACGACGGCCAGT-3'
Universal
Reverse PUCR-2 y^•TTCACACAGGAAACAGCTATGACC-3'

bvg/fha 5'
bvg/fha 3'
PT5'
PT3'
fim2 5'
fim2 3'
fim3 5'

Table 2.4

Supplier
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Biotech
Pharmacia
Biotech

Components of a typical PCR and their concentration

Reagent

Final Concentration

sterile d H 2 0
P C R Buffer (10X)
dGTP
dATP
dTTP
dCTP
D N A template
D N A polymerase
5' primer
3' primer

to final volume

IX
0.2 m M
0.2 m M
0.2 m M
0.2 m M
lng
2.5 Units
0.25 jiM
0.25 ^ M

Since each P C R involves different templates and different primers, the
concentrations of each of the components may have been varied to

achieve optimisation of the reaction. After spot centrifugation, 100 fiL

mineral oil was layered on top of the aqueous reaction mixture to preven

evaporation. The tube was then placed in the thermal cycler and subjecte

to a temperature cycling regime as set out in Table 2.5. Variations to t
basic temperature and time parameters were employed to optimise
product formation.
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Table 2.5

General guide to temperature cycles used for the PCR.

Step Temperature Time Cycles
1.1
1.2
1.3

96°C
55°C
72°C

3 min.
1 min.
2min

2.1
2.2
2.3

96°C
55°C
72°C

40 sec.
50 sec.
lmin.

3

72°C

5 min.

The D N A polymerases used in this study were
thermophilic bacterium Thermus

Taq, from the

aquaticus (Boehringer

Mannheim,

Qiagen or Perkin Elmer) and Pfu from Pyrococcus furosius (Stratagene,
both native and cloned). Mismatches can occur in a P C R w h e n the
polymerase inserts an incorrect base. These "Taq errors" can be reduced by
using a thermostable D N A polymerase which has 3'-5' proofreading
capabilities such as Pfu. To ensure accuracy, m u c h of the work in this
study was done using Pfu to decrease the chances of a Taq error occurring.
As an absolute safeguard against errors, if a difference between promoter
DNA

sequences was found, an independent P C R and cloning was

performed, and the n e w clone sequenced.

2.3.2 Invitrogen TA Cloning System

This PCR specialised cloning system takes advantage of an inherent
property of Taq D N A polymerase. Products amplified by this thermostable
enzyme possess an extra adenine overhang at each end. The vector used
in this strategy (pCR II or pCR2.1) has complimentary thymine overhangs
to facilitate a more efficient "sticky-end" ligation.

Amplification products generated using Taq DNA polymerase were
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cloned into either pCRII or pCR2.1 and transformed into Escherichia coli
INVaF' competent cells. The procedure used was essentially that specified
by the manufacturer.

Ligation
The ligation reaction was initiated by adding 1 to 2 fiL of the P C R product
D N A to be cloned to a microfuge tube containing 2 |iL of precut
pCRII/pCR2.1 (50 ng), 1 |iL of 10X ligation buffer, 1 uL (4 Units) of T4
D N A ligase and d L ^ O to a final volume of 10 uX. This mixture was then
incubated at 12°C overnight

and then stored on ice before the

transformation reaction proceeded.

Transformation
A vial of competent INVaF' cells supplied with the kit were thawed o n
ice and 2 |iL of 0.5 M P-mercaptoethanol was added. A 1 u\L aliquot of the
ligation mix was added and allowed to transform on ice for 30 minutes.
The reaction was then heat shocked at 42°C for 60 seconds and placed o n
ice for 2 minutes. W a r m e d S O C m e d i u m (450 (iL) was added to the
transformation which was then incubated with shaking at 37°C for 60
minutes and plated onto selective Z agar containing ampicillin and
kanamycin, together with X-gal for blue/white selection of possible
clones. N o IPTG was required because the cloning vector does not encode
the lacV\ repressor.

2.3.3 Stratagene pCR Script Cloning Procedure

Thermostable DNA polymerases which have 3' to 5' proofreading ability
such as Pfu or Vent, generate "blunt-ended" products/fragments, thereby
making cloning/ligation a more difficult task. The p C R Script system
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employs a deft combination of ligase and the rare cutter restriction
endonuclease Srf I to maximise the cloning efficiency. Re-ligation of the
vector without an insert results in the formation of an Srfi restriction site.
Also present in the ligation mixture, this eight base pair cutter
immediately reopens the vector (leaving blunt ends), increasing the
chances of insert : vector ligation.

Amplification products generated using Pfu DNA polymerase were
ligated into p C R Script and transformed into supercompetent E. coli XL1Blue M R F ' K a n (Stratagene) cells. The protocol followed was essentially
that specified by the manufacturer.

Ligation
Prior to cloning the blunt ended P C R product into the p C R Script vector, a
purification step was required. To the P C R product, an equal volume of 4
M

ammonium

acetate was added, followed by 2.5 volumes of 1 0 0 %

ethanol. The D N A was then centrifuged at 10 OOOg for 20 minutes and the
pellet washed with 7 0 % ethanol and air dried. The product was then
resuspended in dLL^O to the original volume. Between 2 and 4 uX of this
reprecipitated D N A product was mixed with 1 |0,L of p C R Script (10 ng), 1
(XL of lOx reaction buffer, 0.5 uL of A T P , luL (5 Units) of Srfi, 1 uL (4
Units) of T4 D N A ligase and dTL^O to a final volume of 10 |iL. This
mixture was then incubated at room

temperature for 60 minutes,

followed by a 10 minute inactivation step at 65°C.

Transformation
Supercompetent E. coli cells supplied with the kit were thawed on ice. A
40 |iL aliquot was placed into a 15 m L centrifuge tube and 0.7 |iL of 0.5 M
P-mercaptoethanol was added. Following incubation on ice for 10
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minutes with gentle rocking, 2 uX of the ligation mix was added and
allowed to transform on ice for 30 minutes. The reaction was then heat
shocked at 42°C for 45 seconds and placed on ice for 2 minutes. W a r m e d
S O C m e d i u m (450 ^iL) was added to the transformation which was then
incubated with shaking at 37°C for 60 minutes and plated onto ampicillin
selective Z agar containing X-gal and IPTG for blue/white selection of
possible clones.

2.4 Detection and Analysis of DNA
2.4.1 Agarose Gel Electrophoresis

Agarose gel electrophoresis was used to detect the presence of DNA and
determine the size of restriction fragments. A n appropriate amount of
restriction enzyme digested D N A was added to 5 |iL of loading buffer and
applied to 1 % agarose/TAE gels. Electrophoresis took place at 50 V in a
Bio Rad Mini S u b ™ D N A Cell powered by a Bio Rad Power Pack 300 for
an appropriate period of time. The gel was then stained in an aqueous 1
H g / m L solution of ethidium bromide and the intercalated D N A viewed
under ultra-violet light (UV Transilluminator, U V P ) . Typically, lambda
bacteriophage D N A

(Boehringer-Mannheim) digested with Hind III

restriction enzyme or lkb Ladder (Gibco BRL) were used as molecular
weight markers, to determine the size of D N A fragments. The fluorescent
D N A bands were documented using a Polaroid MP-4 L C land camera and
Polaroid 667 film. Alternatively, a Novaline gel documentation system
was used.
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2.4.2 Elution of D N A from Agarose Gels

Occasionally, certain separated bands of DNA were recovered from
agarose gels for further analysis. This was done as an extra purification
step, or to separate low molecular weight P C R products from excess
primers prior to cloning. The D N A

of interest was electrophoresed

through 0.7% agarose gel and the fragment to be eluted excised using a
sterile scalpel. The piece of agarose containing the fragment was then
subjected to the Bresa-Clean™ procedure (Bresatec). This system involves
melting the gel in buffer and adding a silica based matrix. The silica beads
reversibly bind the D N A n o w in solution and the complex is washed and
then eluted from the matrix with sterile d H 2 0 . The band of agarose
containing the D N A

to be retrieved was excised and placed in a

microcentrifuge tube containing 3 volumes of Bresa-Salt™. Incubation at
55°C for 5-10 minutes with occasional vortexing melts the gel sliver,
forming a homogeneous solution. Addition of 6 (iL of Bresa-Bind™ silica
matrix and incubation for five minutes at room temperature allows the
D N A to bind the matrix. The silica-DNA complex was then pelleted and
washed with a volume of Bresa-Wash™ equal to the initial amount of
salt used. The wash solution was then removed by centrifugation, the
complex was dried and resuspended in d H 2 0 . Incubation at 55°C for 5
minutes, breaks the interaction between the D N A and the silica matrix
and the D N A is released into solution. The silica is then pelleted and the
D N A solution transferred to a fresh tube.

2.4.3 Southern Hybridisation Analysis of DNA

The transfer of DNA onto a nylon membrane for detection of specific
fragments is based on the technique pioneered by Southern (1975).
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Preparation
The D N A to be analysed was electrophoresed through a 0.7% agarose gel
and visualised using ethidium bromide intercalation. The gel was then
placed in a glass dish and submerged in 0.25 M HC1. T w o washes in the
acid solution, of 10 minutes duration were performed, followed by a brief
rinse in d H 2 0 . The gel was then subjected to 2 washes of 10 minutes in a
solution containing 1.5 M NaCl and 0.5M N a O H . This was followed by a
neutralisation step consisting of 4 washes of 10 minutes in a solution of 1
M Tris.HCl and 1.5 M NaCl (pH 8.0).

Transfer
The Southern transfer apparatus was set up as follows. A wick was
constructed by positioning a large strip of filter paper across a glass plate
spanning a large glass dish. The gel was lowered onto the wick without
the introduction of air bubbles. Gel sized pieces of filter paper and nylon
membrane (Boehringer Mannheim, positively charged) were soaked in
2X SSC. The membrane was lowered onto the gel, followed by 5 pieces of
filter paper. A stack of tissue paper 7 c m high was positioned atop the
filter paper and a weight of 1 kg applied. The set-up was surrounded with
cling wrap to prevent "short circuiting" of the blot. The glass dish was
filled with 10X SSC and the D N A was allowed to transfer overnight, after
which the membrane was cross-linked for 3 minutes at 254 n m using a
Stratagene U V Stratalinker 1800 to fix the D N A onto the membrane.

Probe Labelling
The D N A to be used as a hybridisation probe was labelled using nick
translation. This involves incubating the probe D N A with a mixture of
the enzymes DNase I, which "nicks" the sequence and D N A polymerase I,
which fills in the gaps created by the DNase I. S o m e of the nucleotides
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thus reincorporated are radiolabeled, in this case with

32

P and are

therefore detectable on X-ray film.

The DNA to be labelled (approx. 1 jig) was placed on ice in a microfuge
tube. Added to the tube was a mixture of dCTP, d G T P and dTTP at final
concentrations of 25 u M each. A n aliquot of 50 |iCi of radiolabelled [a-32P]d A T P (Bresatec, ICN) was then added to a final concentration of 3 |iM.
The solution was m a d e up to 40 uX with water and the buffered enzyme
mixture (Gibco BRL) was added (200 pg DNase I; 2 Units D N A polymerase
I). Following a 1 hour incubation at 15°C, the reaction was halted by the
addition of 5 uX of a 200 m M E D T A solution (pH 8.0). Labelled D N A was
separated from unincorporated

nucleotides by passing the reaction

through an STE buffer equilibrated Sephadex® G50 (Pharmacia) column.
Constructed using a 1 m L syringe and glass wool, the spin column allows
the passage of the large plasmid D N A , whilst retarding the movement of
the free nucleotides as they remain in the pores of the Sephadex® beads.

Hybridisation
The membrane was placed in a Hybaid incubation bottle and 5 m L of
prehybridisation solution was added. This solution contains various
blocking reagents and detergents. The membrane was prehybridised at
65°C in a Hybaid Mini Oven M k II for 6 hours and the denatured

32

P

labelled probe was added. The probe was allowed to hybridise to the
membrane overnight at 65°C. To remove any non-specific binding, the
blot was washed twice at 42°C for 5 minutes with 0.2% SDS in 5X SSC.
This wash step was then repeated with 0.2% SDS in 2X SSC and 0.1% S D S
in IX SSC. The blot was removed from the bottle and allowed to dry o n
paper towel.
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Detection
After the membrane was completely dry, it was wrapped neatly in cling
wrap and exposed to X-ray film (Fuji) for an appropriate period of time,
dependant on the radioactive strength of the probe and the degree of
binding. The film was then developed in a darkroom. This was done by
immersion in X-ray developer (GBX, Kodak) for 1-2 minutes, rinsed with
water and held in X-ray fixer (GBX, Kodak) until transparency became
evident. The film was rinsed thoroughly with water and air dried before
viewing hybridised bands.

2.4.4 Restriction Endonuclease Analysis of DNA

The DNA to be digested (usually 5-10 uX) was added to a microfuge tube
together with 2 uX of an appropriate 10X restriction buffer. The v o l u m e
was m a d e up to 19 jxL with d H 2 0 and 1 uX (10 Units) of restriction
enzyme (Boehringer-Mannheim) added. The tube was then incubated for
at least 60 minutes at 37°C. Deactivation of the enzyme was then achieved
by incubation of the tube at 65°C for 10 minutes.

2.4.5 Ligation of DNA
Appropriate amounts of the DNA to be ligated were combined with dH20
(to a volume of 35 uX) in a sterile microfuge tube at 60°C and incubated
for 5 minutes. The tube was then incubated for 30 minutes each at 37°C,
room temperature and 10°C, then placed on ice. After the addition of 4 ^iL
of 10X ligation buffer and 1 ^iL (2 Units) of T 4 D N A ligase (BoehringerMannheim), the tube was stored at 12°C overnight. The ligase enzyme
was then deactivated at 65°C for 10 minutes.
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2.4.6 Competent Cell Preparation

Cells to be made chemically competent were inoculated into 200 mL of LB
and incubated with agitation at 37°C until an optical density of
approximately 0.5 at O D 5 6 0 was attained. Following centrifugation at 5 000
g for 10 minutes at 4°C, the supernatant was discarded and the cells placed
on ice for 10 minutes. The cells were resuspended in 100 m L of chilled 0.1
M

M g C l 2 and centrifuged again under the same conditions. The

supernatant carefully poured off. The pellet was resuspended in 10 m L of
chilled 0.1 M CaCl 2 and stored on ice.

2.4.7 Transformation of DNA

Transformation of plasmid DNA into chemically competent cells was
accomplished using the method of Cohen (1972). To 200 uX of competent
cells on ice, either 5 uX of uncut plasmid D N A or 20 uL of a ligation
mixture was added. The cells were placed on ice for 60 minutes before a 5
minute heat shock step was carried out at 37°C. The cells were pelleted at
10 000 g for 1 minute and the supernatant discarded. The pellet was
carefully resuspended in 0.5 m L of LB and incubated without shaking at
37°C for 60 minutes. The suspension was then aliquotted out onto
selective agar plates and incubated at 37°C until transformant colonies
appeared.

2.4.8 DNA Sequence Analysis

Sequencing Reactions
Plasmids containing B. pertussis promoters were sequenced using either
an ABI 373 or 377 system. The plasmid D N A to be sequenced was
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extracted using either the Qiagen Spin-Prep or the Pharmacia Flexi-Prep
methods. The amount of DNA required for each sequence reaction
ranged between ~200 ng and 1 (Xg. Sequencing reactions were performed
in 20 uX volumes either in 0.1 mL microfuge tubes in a Perkin Elmer
GeneAmp9600 thermal cycler or in 0.5 mL tubes in a Hybaid Thermal
Reactor. Sequencing reactions were set up using 8 oX of sequencing
reaction mix (Perkin Elmer), 5 ng of oligonucleotide primer and 500 ng of
plasmid template DNA. A total of 25 cycles of either of the cycling
parameters listed in Table 2.6 were used. Alternative 1, with a longer
denaturation step was used especially when the GC content of DNA to be
sequenced was particularly high.

Table 2.6 Alternative parameters used for sequencing reactions

Step Alternative 1 Alternative 2
Denaturation
Annealing
Polymerisation

96°C; 55 sec.
50°C; 15 sec.
62°C; 4 min.

95°C; 10 sec.
50°C; 5 sec.
60°C; 4 min.

The 20 uX sequencing reaction was then precipitated with the addition of
2 uX of 3 M sodium acetate (pH 4.6) and 50 uX of chilled ethanol.
Incubation at -20°C for 10 minutes accelerated this process. Centrifugation
at 16 000 g for 20 minutes pelleted the DNA which was then washed with
250 uX of 70% ethanol and air or vacuum dried. Resuspension of the
pellet took place in 5 uX of formamide loading buffer. The sample was
then heated to 90°C for 2 minutes to promote denaturation and then
placed on ice prior to loading onto the gel.

Sequencing Gel Electrophoresis
Polyacrylamide sequencing gels were made using 4% acrylamide (19:1
acrylamide: bis-acrylamide; Bio-Rad; Amresco) buffered with IX TBE and
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containing 6 M

urea. The gel solution was exposed to amberlite ion

exchange resin, filtered through
(Schleicher

&

Schuell)

and

polymerisation with a m m o n i u m

a 0.2 fim

degassed

for

cellulose nitrate filter
10 minutes

prior

to

persulfate and T E M E D and injected

into an ABI casting apparatus. After a curing time of 2 hours, the gel was
pre-run for 1 hour until the gel temperature was maintained at a constant
48°C. Samples (2 uX) were loaded onto the gel with the aid of a shark
tooth comb and gel loading pipette tips. The gel was then run for 10 hours
on an ABI 373 or 377 D N A sequencer at a constant 37 W

(-2350 V, 16

mAmp).

2.5 Microbiological Techniques
2.5.1 Bacterial Conjugation

The bacterial strains to be mated were grown on appropriate medium
after which one loopful of each strain was resuspended in 500 ^L of sterile
0.7% saline solution. This mixture was plated out onto non-selective
m e d i u m and incubated overnight at 37°C, allowing the strains to mate. A
loopful of the resultant growth was resuspended in 1 m L of a sterile 0.7%
saline solution, tenfold serially diluted and plated out onto selective agar.

2.5.2 Replica Plating

Patching onto replica agar plates was performed using sterile wooden
toothpicks. Individual toothpicks were used to remove (pick) individual
bacterial colonies from growth plates and patch them onto replica plates
in sets of 50 or 100 colonies per plate.
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2.6 Characterisation of Recombinant Bacterial
Strains
2.6.1 Poly acrylamide Gel Electrophoresis

Newly formed recombinant bacterial strains were characterised and
compared to parental strains using a polyacrylamide gel electrophoresis
(PAGE) system modified from Laemmli (1970), western blot analysis and
enzyme linked immunosorbent

assay (ELISA) to examine

protein

expression.

Sample Preparation
A n appropriate number of cells (~106 cells/mL) were resuspended in 100
|iL of a sterile 0.7% sodium chloride solution in a microfuge tube. To this,
an equal volume of P A G E cracking buffer was added and the tube
incubated at 95°C for 10 minutes. To aid in the disintegration of cell
debris, the solution was subjected to a brief period of sonication using a
Branson Sonifier 250 until opacity was sufficiently diminished.

Electrophoresis and Staining
A

homogeneous

10 or 1 5 % polyacrylamide (35:0.8 acrylamide: bis-

acrylamide, Bio-Rad) running gel was used to resolve proteins, whilst a
4 % stacking gel allowed for concentration and even running of samples.
Protein samples were electrophoresed in a Bio-Rad Mini Protean II gel
apparatus powered by a Bio-Rad Power Pack 300. The gel was run at 100 V
for 1-2 hours in Tris/Glycine buffer, after which the protein bands were
stained for 3 hours using Coomassie Brilliant Blue. Excess stain was then
removed by washing in P A G E Destain for 4 hours or overnight.
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2.6.1 Western Blot Analysis

Following the electrophoretic separation of proteins by PAGE, transfer
onto nitrocellulose (western blotting), a process developed by Burnette
(1981), w a s performed.

Transfer onto Nitrocellulose
After the stacking gel had been removed, the gel, together with a piece of
nitrocellulose

(pore size: 0.45|im, Bio-Rad)

or nylon

membrane

(positively charged, Boehringer Mannheim) of equal size w a s equilibrated
for 15 minutes in western buffer. Five sheets of filter paper, pre-soaked in
the same buffer were individually placed onto the anode of the transfer
apparatus, a Bio-Rad Trans-Blot® Semi-Dry transfer cell. These were
followed by the nitrocellulose membrane, the gel and another five filter
papers. Air bubbles were removed after the addition of each layer. T h e
cathode w a s placed on top of the stack and a constant voltage of 15 V was
passed through the system for 20 minutes.

Detection of Proteins
Immediately following transfer, the nitrocellulose was placed in a
blocking solution ( 5 % skim milk powder in PBS) and rocked gently at
room temperature for 60 minutes. The blocker was discarded and an
appropriate dilution of the primary antibody (a cocktail of anti-pertussis
toxin monoclonal antibodies E19, E205 and E251 (Walker et al, 1991b)
diluted appropriately in PBS) was applied. After at least 60 minutes
incubation time, the antibody solution was discarded and the m e m b r a n e
washed in PBS (3 x 10 minutes) to remove all traces of unbound antibody.
The secondary antibody solution, an anti-mouse alkaline phosphatase
conjugate (Boehringer Mannheim), was added and incubation took place
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for a further 60 minutes. This solution was discarded and another 3 x 10
minute washes in PBS followed. A chemiluminescent detection system
based on Lumigen P P D or Lumi-Phos 530 (Boehringer M a n n h e i m ) was
used. The manufacturer's suggested protocol was strictly adhered to w h e n
using this system as an alkaline phosphatase substrate.

2.6.3 Enzyme Linked Immuno-Sorbent Assay (ELISA)

Bordetella culture samples were taken at the end of log-phase growth
(~109 cells/mL). The

cells were

separated from

the m e d i u m

by

centrifugation at 10 OOOg for 10 minutes and heat killed at 65°C for 15
minutes. A n appropriate dilution (1/5) of each sample was prepared for
the ELISA assay. Supernatant and cellular fractions were tested for the
presence of pertussis toxin using a non-competitive, simultaneous
sandwich assay.

Plates used for the detection of PT or FHA were coated with antibodies
against these proteins. Plates used in the detection of serotype 2 or 3
fimbriae or pertactin were coated with B. pertussis cells. Horse radish
peroxidase (HRP) conjugated monoclonal antibodies (mAb), specific for
each antigen were used as the secondary antibody. The B. pertussis
samples were added to plate wells, together with the H R P conjugated
m A b and incubated for 1 hour at room temperature. If present in the
sample, the antigen is bound specifically by the H R P conjugated m A b and
the immobilised antibody simultaneously. O n the addition of N B T
substrate, H R P catalyses the formation of a coloured product. This
reaction was allowed to proceed until the absorbance of a positive control
well reached a fixed level, w h e n sulfuric acid (0.25 M , final concentration)
was added to stop the reaction. The absorbances, indicative of the a m o u n t
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of antigen present were then measured spectrophotometrically at 450 n m
using a Bio-Rad Model 3550 Microplate Reader. Pre-coated ELISA plates
were supplied by CSL Ltd.
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Chapter Three

Results

Part A. Pertussis Toxin Expression
in B. bronchiseptica
The current strategy for the vaccination against whooping cough is to
immunise

with a component vaccine, consisting of detoxified and

purified virulence determinants from B. pertussis. Included in all such
vaccines produced thus far has been pertussis toxoid. Therefore the
expression of large amounts of genetically detoxified P T is required. T h e
expression of P T in B. pertussis itself is inherently low and this bacterium
is also slow-growing and nutritionally fastidious. Production of P T in £.
coli has also not been achieved to an acceptable extent due to the
incompatibility of gene expression signals, inclusion body formation and
posttranslational processing problems. Therefore, the basis of this work is
to use the closely related species, B. bronchiseptica, to express and secrete
PT. This species is faster growing and less fastidious than B. pertussis and
due to the high homology to B. pertussis was thought to be an excellent
candidate P T production species.

3.1 Characterisation of Original Strains
The strain from which the PT expression locus was to be cloned, ATCC
10580:-.TnfusPTl is a permanently avirulent strain of B. bronchiseptica,
genetically modified to produce large amounts of pertussis toxin (Walker
et al, 1991a). It w a s constructed by cloning a promoterless P T operon into
a suicide vector where it was randomly transposed into the c h r o m o s o m e
of an avirulent B. bronchiseptica strain under the control of a strong
constitutive promoter (Walker et al, 1991a). The P T production status of
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this strain was analysed using polyacrylamide gel electrophoresis and
western blotting techniques. It was found that the PT expression levels of
ATCC 10580::TnfusPTl had remained unchanged since the original study
(Walker et al, 1991a) (result not shown). Although the permanent loss of
virulence in this strain is due to deletions in of the bvg locus, the
avirulent (non-haemolytic) status of ATCC 10580::Tn/usPT2 was
confirmed by culturing on Bordet Gengou agar.

In this study, isogenic bug-positive and bug-negative strains of B.
bronchiseptica were used to compare PT expression and secretion levels.
Thus, the virulent B. bronchiseptica strain BB7865 and the isogenic
avirulent strain BB7866 (Monack et al, 1989) were tested for haemoly tic
activity. To obtain a second set of isogenic strains, it was necessary to
create a bug-negative derivative of the virulent (haemolytic) B
bronchiseptica strain 5376. This was achieved by continued subculture of
this strain on Bordet Gengou agar. Eventually, large, flat, non-haemolytic
spontaneous avirulent mutant colonies were isolated and one designated
B. bronchiseptica 5377 (result not shown). Naturally, a non-haemolytic
phenotype may also result from a mutation in the cya operon encoding
adenylate cyclase and associated accessory proteins. Proof that the nonhaemolytic phenotype displayed by 5377 was caused by a spontaneous
mutation in the bvg operon was therefore required. It was demonstrated
that B. bronchiseptica 5377, was genuinely avirulent when the addition of
pMW132 (Walker et al, 1991a) (Appendix III) converted the phenotype to
haemolytic (results not shown), thereby complementing the mutation.
This plasmid contains the genes encoding the bvg two component signal
transduction system.
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3.1.1

Isolation of Spontaneous Resistance Mutants

To aid in the selection of transconjugants in subsequent mating
experiments, all four recipient strains (the virulent B. bronchiseptica 5376
and BB7865, and the isogenic avirulent strains 5377 and BB7866) were
subjected to passaging on agar containing rifampicin until spontaneous
resistant mutant colonies arose. The ease with which

spontaneous

rifampicin resistant mutants were isolated, created the possibility of this
phenomenon occurring in subsequent matings. Therefore the rifampicin
resistant recipient strains were also passaged on agar containing nalidixic
acid to allow for double resistance mutants to be used in further matings.
During this process, it w a s found that BB7865, and BB7866, possessed a
natural resistance to nalidixic acid. Rifampicin/nalidixic acid double
resistance mutants of BB7865, BB7866, 5376 and 5377 were isolated. These
strains, designated BB7865 Rif, BB7866 Rif r , 5376 Rifr Nal r , and 5377 Rifr
Nal r were used as recipients in subsequent conjugation experiments. T h e
donor strain, B. bronchiseptica A T C C 10580::Tn/usPT2 was found to be
sensitive to both of these antibiotics.

3.1.2 Genetic Analysis of B. bronchiseptica for the Presence of
Pertussis Toxin Secretion Genes

With the failure of B. bronchiseptica ATCC 10580::TnfusPTl to secrete PT
in an earlier study (Walker et al, 1991a), and the characterisation of the
ptl genes of B. pertussis which are required for pertussis toxin secretion
(Weiss et al, 1993) it was important

to determine

whether

B.

bronchiseptica possesses an intact ptl operon. Most of the 60 base
differences in the ptlA-ptlC region of B. pertussis and B. bronchiseptica
are situated around the ptlA gene (Locht and Keith, 1986; Nicosia et al,
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1986; Weiss et al, 1993). The homology between B. pertussis and B.
bronchiseptica ptlB and ptlC genes is very high, with only 5 base
differences in 924 base pairs. Although B. bronchiseptica Ptl proteins are
not detected in immunoassays, only low levels of three of the Ptl proteins
could be detected in B. pertussis (Johnson and Burns, 1994). Replacement
of the B. bronchiseptica Fptx promoter with the B. pertussis Fptx promoter
results in detectable expression of PtlF in western blots (Kotob et al, 1995)
suggest that B. bronchiseptica m a y contain functional ptl genes, and only
the promoter was non-functional. It was assumed that homologous
sequences at both ends of the operon would be indicative of a complete
ptl operon. Thus, B. bronchiseptica chromosomal D N A was probed for
the presence of the ptlH gene at the 3' end of the operon. The EcoRI
restricted D N A of three strains of B. bronchiseptica and one strain of B.
pertussis underwent Southern hybridisation analysis (Figure 3.1). T h e
P C R amplified 0.5 kb ptlH fragment was radiolabeled and used as a probe.
It was found that all strains tested exhibited equal binding, suggesting that
the genome of B. bronchiseptica contains sequences homologous to the
ptlH gene of B. pertussis.
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Genetic analysis of pertussis toxin secretion genes. (A) Diagrammatic

representation of the ptl operon and amplification of the ptl gene fragment (ptlH)

is essential for PT secretion in B. pertussis. Specific oligonucleotide primers (arr
were designed for the amplification of the 512 bp fragment (shaded box) using PCR
technology. Primers used for this procedure, PTSECRTN 5' and PTSECRTN 3' are listed

Table 2.3. (B) Southern hybridisation of EcoRI digested chromosomal DNA of three B.

bronchiseptica strains, ATCC 10580 (lane 1), 5377 (lane 2), BB7866 (lane 3) and B. p
Tohama I (lane 4) using the
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P labelled 0.5 kb ptlH fragment as a probe (lane 5).

Molecular weight markers (kb) are indicated.
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3.2 In vivo Cloning of the Pertussis Toxin
Producing Locus
The cloning of the PT expression locus of ATCC 10580::TnfusPTl,
encompassing the P T operon, the B. bronchiseptica promoter (PBb) and
the kanamycin resistance gene was first attempted using cosmid cloning
techniques. A number of kanamycin resistant clones were obtained,
however whilst all contained the kanamycin resistance gene, none of
these contained sequences homologous to the recombinant P T operon as
determined by Southern hybridisation analyses (results not shown).
Possibly the genetic locus containing the P T operon controlled by P B b is
either unstable in E. coli or produces gene products which are lethal to E.
coli. With the failure of cosmid cloning to isolate the P T expression locus
for transfer to B. bronchiseptica strains, an in vivo technique was
developed.

Two mating experiments were required for the in vivo cloning of the
TnfusPT

P T expression locus. Firstly, pR751::Tn823 was conjugally

transferred from E. coli Q358 (pR751::Tn813) into B. bronchiseptica A T C C
10580::Tn/ttsPrL In the second mating, chromosome transfer between B.
bronchiseptica A T C C 10580:-.TnfusPTl (pR751::TnS13) and the rifampicin
and nalidixic acid resistant derivatives of B. bronchiseptica strains
occurred. Transconjugants containing the P T expression locus were
identified by dual antibiotic selection for transfer (kanamycin resistance)
in the recipient strains (rifampicin resistance).

3.2.1 Transfer and Integration of pR751::Tn523

Escherichia coli Q358 (pR751::TnS13) (Bowen and Pemberton, 1985)
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harbours the trimethoprim resistant, broad host range plasmid pR751
(Jobanputra

and

Datta, 1974), containing

the

cointegrate-forming

transposon, Tn813 (Diver et al, 1983). Transposon Tn813, is a transposase
positive (tnpA+), resolvase negative mutant (tnpR') derivative of the
mercury resistant transposon Tn22 (Grinstead et al, 1982). Plasmid pR751
(48 kb) possesses transfer genes (tra) and an origin of transfer (oriT),
allowing for the conjugal transfer of the plasmid D N A between donor
and recipient strains. The entire plasmid then integrates into the recipient
chromosome via the transposase of Tn813. Since the resolvase capability
of this entity is non-functional due to a deletion mutation (Diver et al,
1983), the plasmid D N A remains part of the recipient chromosome. T h e
tra genes and oriT of pR751, n o w resident on the bacterial genome, thus
transform the chromosome into a high frequency recombinant. This
enables the principal of chromosome transfer to occur in subsequent
conjugation experiments.

The strain carrying the PT expression locus, Bordetella bronchiseptica
ATCC

10580::Tn/wsPT2

was

mated

with

Escherichia coli Q358

pR751::Tn823 (Figure 3.2). The resultant growth from this mating was
plated onto SS-X agar containing kanamycin and trimethoprim to select
for B. bronchiseptica transconjugants ( A T C C 10580:-.TnfusPTl containing
pR751::TnS23). This mating selected for the transfer of the conjugative
plasmid into the P T expression strain of B. bronchiseptica. The frequency
of transfer of this mating was calculated as 3.2 x 10'1 transconjugants per
recipient cell (Table 3.1). A single transconjugant from this mating was
tested separately, on

urease

agar, SS-X

agar supplemented

with

cephalexin, and Bordet Gengou agar. After it was confirmed that this
clone w a s a non-haemolytic, urease positive B. bronchiseptica strain, it
was designated A T C C

10580::Tn/ws?n (pR751::Tn823) and used in
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Q358 pR751::Tn813

A T C C 10580::Tn/MsPri

V.

O

Kanamycin & Trimethoprim
Selection

A T C C 10580::Tn/«sPTC (pR751::Tn813)

Figure 3.2

Transfer of pR751::Tn823 into A T C C 10580::Tn/usPT2. The Escherichia coli

strain, Q358 (pR751::Tn823) contains the conjugative plasmid pR751, harbouring the

cointegrate forming transposon Tn823 (filled box). When this strain is mated with A

10580::Tn/usPT2, products encoded by the tra genes of pR751 (shaded box) induce the

transfer of the plasmid to the B. bronchiseptica strain. The transposase enzyme enc
Tn#23 catalyses cointegrate formation of pR751::Tn#23 with the chromosome of ATCC
10580::Tn/usPT2. This forms a permanent genomic cointegrate due to the defective

resolvase gene of Tn823. The trimethoprim resistance gene is represented by an open

The PT expression locus of ATCC 10580::Tn/wsPT2 consisted of the promoter PBb, (fill
arrowhead), the PT operon (striped box), and the kanamycin resistance gene (checked
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subsequent experiments. The newly transferred plasmid is capable of
cointegrative transposition into the bacterial chromosome, mediated by
the transposase enzyme of TnS23.

3.2.2 Chromosome Transfer and Homologous Recombination of
the Pertussis Toxin Production Locus

Now integrated into the chromosome, pR751 still has the ability to induce
conjugation. The

transfer of part of the A T C C

10580::Tn/usPT2

chromosome into a recipient can be achieved using the integrated pR751
as a catalyst for this transfer. T w o virulent and two avirulent B.
bronchiseptica strains were each mated with A T C C 10580::TnfusPTl
(pR751::Tn$23) (Figure 3.3) and the resultant growth was plated onto SS-X
agar with kanamycin and rifampicin selection. A s would be expected for
this

mechanistically

difficult

chromosome

transfer

event,

transconjugants arose at a frequency in the order of 10"6-10"8 kanamycin
resistant transconjugants per recipient cell (Table 3.1). D u e to the
promiscuous

nature of the

conjugative

plasmid, the transfer of

trimethoprim resistance occurred at a m u c h higher rate, in the order of
10"1 transconjugants per recipient cell (Table 3.1).

The high number of rifampicin spontaneous mutants formed in the
initial mutation experiments led to an extra precaution w h e n selecting
transconjugants. W h e n the donor, A T C C 10580::Tn/«sPn (pR751::TnS13)
was mated with each of the four B. bronchiseptica recipient strains, there
was a distinct possibility that m a n y of the transconjugants were in fact
merely spontaneous rifampicin resistant mutants of the donor strain. T o
select transconjugants (B. bronchiseptica Rifr Nalr::Tn/usPTl), single K a n r
Rifr colonies growing on selection plates were replica plated onto SS-X
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A T C C 10580::Tn/wsPT3
(pR751::Tn813)

BB7865 Rifr

•Q

Rifampicin & Kanamycin
Selection

BB7865 Rifr::TnfusPTl

Figure 3.3

In vivo transfer of the PT expression locus of Bordetella

bronchiseptica

ATCC 10580::Tn/wsPT2. The newly formed strain, designated ATCC 10580::Tn/usPT2
(pR751::Tn823) was conjugally mated with the B. bronchiseptica strains (eg. BB7865 Rifr).
The tra genes of pR751, once within the chromosome, promotes chromosome transfer. The
transferred section of donor DNA then undergoes homologous recombination to become
integrated into the recipient genome. The PT expression locus is thus transferred to the

recipient strain. The PT expression locus of ATCC 10580::Tn/wsPT2 consisted of the promote
PBb, (filled arrowhead), the PT operon (striped box), and the kanamycin resistance gene
(checked box).

agar with kanamycin and rifampicin selection and onto SS-X agar with
nalidixic acid selection. As spontaneous double mutants are extremely
rare (less than 1 in IO9), the colonies which were kanamycin, rifampicin

and nalidixic acid resistant were selected for further study. The proportion
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Table 3.1

Frequency of transfer data of the P T expression locus (Kan r ) and the

conjugative plasmid pR751::TnS23 (Tpr) from A T C C 10580::Tn/usPT2 (pR751::TnS23) to each
of the B. bronchiseptica recipient strains. Frequency

of transfer

is measured

as

transconjugant cells per recipient cell.

Recipient
Strain

Plasmid
Transfer

Chromosome
Transfer

5376 Rifr Nal r

1.60 x IO'2
8.71 x 10"1

1.04 x 10"6
7.92 x 10"8
1.52 x 10"6

5377 RiF Nal r
BB7865 Rif1
BB7866 RiF

2.50 x IO"2
6.60 x 1 0 4

8.25 x 10"9

of transconjugants expressing resistance to nalidixic acid was ~50%. The
colonies sensitive to nalidixic acid, were assumed to be spontaneous
mutants of the donor strain. The Kan r Rifr Nal r transconjugants were
tested on SS-X agar with trimethoprim selection and exhibited 1 0 0 %
resistance to this antibiotic; presumably, these transconjugants also
contain the plasmid pR751::Tn823 which encodes the trimethoprim
resistance gene. Virulent and avirulent derivatives containing the
mobilised P T expression locus retained the appropriate phenotype as
determined by haemolytic activity on B G agar plates (results not shown).
A selected Kan r Rifr Nal r transconjugant from each of the four matings,
designated

B.

bronchiseptica BB7865

Rifr::Tn/usPT2,

BB7866

Rifr::Tn/wsPT2, 5376 Rifr Nalr::Tn/usPTl, and 5377 Rifr Nalr::Tn/«sPri,
was taken for further analysis using Southern hybridisation, P A G E and
ELISA techniques.
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3.3 Analysis of Recombinant Strains
3.3.1 Southern Hybridisation Analysis

To confirm the success of the in vivo cloning of the PT expression locus,
Southern hybridisation analysis was performed. The chromosomal D N A
of recombinant strains and their respective parental strains was digested
with EcoRI restriction endonuclease

and subjected to agarose gel

electrophoresis. The subsequent restriction profile was then Southern
transferred, and probed with
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P labelled p M W 1 2 7 D N A (Appendix III)

(Walker et al, 1991a). This plasmid contains the recombinant minitransposon Tn/usPT (Figure 3.1). The results presented in Figure 3.4
suggest that the P T expression locus, (P Bb + TnfusPT, 10.5 kb band) was
transferred from A T C C 10580::Tn/usPTl to each of the two virulent and
two avirulent strains of B. bronchiseptica. The 2.2 kb kanamycin
resistance gene and the cryptic P T operon which is present in all B.
bronchiseptica strains (Arico and Rappuoli, 1987) were also detected. The
plasmid p M W 1 2 7 contains an additional reactive band (Figure 3.4B, Lane
12) which represents the suicide plasmid into which the promoterless P T
operon was cloned (pUT::miniTn5/]<m) (Herrero et al, 1990) to form
p M W 1 2 7 . The P T expression system, including the constitutive promoter
from A T C C 10580 (P Bb + TnfusPT, lane 2, 10.5 kb) was cloned, by in vivo
techniques, into virulent and avirulent strains of B. bronchiseptica as
demonstrated in Figure 3.2 and Figure 3.3.
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Figure 3.4

Diagrammatic representation of the PT expression locus (A). PT subunit

genes SI to S5 (open boxes), the kanamycin resistance gene (Kanr; shaded box) and the

constitutive B. bronchiseptica promoter (PBb; filled arrow) are indicated. Only EcoR
restriction enzyme sites are shown. (B) Southern hybridisation analysis of B.

bronchiseptica strains before and after the transfer of the PT expression locus. Tn/
(incorporating the PT operon and kanamycin resistance gene) harboured on plasmid
pMW127 (Walker et al, 1991a) was used to probe the EcoRI digested genomic DNA of

ATCC 10580 (lane 1), ATCC 10580:-JnfusPTl (lane 2), 5377 Rifr Nalr (lane 3), 5377 Rif

Nalr::Tn/usPT2 (lane 4), BB7866 RiF (lane 5), BB7866 RiF::Tn/usPT2 (lane 6), 5376 Ri
Nalr (lane 7), 5376 Rifr Nalr::Tn/usPTl (lane 8), BB7865 Rifr (lane 9), and BB7865

RiF ::TnfusPTl (lane 10). lanes 11 and 12 contain EcoRI digested B. pertussis Toham
pMW127 DNA respectively. Sizes of markers (kilobases) are indicated.
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3.3.2 Protein Analysis of Recombinant B. bronchiseptica Using
P A G E and Western Blotting

The four recombinant B. bronchiseptica clones containing the PT
expression locus were prepared for P A G E analysis. A sample of each
recombinant strain, together with negative (parental strain) and positive
( A T C C 10580::Tn/wsPT2) controls, were subjected to polyacrylamide gel
electrophoresis. The gels were run in duplicate, one being stained with
Coomassie blue R250, and the other undergoing western transfer. T h e
western blot analysis demonstrated the expression of P T by the n e w
recombinant strains containing the P T expression locus (results not
shown). All of the P T producing strains, including B. pertussis exhibited a
band corresponding to the binding of the anti-Si subunit monoclonal
antibody, E19 (Walker et al, 1991b) used as the primary antibody.

3.3.3 Analysis of B. bronchiseptica Strains for Pertussis Toxin
Secretion by E n z y m e Linked Immunosorbent Assay

Western blot analysis confirmed the transfer of the PT expression locus
into two virulent and two avirulent strains of B. bronchiseptica was
successful and that P T production was equivalent to that of the original
strain. Supernatant and cellular fractions of Bordetella cultures were
assayed for the presence of P T using ELISA techniques. Isogenic virulent
and

avirulent

B. bronchiseptica strains and

their P T

producing

derivatives were tested, as was B. pertussis T o h a m a I (Figure 3.5).
Expression of P T by all B. bronchiseptica strains containing the P T
expression locus was cell-associated, whereas the B. pertussis strain
secreted large quantities of P T to the culture supernatant.
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Figure 3.5 Analysis of pertussis toxin secretion by recombinant B. bronchiseptica

strains. Absorbance at 450 nm corresponding to relative PT levels in cell-associated (filled
bars) and culture medium fractions (open bars) of B. bronchiseptica strains (A) ATCC 10580,
(B) ATCC 10580::Tn/wsPTl, (C) 5377 RiF NaF, (D) 5377 Rifr Nalr::Tn/usPTl, (E) 5376 Rifr
Nalr, (F) 5376 RiF Nalr::Tn/wsPTl, (G) BB7866 RiF, (H) BB7866 RiF::Tn/wsPTl, (I)
BB7865 RiF and (J) BB7865 RiF::Tn/wsPT2 were compared to equivalent fractions of (K) B.
pertussis Tohama I using a PT-specific ELISA assay. In contrast to B. pertussis Tohama I
which secreted a large proportion of the PT it produced to the growth medium, the PT
produced by the recombinant B. bronchiseptica strains was cell-associated.

Thus, a system has been developed for the in vivo cloning and transfer of
the PT expression locus of ATCC 10580::Tn/usPTl. The PT expression
locus was transferred to isogenic bug-positive and bug-negative strains of
B. bronchiseptica and the PT secretion levels of these strains was
monitored. It was found that neither virulent nor avirulent B.
bronchiseptica exhibited the ability to secrete PT, confirming that the B.
bronchiseptica ptl genes are not expressed.
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Part B. Genetic Analysis of Bordetella pertussis
Virulence Factor Promoters
Research in the area of whooping cough vaccines is currently
concentrated on the development of n e w generation subunit vaccines. A
number of laboratories around the world are working on acellular
vaccines, using

component

antigens

purified

from

B. pertussis.

Immunogenic antigens important in the protective efficacy of the current
vaccine have recently been tested in h u m a n

field trials of acellular

vaccine preparations (Greco et al, 1996; Gustafsson et al, 1996). These
antigens include pertussis toxin, filamentous haemagglutinin, serotype
specific fimbriae and pertactin.

The current Australian whooping cough vaccine, developed by
C o m m o n w e a l t h Serum Laboratories Australia Ltd. (CSL) consists of a
heat killed whole-cell preparation of Bordetella pertussis included within
the Diphtheria Tetanus Pertussis (DTP) Triple Antigen®. Research at C S L
has been directed towards the selection of stable, virulent-phase B.
pertussis vaccine strains capable of producing high levels of the desired
vaccine antigens. In the endeavours to develop a more effective vaccine
strain of Bordetella pertussis, C S L have, through continued subculture
and selection, obtained non-recombinant naturally occurring mutant
strains which overproduce PT, F H A , serotype specific fimbriae and
pertactin.

Three of these strains, CSL 127S, CSL 137S and CSL 1237S (Table 3.2)
represent clinically significant serotypes of B. pertussis and are excellent
vaccine candidates for either a whole cell vaccine or for the production of
antigens for n e w generation acellular vaccines. H o w e v e r the nature and
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extent of the mutations resulting in antigen expression were not
elucidated at the genetic level. Such mutations, once characterised, m a y
be engineered into other B. pertussis vaccine strains to improve antigen
yield.

3.4 Characterisation of Original CSL Strains
Three parental (wild-type) and three selected (overexpressing) strains
were initially cultured on SS agar supplemented with cephalexin and
Bordet G e n g o u agar to ensure their virulence status. All were found to be
haemolytic

Bordetella pertussis strains

exhibiting

small

colony

morphology indicative of virulent phase organisms (results not shown).

The antigen production of these strains was analysed using an ELISA.
Data characterising the amount of antigen overproduction by the selected
B. pertussis strains as compared with their respective parental strains
were performed at C S L (Table 3.2). A problem arose at this point of the
study w h e n it w a s found that one of the parental strains, C S L 137 could
not be analysed for virulence antigen expression. The strain, possibly after
being passaged m a n y times on agar plates during the selection process at
CSL, seems to have lost the ability to grow in defined liquid SS m e d i u m .
The antigen expression levels of the selected strain, C S L 137S cannot be
compared to those of the parental strain, only those of the other C S L
strains.

The selected B. pertussis strains demonstrate overexpression of different
proteins which were therefore postulated to be the result of mutations at
different genetic loci. This study aimed to determine the genetic basis of
these mutations.
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Table 3.2

Virulence factor production by C S L B. pertussis strains. All figures are

concentrations measured in |Xg/mL except those for pertactin, which are concentrations
measured in EIA units/mL. Abbreviations: N D , not detected.

Strain

PT

CSL 127
CSL 127S

3.5
5.5

CSL 137S
CSL 1237
CSL 1237S

FHA

Fim2

Fim3

Pertactin

0.5
23.5

0.4
7.3

ND
ND

12
14

10.8

49

ND

6.8

351

5.2
9.8

64
40

1.1
1.7

1.6
3.1

79
106

The chromosomal D N A

from each strain was extracted, and using

appropriate oligonucleotide primers, the relevant promoter and ribosome
binding regions were amplified using P C R techniques. The amplified
promoter D N A was then cloned into a plasmid cloning vector. The D N A
sequence of the amplified promoter and ribosome binding region
obtained from each P C R reaction was elucidated to determine the location
of any differences (arising from mutations) between the selected and
parental strains.

3.5 Analysis of CSL 127 Strains
Searching for an upregulation in the fimbrial production of potential
vaccine strains, researchers at C S L Ltd. detected and isolated CSL 127S, a
putative spontaneous mutant of the parental strain C S L 127. This strain
exhibits an almost 20 fold increase in Fim2 production compared with the
parental strain. A n upregulation of F H A expression (47 fold) was also
observed. D u e to the linkage of the fimbrial and F H A accessory genes
(fimB-fimD,fhaC), it was therefore hypothesised that the overexpression
exhibited by this strain m a y be the result of a mutation in the promoter of
the fimbrial/FHA accessory genes.
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The fimbrial serotype expressed by B. pertussis is dependent upon the
transcription from the major fimbrial subunit genes. Strain C S L 127
expresses serotype 2 fimbriae. The serotype can change in vivo by a
switching of promoter activation termed

fimbrial phase variation

(Willems et al, 1990). Sequence data of fimbrial genes, has revealed s o m e
interesting features of fimbrial promoter

architecture (Figure 1.12)

(Pedroni et al, 1988; Locht et al, 1992; Willems et al, 1992). Alteration in
the number of cytosine residues in the "C stretch" of the promoter is the
source of fimbrial phase variation (Willems et al, 1990). The distance
between the putative -10 box and the B v g A binding site (Figure 1.12) m a y
be crucial for the activation of transcription, and an alteration in the
number of cytosine residues in the C stretch affects this distance (Willems
et al, 1990).

The genes encoding accessory proteins required for the correct delivery
and presentation of both fimbriae and F H A , fimC, fimD, and fhaC are
translationally linked (Willems et al, 1993). All three of these genes
overlap and there is a putative Shine-Dalgarno site directly upstream of
fimC, the first of these genes. Translation of fimD

m a y require the

translation of fimC to prevent the creation of a hairpin loop just prior to
the end of the fimC

m R N A . This would allow continual ribosomal

attachment and translation of fimD (Willems et al, 1993; Willems et al,
1994).

3.5.1 Amplification of CSL 127 Promoter Regions

Genomic DNA of both the parental (CSL 127) and selected (CSL 127S)
strains was extracted. This D N A

was then tested for purity and

concentration then diluted to an appropriate level for use as template

Ill

D N A in P C R amplification reactions. Regions of D N A encompassing the
putative promoters and ribosome binding sites of each of five relevant
genes were amplified using P C R technology.

The bvg/fha Intergenic Region
The 470 base pair region between the fhaB gene and the bvg operon
contains a number of virulence regulated and non-regulated promoters.
The entire region was amplified using the oligonucleotide primers
bvg/fha 5' and bvg/fha 3' (Figure 3.6).

The double stranded DNA PCR products shown in Figure 3.6 were then
eluted from the gel to remove contaminating unincorporated nucleotides
and excess primer D N A . The bvg/fha intergenic regions of CSL 127 and
CSL 127S were amplified using Pfu D N A polymerase.

The Pertussis Toxin Gene Promoter Region
The 304 base pair region containing the CSL 127 and CSL 127S pertussis
toxin gene promoter and Shine Dalgarno sequence was amplified using
the oligonucleotide primers P T 5' and P T 3' (Figure 3.7).

The double stranded DNA PCR products shown in Figure 3.7 were then
eluted from the gel to remove contaminating unincorporated nucleotides
and excess primer D N A . The P T promoter regions of CSL 127 and CSL
127S were amplified using Taq D N A polymerase.

The Fimbrial Accessory Genes Promoter Region
The 800 base pair region containing the CSL 127 and CSL 127S fimbrial
accessory gene promoter and Shine Dalgarno sequence was amplified
using the fim access 5' and fim access 3' primers (Figure 3.8).
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Figure 3.6

Amplification of the bvg/fha intergenic regions of CSL 127 and CSL 127S.

A. Genetic organisation of the bvg/fha intergenic region (Arico et al, 1989; Domeni
al, 1990). Open arrows represent bvgA and fhaB genes, with arrows indicative of the

direction of translation. Promoter regions bvg Pv P2, P3, and P4 as well as P^a are s

Start codons for each gene are boxed. Putative -10 and -35 boxes for fhaB are desig

Oligonucleotide primers are represented by long arrows. The non-homologous section o
bvg/fha 5' primer (Smal site) and the corresponding region of the bvg/fha 3' primer

(BamHl site) are shown in bold type. B. Agarose gel electrophoresis of amplified bvg
intergenic regions of CSL 127 (lane 1) and CSL 127S (lane 2). Amplified bands are
indicated.

(fhaB

bvg/fha 3'

GGATCC CCCCTGTACAGGTTCGTGTTCATATTCCGACCAGCGAAGTGAAGTAATCG
GGGGACATGTCCAAGCACAApTA|TAAGGCTGGTCGCTTCACTTCATTAGC
GCAGAATCCGTTATCGGCCTGCTCGTTTTAGGTTTTGAAATCCAGTGCCA
CGTCTTAGGCAATAGCCGGACGAGCAAAATCCAAAACTTTAGGTCACGGT 100
•l fha

TAGTCTGGATAAACCTCAGCACTTCGTCAGTCAGTAATGATCCCGTCCAT
ATCAGACCTATTTGGAGTCGTGAAGCAGTCAGTCATTACTAGGGCAGGTA
Pa ^
CAATGGATATTTATACAAGACTTGTAGGAAATTTCTTAGTCAAACCATCA
GTTACCT^TAAATATpTTCTGAACATCCTTTAAAG^ATCAGTTtTGGTAGT 200
fhaB -10
fhaB -35
AACCCTGTCCGGCACGTATAGGCGTGCGCCGACAACCCGCTCCCCGGCCC
TTGGGACAGGCCGTGCATATCCGCACGCGGCTGTTGGGCGAGGGGCCGGG
GCCGCGGGTGCCAGCGCAGGAATTCAGACTTTTCCTATTTTGGTATAGGA
CGGCGCCCACGGTCGCGTCCTTAAGTCTGAAAAGGATAAAACCATATCCT 300

P,

^

TACTGTTTAGCAGCACTCATGCCCGTATCGTTGCTTGCTGACGTATAGGA
ATGACAAATCGTCGTGAGTACGGGCATAGCAACGAACGACTGCATATCCT
P2
^
GAATGTGAAATTTCGCAGCCATTCCTTTGACGCATCAATGACATTACGCG
CTTACACTTTAAAGCGTCGGTAAGGAAACTGCGTAGTTACTGTAATGCGC 400
TTGCAGGATTTTTTTCTCGCCACGAAACTCAAAGCATATTCTTCTTATC§]
AACGTCCTAAAAAAAGAGCGGTGCTTTGAGTTTCGTATAAGAAGAATAGT
ITGITACAACAAAGTCCTCATC
ACATGTTGTTTCAGGAGTAG G G C C C
bvg/fha 5'

B

bvg/fha intergenic
region

bvgAS
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Figure 3.7

Amplification of the pertussis toxin genes promoter regions of C S L 127 and

CSL 127S. A. Sequence and organisation of the Pptx promoter (Locht and Keith, 1986;
Nicosia et al, 1986). Open arrow represents PT subunit genes, with the arrow indicative of
the direction of translation. Putative -10 and -35 boxes are indicated, as are 2 putative
overlapping consensus ribosome binding sites (SD, overlapping open boxes).
Oligonucleotide primers are represented by long arrows with attached restriction enzyme
(EcoRI and BamHl) sites shown in bold type. The PT 3' primer includes the first 23 bp of
the SI subunit gene. B. Agarose gel electrophoresis of amplified PT promoter regions of CSL
127 (lane 1) and CSL 127S (lane 2). Amplified bands are indicated.

PT5'
GAATTC GCCAAGCTGAAGTAGCAGCGCAGCCCTCCAACGCGCCATCCCCGTCCGGC
CGGCACCATCCCGCATACGTGTTGGCAACCGCCAACGCGCATGCGTGCAG

100

ATTCGTCGTACAAAACCCTCGATTCTTCCGTACATCCCGCTACTGCAATC
CAACACGGCATGAACGCTCCTTCGGCGCAAAGTCGCGCGATGGTACCGGT
-35
-10
CACCGTCCGGACCGTCJCTGACCECCCTGCCATGGTGTGATCCGjTAAAATA"
GGCACCATCAAAAdGCAG^GGpGAAG^CGGdATGbGTTGCACTCGGGCAA
SD ^
TTCG CCTAGG
PT3'

[ZL)

B

PT gene promoter

200

300
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Figure 3.8

Amplification of the fimbrial accessory gene promoter regions of CSL 127

and CSL 127S. A. Nucleotide sequence of the region between the 3' end of fhaB and t
end of fimB (Willems et al, 1992). Open arrows represent fhaB and fimB genes, with

arrows indicative of the direction of translation. The putative -10 region (open) a
binding sites (shaded) are boxed. The fim access 5' primer, incorporating the last

pairs of the fhaB gene, is represented as a long arrow. The non-homologous section o

primer (EcoRI site) is shown in bold type. The fim access 3' primer, incorporating t

23 base pairs of the fimB gene, is represented as a long arrow. The non-homologous s

of the primer (BamHl site) is shown in bold. Internal primers (+300Forward, -500Rev

used for sequencing are also depicted. Inverted repeats (a, b, c, d) are shown abov

lines. B. Agarose gel electrophoresis of amplified fimbrial/FHA accessory genes prom
regions of CSL 127 (lane 1) and CSL 127S (lane 2). Amplified bands are indicated.

iaB
fim access 5'

e

J2k
TGAAACCAACAAATAGGTAGTCGCGGCCTGCCGCGGCTCGGCGCATGGGG
a
ATTCGCAGGGTTCTCATGCGCCGGCCAATGCCGGATAGCGGTGCAATTGC 100
"a"
"""b
CGACCATTTCGCGCACCGCGCTCAAGGACGTAGGGTCGACGGCAGGCGGG
""b"
ACAGTTTTTGACGTGAAACTGACCGAGTGTCCGCAGGCATTGAATGGTCA 200
GCAAGTGGGATTGTTCTTCGAATCTGGTGGCACGGTTGACTATACGTCGG
=*»
+300F
GAAACCTGTTTGCGTATCGGGCCGATAGTCAGGGCGTCGAACAGGTACCG 300
CAGACGAAAGCCGACAACGTGCAAGCCAATCTGGATGGTTCCGCTATTCA
TTTGGGCCGCAACAAGGGTGCGCAGGCTGCTCAGACGTTTCTGGTATCGC 400
AGACGGCTGGGTC_GTCGACGTACGGGGC_GACCCTGCGCTATCTGGCATGC
TACATCCGTTCGGGCGCTGGTTCCATTGTTGCGGGGAATCTCCGCAGTCA 500
^s.
-500R
GGTGGGGTTCTCCGTGATGTATCCGTAGCCCGTGAAAGAGGGGTCACCCA
600
CTGCGGGGGGCCCCGGTACGGGATGGTCGGCTTGTCACGAGATTCTTGrT
TTCC^TTTCTTTCTTTTCACTCGGTCGCAGCGCCGGCTTGATGCATGCAA
-10
AGCATCGATAGCTACGAACGGCCGCGATTCTTGAATCATDAATACATACG 700
CTTGTGACGGGGCGCTCGCGCAGAGCCGGCCCCAGGGATGGTTTACGCCT
GCATTTACGGTAAAGCGGCAAGGCGGCATGGCGCGCTGGCGCCGGCGGCT CCTAGG
fim access 3'

fimbrial accessory
genes promoter
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The double stranded D N A P C R products shown in Figure 3.8 were then
eluted from the gel to remove contaminating unincorporated nucleotides
and excess primer D N A . The fimbrial accessory genes promoter regions of
CSL 127 and CSL 127S were amplified using Pfu D N A polymerase.

The Type 2 Fimbriae Promoter Gene Region
The 203 base pair region containing the fim 2 gene promoter and Shine
Dalgarno sequence was amplified using the oligonucleotide primers fim2
5' and fim2 3' (Figure 3.9).

The double stranded DNA PCR products shown in Figure 3.9 were then
eluted from the gel to remove contaminating unincorporated nucleotides
and excess primer D N A . The fim2 promoter regions of CSL 127 and CSL
127S were amplified using Taq D N A polymerase.

The Type 3 Fimbriae Promoter Gene Region
The 320 base pair region containing the fim 3 gene promoter and Shine
Dalgarno sequence was amplified using the oligonucleotide primers fim3
5' and fim3 3' (Figure 3.10).

The double stranded DNA PCR products shown in Figure 3.10 were then
eluted from the gel to remove contaminating unincorporated nucleotides
and excess primer D N A . The fim3 promoter regions of CSL 127 and CSL
127S were amplified using Taq D N A polymerase.
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Figure 3.9

Amplification of the fiml gene promoter regions of CSL 127 and CSL 127S.

A. Genetic organisation and DNA sequence of the fiml gene promoter. (Livey et al, 1

The open arrow represents the fiml gene, with the arrow indicative of the directio
translation. Primers are represented by long arrowheads with attached restriction

(EcoRI and BamHl) sites shown in bold type. The fim2 3' primer incorporates the fi

nucleotides of the fiml gene. The C-stretch is underlined and the putative ribosom

binding site is indicated (SD, shaded box). The fim boxes (Riboli et al, 1991) are
shown (open boxes). B. Agarose gel electrophoresis of amplified fiml gene promoter
of CSL 127 (lane 1) and CSL 127S (lane 2). Amplified bands are indicated.

f im2 5'
— — —

T>

GAATTC ACGCTGATGCGCCGGCCCGGCGCCGCCATGGCGCCGGGCCCTGCATGCAC
GGGTCCAGTCCCGATAAAAGCCGCATGCAAAAGGACT(JTTTCCCACAlrCG
G^ATCAG1:CCTCCCCCCCCCCCCTAAGACCTAAGATCGTGGCTCCATAAC
TCTTCTGGCGCC^AGAGG^CCGTGTTACCCATGCAAATCCCTTTCCAACG 200

CGG CCTAGG

B

fiml
promoter

SD

fimiy

fim2 3'

100
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Figure 3.10

Amplification of the fim3 gene promoter regions of CSL 127 and CSL 127S.

A. Genetic organisation and DNA sequence of the fim3 gene promoter (Mooi et al, 199

The open arrow represents the fim3 gene, with the arrow indicative of the directio

translation. Primers are represented by long arrows with attached restriction enzy

(EcoRI and BamHl) sites shown in bold type. The fim3 3' primer incorporates the fi

nucleotides of the fim3 gene. The proposed -10 box is contained within a shaded bo

C-stretch is underlined. The fim boxes (Riboli et al, 1991) are also shown (open b

Agarose gel electrophoresis of amplified fim3 gene promoter regions of CSL 127 (la
and CSL 127S (lane 2). Amplified bands are indicated.

f im3 5'
GAATTC GACGGCGCCCGCCGAACCGGCGCCGGGCAGCTCGGGCGGCGCCACGACGC
CGTCGTCCTGATTCCCGGCCCCGCCGGCCGGCCCCCGTGCCGGCCGGCAC 100
GCCGTCGGGATGCCCGCCCGCGGGCAGGCATGCTAATGGCCTCCGGTAAC
GGAGGCCATTTTCATTGCGCGAAGCCGCCCGCCGATCTGGCGCGATTACC 200
GGCAA^TTCCCACAC^AqCATCAGrjCCCCCCCCCCCCGGAC C TG£|TATTC]
03ATGCCGACGCCAAGCACATGACGGCACCCCTCAGTATCAGAATCACCA 300
TGTCCAAGTTTTCATACCCTG CCTAGG
fim3 3'

\fim3y

B

fiml gene
promoter
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3.5.2 Cloning of CSL 127 Promoter Region D N A

The PCR product of each relevant promoter region was cloned into one of
the three cloning vectors used in this study. Products amplified using Taq
DNA

polymerase were cloned into pCRII or pCR2.1 due to the

compatibility created by the A and T overhangs present on the P C R
product and cloning vector respectively. W h e n

Pfu was used as the

polymerising enzyme, products were cloned into the blunt-ended vector
p C R Script. Ligations into pCRII and pCR2.1 were transformed into
INVaF' cells and ligations involving p C R Script were transformed into
competent XLl-Blue M R F ' Kan cells.

The bvg/fha Intergenic Region
The amplified 470 base pair bvg/fha intergenic regions of CSL 127 and C S L
127S were cloned into p C R Script (Figure 3.11). In the interests of brevity,
only the former of these clonings will be illustrated.

The cloning of the bvg/fha intergenic region of CSL 127 and CSL 127S as
PCR

products into p C R Script was confirmed

by digestion with

endonucleases Eco R V and Sac I. The restricted plasmids (pAS16 and
pASlO) were then electrophoresed through a 1 % agarose gel to separate
the vector and insert fragments (Figure 3.11 B, lanes 1 and 2).

The Pertussis Toxin Gene Promoter Region
The amplified 304 base pair pertussis toxin gene promoter regions of C S L
127 and C S L 127S were cloned into pCRII (Figure 3.12 A). Again, only the
former of these clonings will be illustrated.
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Figure 3.11

Cloning of the bvg/fha intergenic regions of C S L 127 and C S L 127S. A .

Amplification and cloning of the CSL 127 bvg/fha intergenic region into pCR Script. Genes
are represented as open arrows demonstrating the direction of transcription. Promoter
regions are indicated. Specific oligonucleotide primers (thick arrowheads) were used for
the amplification of the bvg/fha intergenic region using PCR technology. The PCR product
was ligated into the Srfi site of pCR Script. The lacZ gene (open arrow) and the ampicillin
(Amp1) resistance gene (open arrow) are indicated, as are Fl and ColEl origins of
replication (filled arrows) and the bvg/fha intergenic region (shaded box). B. Agarose gel
electrophoresis of restricted pAS16 and pASlO, demonstrating release of the bvg/fha
intergenic regions of CSL 127 (lane 1) and CSL 127S (lane 2) from pCR Script and pCRII
respectively.
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Flori
Ampr
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(470 bp)
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^JhaB
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2
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Figure 3.12

Cloning of the PT gene promoter regions of CSL 127 and CSL 127S. A.

Amplification and cloning of the CSL 127 PT gene promoter region into pCRII. Genes

represented as open arrows demonstrating the direction of transcription. Primers us
the amplification of the PT promoter are represented by thick arrowheads. The PCR

fragment was ligated into the dual EcoRI sites of pCRII. The lacZ gene (open arrow),

kanamycin (Kanr) and ampicillin (Ampr) resistance genes (open arrows) are indicated,

are Fl and ColEl origins of replication (filled arrows) and the PT promoter (shaded

B. Agarose gel electrophoresis of restricted pAS18 and pAS12, demonstrating release

the PT promoter regions of CSL 127 (lane 1) and CSL 127S (lane 2) from pCRII and pCR
Script respectively.

127

Viae

lacZ

CSL 127
PT promoter fragment
(304 bp)

H~sT^t>fsT^>is4>|s5>rs3^>
Ampr
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B
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—
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The cloning of the P T gene promoter region of CSL 127 and CSL 127S as
P C R products into pCRII was confirmed by digestion with endonuclease
EcoRI. The

restricted plasmids

(pAS18

and

pAS12)

were

then

electrophoresed through a 1 % agarose gel to separate the vector and insert
fragments (Figure 3.12 B, lanes 1 and 2).

The Fimbrial Accessory Genes Promoter Region
The amplified 800 base pair fimbrial accessory genes promoter regions of
CSL 127 and C S L 127S were cloned into p C R Script (Figure 3.13).

The cloning of the fimbrial accessory genes promoter region of CSL 127
and C S L 127S as P C R products into p C R Script was confirmed by digestion
with endonucleases Eco Rl and Not I. The restricted plasmids (pAS24 and
pAS6) were then electrophoresed through a 1 % agarose gel to separate the
vector and insert fragments (Figure 3.13 B, lanes 1 and 2).

The Type 2 Fimbriae Gene Promoter Region
The amplified 203 base pair fiml gene promoter regions of CSL 127 and
CSL 127S were cloned into pCRII (Figure 3.14).

The cloning of the fiml gene promoter region of CSL 127 and CSL 127S as
P C R products into pCRII was confirmed by digestion with endonuclease
Eco RL The restricted plasmids D N A

(pAS20 and pAS8) were then

electrophoresed through a 1 % agarose gel to separate the vector and insert
fragments (Figure 3.14 B, lanes 1 and 2).

The Type 3 Fimbriae Promoter Gene Region
The amplified 320 base pair fim3 gene promoter regions of CSL 127
(Figure 3.15) and CSL 127S were both cloned into pCR2.1.
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The cloning of the fim3 gene promoter region of CSL 127 and CSL 127S
P C R products into pCR2.1 was confirmed by digestion with endonuclease
Eco Rl (Figure 3.15 A ) . The restricted plasmids (pAS22 and pAS14
respectively) were then electrophoresed through a 1 % agarose gel to
separate the vector and insert fragments (Figure 3.15 B, lanes 1 and 2).

Figure 3.13

Cloning of the fimbrial/FHA accessory genes promoter regions of C S L 127

and C S L 127S. A. Amplification and cloning of the C S L 127 fimbrial accessory genes
promoter region into p C R Script. Genes are represented as open arrows demonstrating the
direction of transcription. Oligonucleotide primers used for the amplification of the
fimbrial accessory genes promoter are represented as thick arrowheads. The P C R product
w a s ligated into the Srfi site of p C R Script. The lacZ gene (open arrow) and the ampicillin
( A m p 1 ) resistance gene (open arrow) are indicated, as are Fl and ColEl origins of
replication (filled arrows) and the fimbrial/FHA

accessory genes promoter region

(shaded box). B. Agarose gel electrophoresis of restricted pAS24 and pAS6, demonstrating
release of the fimbrial accessory genes promoter regions of C S L 127 (lane 1) and C S L 127S
(lane 2) from p C R Script and pCRII respectively.
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Figure 3.14

Cloning of the fiml gene promoter regions of CSL 127 and CSL 127S. A.

Amplification and cloning of the CSL 127 fiml gene promoter into pCRII. Genes are

represented as open arrows demonstrating the direction of transcription. Primers u

the amplification of the fiml gene promoter are represented by thick arrowheads. T
PCR fragment was ligated inside the dual EcoRI sites of pCRII. The lacZ gene (open

arrow), and the kanamycin (Kanr) and ampicillin (Ampr) resistance genes (open arrows
are indicated, as are Fl and ColEl origins of replication (filled arrows) and the

promoter (shaded box). B. Agarose gel electrophoresis of restricted pAS20 and pAS8,
demonstrating release of the PT promoter regions of CSL 127 (lane 1) and CSL 127S
from pCRII and pCR Script respectively.
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Figure 3.15

Cloning of the fim3 gene promoter regions of CSL 127 and CSL 127S. A.

Amplification and cloning of the CSL 127 fim3 gene promoter into pCR2.1. Genes are

represented as open arrows demonstrating the direction of transcription. Primers u

the amplification of the fim3 gene promoter are represented by thick arrowheads. T

PCR fragment was ligated inside the dual EcoRI sites of pCR2.1. The lacZ gene (open

arrow), and the kanamycin (Kanr) and ampicillin (Ampr) resistance genes (open arrows
are indicated, as are Fl and ColEl origins of replication (filled arrows) and the

promoter region (shaded box). B. Agarose gel electrophoresis of restricted pAS22 a

pAS14, demonstrating release of the fim3 promoter regions of CSL 127 (lane 1) and C
127S (lane 2) from pCR2.1.
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3.6 Analysis of C S L 137 Strains
A major problem with the analysis of the CSL 137 series was the fact that
the parental strain, C S L 137 cannot be grown in defined liquid m e d i u m .
Therefore the antigen expression levels of the selected strain, C S L 137S
can only be compared to those of the other C S L strains. Strain C S L 137S
was selected for the production of large amounts of serotype 3 specific
fimbriae (Table 3.1). However, the production of other antigens is also
high. This strain demonstrates the greatest expression levels of P T and
pertactin of all the C S L strains. D u e to the complex pattern of antigen
expression levels and the lack of a parental strain comparison, it was
difficult to assign a possible cause for the expression levels of this strain. It
was hypothesised that perhaps a favourable mutation

in the bvg

promoter region might cause an overexpression of PT, fim3 and pertactin.
The expression of F H A is usually tuned to the levels of BvgA. High levels
of F H A are associated with an increased production of this transcriptional
activator. The F H A production by C S L 137S could perhaps be described as
"moderate" in comparison to other strains in the C S L series. Certainly it
is moderate w h e n compared to the high levels of expression of PT, fim3
and pertactin by this strain. The paradox of course being that w h y would
the levels of F H A not increase by a level similar to (or greater than,
considering the usual link in expression levels) the other virulence
controlled proteins assayed. The promoter regions of the genes encoding
F H A and B v g A S sit adjacent to one another on the genome. If there was a
favourable mutation in the bvg promoter, which upregulated virulence
antigen expression, it is possible that the same mutation could cause a
detrimental effect to the transcription of fhaB, or at least effect fhaB
promoter architecture in such a w a y that upregulation of F H A expression
was not observed.
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If no difference in the sequence of the bvg/fha intergenic regions of CSL
137 and C S L 137S is observed, then mutations at promoter regions of each
of the overexpressed genes would be considered likely. Although this
study is not analysing the pertactin promoter of these strains, alterations
in the P T promoter (especially in the B v g A binding site or direct repeat
regions) and fim3 promoter (particularly in the C stretch) were considered
possible outcomes.

3.6.1 Amplification of CSL 137 Promoter Regions

The relevant promoter regions of both the parental and selected CSL 137
strains were amplified using either Taq or Pfu D N A polymerase. This was
achieved using the same procedures used for the amplification of the
equivalent regions in the C S L 127 strains.

The CSL 137 and CSL 137S PCR products shown in Figure 3.16 were eluted
from the gel to remove any unincorporated nucleotides or excess primer
D N A and ligated into cloning vectors.

3.6.2 Cloning of CSL 137 Promoter Region DNA

The PCR product of each relevant promoter region was cloned into either
of the three cloning vectors used in this study. Ligations into pCRII and
pCR2.1 were transformed into I N V a F ' cells and ligations involving p C R
Script were transformed into competent XLl-Blue M R F ' Kan cells.

The bvg/fha Intergenic Region
The amplified 470 base pair bvg/fha intergenic regions of C S L 137 and C S L
137S were both cloned into p C R Script to form pAS36 and pAS26
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Figure 3.16
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Amplification of the relevant gene promoter regions of CSL 137 and CSL

137S. Agarose gel electrophoresis of the PCR amplified promoter regions of CSL 137

lanes) and CSL 137S (even lanes). The bvg/fha intergenic region (lanes 1 and 2), PT

promoter (lanes 3 and 4), fim/FHA accessory genes promoter (lanes 5 and 6), fiml ge

promoter (lanes 7 and 8) and fim3 gene promoter (lanes 9 and 10) were all PCR ampli
and rim through a 1% agarose gel.

respectively (Figure 3.17). These clonings were confirmed by digestion
with endonucleases Eco RV and Sac I. The restricted plasmid DNA was
then electrophoresed through a 1% agarose gel to separate vector and
insert fragments (Figure 3.17, lanes 1 and 2).

The Pertussis Toxin Gene Promoter Region
The amplified 304 base pair pertussis toxin gene promoter regions of CSL
137 and CSL 137S were both cloned into pCR Script to form pAS38 and
pAS28 respectively. These clonings were confirmed by digestion with
endonucleases Eco Rl and Not I. The restricted plasmids were then
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electrophoresed through a 1 % agarose gel to separate vector and insert
fragments (Figure 3.17, lanes 3 and 4).

The Fimbrial Accessory Genes Promoter Region
The amplified 800 base pair fimbrial accessory genes promoter regions of
C S L 137 and C S L 137S were both cloned into pCR2.1 creating pAS44 and
pAS34 respectively. These clonings were then confirmed by digestion
with endonuclease Eco Rl. The restricted plasmid D N A w a s then
electrophoresed through a 1 % agarose gel to separate the vector and insert
fragments (Figure 3.17, lanes 5 and 6).
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pCRII
p C R Script

fim/FHA access.

fim3
fiml

Figure 3.17

Cloning of the relevant promoter regions of CSL 137 and CSL 137S. Agarose

gel electrophoresis of restricted plasmids, demonstrating release of the various cloned
promoter regions of CSL 137 (odd lanes) and CSL 137S (even lanes) from pCR Script and
pCRII/pCR2.1. The plasmids pAS36 and pAS26 (lanes 1 and 2), pAS38 and pAS28 (lanes 3
and 4), pAS44 and pAS34 (lanes 5 and 6), pAS40 and pAS30 (lanes 7 and 8) and pAS42 and
pAS32 (lanes 9 and 10) were restricted using appropriate enzymes and n m through a 1 %
agarose gel.
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The Type 1 Fimbriae Gene Promoter Region
The amplified 203 base pair fiml gene promoter regions of CSL 137 and
CSL 137S were cloned into p C R Script and pCR2.1 forming pAS40 and
pAS30 respectively. The cloning of these P C R products was then
confirmed by digestion with endonucleases Eco Rl and Not I for pAS40
and Eco Rl for pAS30. The restricted plasmids were then electrophoresed
through a 1 % agarose gel to separate the vector and insert fragments
(Figure 3.17, lanes 7 and 8).

The Type 3 Fimbriae Promoter Gene Region
The amplified 320 base pair fim3 gene promoter regions of CSL 137 and
CSL 137S were both cloned into pCR2.1 creating pAS42 and pAS32
respectively. The cloning of the fim3 gene promoter region of CSL 137
and C S L 137S P C R products into pCR2.1 was then confirmed by digestion
with restriction endonuclease Eco R L The digested plasmids were then
electrophoresed through a 1 % agarose gel to separate the vector and insert
fragments (Figure 3.17, lanes 9 and 10).

3.7 Analysis of CSL 1237 Strains
Strain CSL 1237S which overexpresses a number of virulence
determinants (Fim 3, Fim2, F H A and PT) with respect to the parental
strain (Table 3.1), m a y have arisen via mutations in and around the
promoter of the bvg locus. A mutation in a vital section of the bvg
promoter would almost certainly affect the expression of most, if not all,
virulence factors. Again, like that of the CSL 137 series, the expression of
F H A is at a "normal" level, and in fact the levels of this protein in the
selected strain C S L 1237S are decreased compared to the parental strain.
Interestingly, the increase in expression of the other four antigens assayed
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was similar, with C S L 1237S exhibiting a 1-2 fold increase in each, w h e n
compared to the parental strain. This small but equivalent increase m a y
represent a favourable mutation in a less significant region of the bvg
promoter, which, as m a y be the case in the CSL 137 series, is also
detrimental to F H A production.

3.7.1 Amplification of CSL 1237 Promoter Regions

The relevant promoter regions of both the parental and selected CSL 1237
strains were amplified using either Taq or Pfu D N A polymerase. This was
achieved using the same procedures used for the amplification of the
equivalent regions in the CSL 127 and CSL 137 series.

The CSL 1237 and CSL 1237S PCR products shown in Figure 3.18 were
eluted from the gel to remove any unincorporated nucleotides or excess
primer D N A and ligated info cloning vectors.

3.7.2 Cloning of CSL 1237 Promoter Region DNA

The PCR product of each relevant promoter region was cloned into either
of the two cloning vectors used in this study. Ligations into pCRII and
pCR2.1 were transformed into I N V a F ' cells and ligations involving p C R
Script were transformed into competent XLl-Blue M R F ' Kan cells.

The bvg/fha Intergenic Region
The amplified 470 base pair bvg/fha intergenic regions of CSL 1237 and
C S L 1237S were cloned into p C R Script and p C R II, to form pAS56 and
pAS46 respectively (Figure 3.17). These clonings were confirmed by
digestion with endonucleases Eco R V and Sac I. The restricted plasmid
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fim/FHA access.

fim.3
fiml

Figure 3.18

Amplification of the relevant gene promoter regions of CSL 1237 and CSL

1237S. Agarose gel electrophoresis of the PCR amplified promoter regions of CSL 123

lanes) and CSL 1237S (even lanes). The bvg/fha intergenic region (lanes 1 and 2), P

promoter (lanes 3 and 4), fim/FHA accessory genes promoter (lanes 5 and 6), fiml ge

promoter (lanes 7 and 8) and fim3 gene promoter (lanes 9 and 10) were all PCR ampli
and run through a 1% agarose gel.

DNA was then electrophoresed through a 1% agarose gel to separate
vector and insert fragments (Figure 3.19, lanes 1 and 2).

The Pertussis Toxin Gene Promoter Region
The amplified 304 base pair pertussis toxin gene promoter regions of CSL
1237 and CSL 1237S were both cloned into pCR Script to form pAS58 and
pAS48 respectively. These clonings were confirmed by digestion with
endonucleases Eco Rl and Not I. The restricted plasmid DNA was then
electrophoresed through a 1% agarose gel to separate vector and insert
fragments (Figure 3.19, lanes 3 and 4).
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The Fimbrial Accessory Genes Promoter Region
The amplified 800 base pair fimbrial accessory genes promoter regions of
C S L 1237 and C S L 1237S were both cloned into pCR2.1 creating pAS64 and
pAS54 respectively. These clonings were then confirmed by digestion
with

endonuclease

Eco R L

The restricted plasmids

were

then

electrophoresed through a 1 % agarose gel to separate the vector and insert
fragments (Figure 3.19, lanes 5 and 6).

1 234 5 67 8 9 10

pCRII
p C R Script

fim/FHA access.
bvg/fha
PT

Figure 3.19

fim.3
fiml

Cloning of the relevant promoter regions of CSL 1237 and CSL 1237S.

Agarose gel electrophoresis of restricted plasmids, demonstrating release of the various
cloned promoter regions of CSL 1237 (odd lanes) and CSL 1237S (even lanes) from pCR
Script and pCRII/pCR2.1. The plasmids pAS56 and pAS46 (lanes 1 and 2), pAS58 and

pAS48 (lanes 3 and 4), pAS64 and pAS54 (lanes 5 and 6), pAS60 and pAS50 (lanes 7 and
and pAS62 and pAS52 (lanes 9 and 10) were restricted using appropriate enzymes and run
through a 1% agarose gel.

The Type 1 Fimbriae Gene Promoter Region
The amplified 203 base pair fiml gene promoter regions of CSL 1237 and
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C S L 1237S were cloned into p C R Script and pCRII forming pAS60 and
pAS50 respectively. The cloning of these P C R products was then
confirmed by digestion with endonucleases Eco Rl and Not I for pAS60
and endonuclease Eco Rl for pAS50. The restricted plasmids were then
electrophoresed through a 1 % agarose gel to separate the vector and insert
fragments (Figure 3.19, lanes 7 and 8).

The Type 3 Fimbriae Promoter Gene Region
The amplified 320 base pair fim3 gene promoter regions of CSL 1237 and
CSL 1237S were both cloned into pCR2.1 creating pAS62 and pAS52
respectively. The cloning of these P C R products into pCR2.1 was then
confirmed by digestion with restriction endonuclease Eco RL The digested
plasmids were then electrophoresed through a 1 % agarose gel to separate
the vector and insert fragments (Figure 3.19, lanes 9 and 10).

3.8 Sequence Analysis of Promoter Regions
The plasmids containing all of the relevant promoter region DNA from
each of the three parental and three selected CSL strains were D N A
sequenced in an attempt to identify any genetic differences.

3.8.1 The bvg/fha Intergenic Region

Promoter region DNA from the bvg/fha intergenic regions of the six
strains contained in plasmids pASlO, pAS16, pAS26, pAS36, pAS46 and
pAS56 was sequenced. The data generated by the ABI Prism 377
sequencing software was transferred to MacVector where the sequences
were aligned (Figure 3.20).
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Initially, a difference was found in the bvg/fha intergenic region of C S L
1237S, the strain which shows a small increase in all virulence factors
assayed except F H A (pAS46) (Figure 3.20). This difference is in a region
close to the bvg F4 promoter region that is conserved between the P 4 and
the Pa,fl promoters (Scarlato et al, 1990). This is also a region that shows a
high degree of homology to the proposed Shine-Dalgarno ribosome
binding sequence of the B. pertussis fiml and fim3 genes (Livey et al,
1987; M o o i et al, 1990). The possibility of a change in the D N A sequence
here causing a small but equivalent alteration in the expression of a
number of virulence regulated genes was exciting. A cytosine to adenine
transition in this region resulting in the increased expression of B v g A ,
via an upregulation

of either transcription or translation, could

theoretically increase the levels of virulence factor production. A decrease
in F H A production might also be accounted for by an upregulation in the
transcription from the bvg F4 promoter. The production of fhaB

mRNA

m a y be affected by the excess sense strand sterically hindering the binding
of transcriptional activators or R N A polymerase.

Due to the discovery of this difference, this region was amplified again in
an independent P C R and cloned. This plasmid (pAS47) was then
sequenced to determine whether the difference was a genuine genetic
change or merely a D N A polymerase error. Unfortunately, the latter was
true with the sequence exhibiting 1 0 0 % homology to that of the parental
gene sequences.
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Figure 3.20

Aligned D N A sequence comparison from the bvg/fha intergenic region of

each of the CSL strains. Primer sequences are underlined. The Taq error (see text) i

CSL 1237S sequence is shown as a C to A transition. Primers used for PCR are underli

CSL
CSL
CSL
CSL
CSL

127CCCCTGTACAGGTTC:GTGTTCATATTCCaAr:(-:ACyr,AAr;TaAariTAATCG
127S
137
137S
.......
1237

CSL 1237S

WW.'.'.'.'.'.

CSL
CSL
CSL
CSL
CSL
CSL

127 GCAGAATCCGTTATCGGCCTGCTCGTTTTAGGTTTTGAAATCCAGTGCCA
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 TAGTCTGGATAAACCTCAGCACTTCGTCAGTCAGTAATGATCCCGTCCAT
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 CAATGGATATTTATACAAGACTTGTAGGAAATTTCTTAGTCAAACCATCA
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 AACCCTGTCCGGCACGTATAGGCGTGCGCCGACAACCCGCTCCCCGGCCC
127S
137
137S
1237
1237S

CSL 127 GCCGCGGGTGCCAGCGCAGGAATTCAGACTTTTCCTATTTTGGTATAGGA
CSL 127S
CSL 137
CSL 137S
CSL 1237
CSL 1237S
CSL 127 TACTGTTTAGCAGCACTCATGCCCGTATCGTTGCTTGCTGACGTATAGGA
CSL 127S
CSL 137
CSL 137S
CSL 1237
CSL 1237S
CSL 127 GAATGTGAAATTTCGCAGCCATTCCTTTGACGCATCAATGACATTACGCG
CSL 127S
CSL 137
CSL 137S
CSL 1237
CSL 1237S
CSL 127 TTGCAGGATTTTTTTCTCGCCACGAAACTCAAAGCATATTCTTCTTATCA
CSL
CSL
CSL
CSL
CSL
CSL
CSL
CSL
CSL
CSL
CSL

127S
137
137S
1237
1237S
1 71 TGTACAACAAAGTCCTCATC
127S
137
137S
1237
1237S

A

-• •
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3.8.2 The Pertussis Toxin Gene Promoter Region

Promoter region DNA from the pertussis toxin gene of the six stra
contained in plasmids pAS12, pAS18, pAS28, pAS38, pAS48 and pAS58
CSL
CSL
CSL
CSL
CSL
CSL

127 GCCAAGCTGAAGTAGCAGCGCAGCCCTCCAACGCGCCATCrCirGTrrGGr
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 CGGCACCATCCCGCATACGTGTTGGCAACCGCCAACGCGCATGCGTGCAG
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 ATTCGTCGTACAAAACCCTCCATTCTTCCGTACATCCCGCTACTGCAATC
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 CAACACGGCATGAACGCTCCTTCGGCGCAAAGTCGCGCGATGGTACCGGT
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 CACCGTCCGGACCGTGCTGACCCCCCTGCCATGGTGTGATCCGTAAAATA
127S
137
137S
1237
1237S

CSL lOTr^Ar-ra^aaaarry^rcaryraaAnArrra^

CSL
CSL
CSL
CSL
CSL
CSL
CSL
CSL
CSL
CSL
CSL

127S
137
137S
1237
1237S
127TTCG
127S
137
137S
1237
1237S

Figure 3.21

Aligned D N A sequence from the pertussis toxin gene promoter region of

each of the CSL strains. Primers used for PCR are underlined.
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was sequenced. The data generated by the ABI Prism 377 sequencing
software was transferred to M a c Vector where the sequences were aligned
(Figure 3.21).

The CSL strains exhibited 100% homology within the pertussis toxin gene
promoter region. There was also no difference observed in this region
between the C S L series and the original sequences published by Locht and
Keith, (1986) and Nicosia et al (1986).

3.8.3 The Fimbrial Accessory Genes Promoter Region

Promoter region DNA from the fimbrial accessory genes of the six strains
contained in plasmids pAS6, pAS24, pAS34, pAS44, pAS54 and pAS64
was sequenced. The data generated by the ABI Prism 377 sequencing
software was transferred to MacVector where the sequences were aligned
(Figure 3.22).

Although it was hypothesised that there may be a difference in this region
between strains C S L 127 and C S L 127S to explain the upregulation in both
serotype 2 specific fimbriae and F H A , no difference was observed.

The region targeted as the fimbrial accessory genes promoter in this study
was the 800 nucleotide base pairs between the fhaB gene (including the
final 20 bp) and the fimB gene (including the first 23 bp). After these
original oligonucleotide primers were designed and constructed and
experiments initiated, it was proposed that fimC, fimD, and fhaC were
translationally linked (Willems

et al, 1993; Willems

et al, 1994)

indicating that the linkage of the fimbrial/FHA accessory genes was at the
level of translation. Therefore the area of the genome targeted in this
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CSL 127TGAAACrAArAAATAr^r rAr _ rro ^ nn ^^^^^„ ncCTccccc ,„ T ..^
CSL 127S

CSL
CSL
CSL
CSL

137
137s
1237
1237S

'.'.'.WW.'.'.'.'.'.'.' " "
!'.!!!!!!!!'.!'""
WWW.
WWW. ....... WWW

CSL 127ATTCGC^GGGTTCTCATGCGCCGGCCAATGCCGGATAGCGGTGCAATTGC
CSL 127S

CSL 137
CSL 137S
CSL 1237

CSL 1237S
CSL
CSL
CSL
CSL
CSL

WW,
. .......WW .

••••••••••••

ill!!!'.!!!!!!!!'"'""'"'

...WW. . .

127 CGACCATTTCGCGCACCGCGCTCAAGGACGTAGGGTCGACGGCAGGCGGG
127S
137
137S
1237

CSL 1237S

WW

CSL 127 ACAGTTTTTCACGTGAAACTGACCGAGTGTCCGCAGGCATTGAATGGTCA
CSL 127S

CSL 137
CSL 137S
CSL 1237

W . ......WW... . .
" " ' 'W.
......WW.

CSL
CSL
CSL
CSL
CSL
CSL
CSL

1237S
!!.!!!
127 GCAAGTGG<^TTGTTCTTCGAATCTGGTGGCACGGTTGACTATACGTCGG
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 GAAACCTGTTTGCGTATCGGGCCGATAGTCAGGGCGTCGAACAGGTACCG
127S
,
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 CAGACGAJ^GCCGACAACGTGCAAGCCAATCTGGATGGTTCCGCTATTCA
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127TTTGGGCCGCAACAAGGGTGCGCAGGCTGCTCAGACGTTTCTGGTATCGC
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 AGACGGCTGGGTCGTCGACGTACGGGGCGACCCTGCGCTATCTGGCATGC
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 TACATCCGTTCGGXKGCTGGTTCC^TTGTTGCGGGGAATCTCCGCAGTCA
127S
137
137S
1237
1237S
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CSL
CSL
CSL
CSL
CSL
CSL

127 GGTGGGGTTCTCCGTGATGTATCCGTAGCCCGTGAAAGAGGGGTCACCCA
127S
137
!!!!!'.!!!!!!!!!"
137s
I!!!!!!!!!!!!"'
1237
11!!!!!!!!!
1237s
!!!!!!!!!

CSL
CSL
CSL
CSL
CSL
CSL

127 CTG<:GGGGGGCCCCGGTACGGGATG<5TCGGCTTGTCACGAGATTCTTGTT
127S
137
!.!!!!!!!!!!!!!!!
137s
!!!!!!!!!!!
1237
!.!!!!!!
] [[
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127TTCCATTTCTTTCTTTTC^CTCGGTCGCAGCG^^
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 AGCATCGATAGCTACGAACGGCCGCGATTCTTGAATCATGAATACATACG
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 CTTGTGACGGGGCGCTCGCGCAGAGCCGGCCCCAGGGATGGTTTACGCCT
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 GCATTTACGGTAAAGCGGCAAGGCGGCATGGCGCGCTGGCGCCGGCGGCT
127S
137
137S
1237
1237S

Figure 3.22

1

Aligned D N A sequence from the fimbrial accessory promoter region of each

of the CSL strains. Primers used for PCR are underlined.

study as the fim/FHA accessory genes promoter region was potentially
not the only area requiring sequence analysis. The other appropriate area
where a mutation might cause an alteration in the expression of fimbriae
and FHA may be the region between fimB and fimC. To determine if this
was the case, oligonucleotide primers were designed to amplify the region
of DNA immediately upstream of the fimC gene. It was thought that if
there was a change in this region, it would be restricted to the strain
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overexpressing both fimbriae and F H A . For this reason, only strains CSL
127 and C S L 127S were subjected to the amplification, cloning and
sequencing process. A 473 base pair region was sequenced, revealing n o
difference between the parental strain and the selected strain (results not
shown).

3.8.4 The Type 2 Fimbriae Gene Promoter Region

Promoter region DNA from the fiml gene of the six strains contained in
plasmids pAS8, pAS20, pAS30, pAS40, pAS50 and pAS60 was sequenced.
The data generated by the ABI Prism 377 sequencing software was
transferred to MacVector where the sequences were aligned (Figure 3.23).

Due to the upregulation of fimbriae and FHA, it was hypothesised that a
difference between C S L 127 and C S L 127S would be observed in either the
fimbrial accessory genes promoter region, or the fimC upstream region.
While no differences were detected in either of these regions, an
alteration to the fiml gene promoter was discovered (Figure 3.23). This
difference was traced to the C stretch, a region involved in fimbrial phase
variation. While the fiml gene promoter of the parental strain CSL 127
contained 17 cytosine residues within the C stretch, the corresponding
region of the overexpressing strain, C S L 127S contained only 16 residues.
The 16 cytosine C stretch is equivalent to the original published sequence
of the Wellcome 28 strain (Livey et al, 1987). The results of this study m a y
indicate that 16 residues is the optimum number for expression of type 2
fimbriae. The fim2 expression of C S L 127 (which possesses 17 nucleotides
within the C stretch) is 20 fold less than the selected strain with only 16
nucleotides. The C S L 1237 series strains contain 15 residue C stretches and
display 4 and 6 fold less fim2 expression compared to that of C S L 127S.
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CSL
CSL
CSL
CSL
CSL
CSL

127ACGCTGAT(yp^rryyrrrer^r^^
127S
137
!!!!!!!!!!!!!!
137s
!!!!!!
1237
!!!!!!!
1237S

•••••••••

CSL 127 GGGTCCAGTCCCGATAAAAGCCGCATGCAAAAGGACTGTTTCCCACATCG
CSL 127S

CSL 137
CSL 137s
CSL 1237

CSL 1237s

! 111!!! 111!! 11111' 1
!!!!!!!!!!!!
! 1!!! 1!!!!!!!.!!!

!! 11!!!! 11!! 1"

CSL
CSL
CSL
CSL
CSL
CSL

127 GAATCAGCCCTCCCCCCCCCCCCCTAAGACCTAAGATCGTGGCTCCATAA
127S
137
!!!!!!!!!
137S
W\[
1237
C
—
1237S
C
—

CSL
CSL
CSL
CSL
CSL
CSL

127 CTCTTCTGGCGCCAAGACGCCCGTGTTACCCATGCAAATCCCTTTCCAAC
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127GCGC
127S
137
137S
1237
1237S

Figure 3.23

Aligned D N A sequence from the fiml promoter region of each of the CSL

strains. Dashes have been introduced to increase alignment. Primers used for PCR ar
underlined. The differences in the sequence are displayed as T to C transitions in
1237 strains and dashes in the C stretch.

3.8.5 The Type 3 Fimbriae Promoter Gene Region

Promoter region D N A from the fim3 gene of the six strains contained in
plasmids pAS14, pAS22, pAS32, pAS42, pAS52 and pAS62 was sequenced.

The data generated by the ABI Prism 373/377 sequencing software was

transferred to MacVector where the sequences were aligned (Figure 3.24).
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CSL 127GACGGCGCCC(yraAArrc^rr^pry^^n^rrpr^^^^Poa|0r;?t|r.^
CSL 127S

CSL 137
CSL 137s
CSL 1237

11!111111!1!11111
! 1! 1! 111! 111! 1! 1! 1! 1!
!111111!111!.11

CSL 1237S
CSL
CSL
CSL
CSL
CSL
CSL

127 CGTCGTCCTGATTCCCGGCCCCGCCGGCCGGCCCCCGTGCCGGCCGGCAC
127S
137
!.!!!!!
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 GCCGTCGGGATGCCCGCCCGCGGGCAGGCATGCTAATGGCCTCCGGTAAC
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127GGAG<^CATTTTCATTGCGCGAAGCCGCCCGCCGATCTGGCGCGATTACC
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 GGCAAATTCCCACACAACCATCAGCCCCCCCCCC
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

127 CTGATGCCGACGCCAAGCACATGACGGCACCCCTCAGTATCAGAATCACC
127S
137
137S
1237
1237S

CSL
CSL
CSL
CSL
CSL
CSL

1 0.1 ATGTCCAAGTTTTCATACCCT
127S
137
137S
1237
1237S

Figure 3.24

GGACCTGATATT
CCCC
CCCC —
C —

Aligned D N A sequence from the fim3 promoter region of each of the CSL

strains. Dashes have been introduced to improve alignment. Primers used for PCR are

underlined. The differences in the sequence are displayed as extra cytosine residue
dashes in the C stretch.

The differences demonstrated in the fim3 gene promoter (Figure 3.24)
were not an unexpected result. The difference between the CSL 137 strains
in the number of cytosine residues within the C stretch of the fim3
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promoter w a s actually the most anticipated mutation a m o n g the entire
C S L series.

However the exact changes observed were not predicted. Fimbrial phase
variation involves genetic changes in the C stretch (Mooi et al, 1990).
Although data concerning fimbrial expression levels of the parental
strain could not be obtained, an alteration in this "hot spot" seems to
have led to an overexpression of type 3 fimbriae in C S L 137S. The number
of nucleotides within the C stretch has previously been shown to be
important in fimbrial expression levels (Mooi et al, 1990; Riboli et al,
1991). Strains which produce large amounts of type 3 fimbriae (variants of
the Wellcome 28 strain) were found to contain 14 nucleotides in the C
stretch, while this region in strains deficient in type 3 fimbriae (Tohama I)
contained 13 or less nucleotides (Mooi et al, 1990; Riboli et al, 1991). T h e
results of the current study with the non-engineered overexpressing
mutant C S L 137S, somewhat contradict these previous observations. In
this study, the overexpressing strain contains a 13 residue C stretch and
the parental strain, a 14 residue C stretch. The implications of this
difference lie in the area of the complexity of fimbrial expression and
phase variation. Alterations in the C stretch region m a y not be the sole
source of fimbrial phase variation.

Differences within the fimbrial promoter regions between parental and
selected B. pertussis strains were observed, however not all were easily
predictable. The upregulation in type 3 fimbriae expression in C S L 137S in
comparison to its parent strain C S L 137 was found to be caused by a
difference in the promoter region of the fim3 gene. This difference was
expected between these two strains because of the increase in production
in only a single protein. The strain overexpressing type 2 fimbriae and
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F H A (CSL 127S) with respect to its parental strain (CSL 127) w a s expected
to exhibit changes in the fimbrial accessory genes, however this was not
the case. Although the difference in F H A production in these strains
cannot be fully explained, the expression of large amounts of fim3 in the
selected strain is attributable to a difference in the C-stretch of the
promoter region of the fiml gene. The final pair of strains, the C S L 1237
series were predicted to possess D N A sequence differences with respect to
one another within the bvg/fha intergenic region, due to altered
expression levels of a number of virulence factors. The expression levels
of the parental and selected strain were not greatly varied, and, perhaps
reflecting this, no differences were found at the D N A level at the sites
sequenced.

These studies offer an opportunity to further expand the knowledge of
the mechanisms of h o w the virulence genes of B. pertussis are controlled.
It is anticipated that the identified mutations can be incorporated into
other strains to increase antigen production for the preparation of n e w
generation acellular vaccines.
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Chapter Four

Discussion

Whooping cough, the severe childhood respiratory disease, is caused by
the obligate h u m a n pathogen, Bordetella pertussis (Bordet and Gengou,
1906). The traditional whole cell vaccine used for the prevention of the
disease is currently under scrutiny due to reported side effects. T h e
subsequent decline in vaccine usage has inevitably led to a worldwide
increase in the occurrence of whooping cough (Robinson et al, 1985,
R o m a n u s et al, 1987). The preparation of safer, less reactogenic vaccines is
at present concentrated o n the production of purified recombinant
antigens for inclusion in acellular vaccine preparations. Recent vaccine
trials have demonstrated that important antigens include pertussis toxin,
filamentous haemagglutinin, pertactin and serotype specific fimbriae
(Greco et al, 1996; Gustafsson et al, 1996). The production of these vaccine
i m m u n o g e n s in a simple, cost-effective manner is one of the most
important

requirements

in the development

of future

vaccine

preparations.

The present study is focussed on the gene expression of different antigens
of Bordetella pertussis, and more specifically, on the promoters of
virulence genes. The first section of this thesis dealt with the cloning of a
pertussis toxin expression locus, including a constitutive promoter. T h e
latter part has explored the virulence gene promoter regions of a n u m b e r
of antigen overexpressing whooping cough vaccine strains.

A detoxified form of PT is considered to be an excellent candidate
protective antigen for any acellular component vaccine preparation. T h e
incompatibility of P T gene expression signals with respect to Escherichia
coli m a k e the production of P T in this organism difficult to achieve
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(Burnette et al, 1988; Nicosia et al, 1987). Production of the toxin in
virulent B. pertussis is hampered due to a number of factors, such as slow
growth rates, fastidious nutritional requirements and a tightly regulated
expression system. Another

uncertainty here is the risk that co-

purification of low levels of other virulence regulated toxins could occur
in vaccine preparations. Expression and secretion of P T in organisms
other than virulent phase B. pertussis has been attempted by a n u m b e r of
laboratories. Plasmids containing a B. pertussis P T operon introduced into
B. bronchiseptica were found to produce levels of P T similar to those of B.
pertussis (Lee et al, 1989). W h e n

the location of expressed P T was

examined in these recombinant B. bronchiseptica strains, most of the P T
remained

intracellular, however

significant amounts

were actually

detected in the culture m e d i u m . A similar result was obtained w h e n
genetically altered pertussis toxoid was expressed in B. parapertussis and
B. bronchiseptica (Pizza et al, 1989). These studies suggested that the two
species incapable of P T expression m a y in fact possess the ability to secrete
the toxin, catalysing further research in this area. Expression of P T in
A T C C 10580::Tn/usPn, an avirulent B. bronchiseptica strain, is controlled
by the strong constitutive promoter, P B b (Walker et al, 1991a). Production
levels of P T were promising, however all of the toxin was located in the
periplasm, making this an unsuitable vaccine expression strain.

One of the goals of this study was to determine whether B. bronchiseptica
could secrete PT, using A T C C 10580::Tn/«sPTl to develop a P T expression
system in virulent and avirulent strains of B. bronchiseptica. T h e
examination of P T secretion in these P T producing recombinant strains
would determine if the secretion of P T is possible in B. bronchiseptica,
and whether it is bvg-regulated.
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The first strategy used to clone the P T expression locus of A T C C
10580:-.TnfusPTl w a s to construct a cosmid library. A number of potential
clones were isolated, however

Southern blot analysis using three

different probes containing P T sequences failed to detect the P T expression
locus. It w a s hypothesised that either one of the gene products of the
expression locus m a y have been lethal to E. coli, or the expression locus
D N A w a s unstable. The isolation of expression locus clones would have
allowed for the characterisation and sequencing of the Pg^ promoter of
the P T expression locus. It was envisaged that this promising promoter
would then be used for the expression of other important whooping
cough vaccine antigens.

With the failure of cosmid cloning experiments, the pertussis toxin
expression

locus

of

B.

bronchiseptica A T C C

10580::TnfusPTl,

incorporating P B b , was transferred into virulent and avirulent strains of
B. bronchiseptica using an in vivo cloning technique. The tra genes of the
plasmid pR751, w h e n integrated into a chromosome, have the ability to
induce conjugal transfer to a recipient bacterium. Transposon

Tn813

contains a defective resolvase gene, therefore once it transposes into the
chromosome it cannot resolve the cointegrate formed. E. coli Q358
(pR751::TnS13) was conjugally mated with the original avirulent B.
bronchiseptica P T

expressing

strain, A T C C

10580::Tn/usPTl. This

permitted pR751::TnS13 to transpose into the chromosome of A T C C
10580::Tn/wsPn, thereby facilitating chromosome transfer in subsequent
conjugal mating experiments. Using this technique, the P T expression
locus was successfully cloned in vivo into derivatives of virulent and
avirulent B. bronchiseptica strains. The levels of P T expression in strains
of B. bronchiseptica containing the P T expression locus were similar to
the original strain. Secretion analysis demonstrated that all of the
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recombinant B. bronchiseptica strains examined in this study failed to
secrete P T into the culture m e d i u m , whereas B. pertussis T o h a m a I was
found to secrete significant amounts of PT.

The discovery of the B. pertussis ptl operon, required for PT secretion, led
to an investigation

into the presence of the ptl operon

in B.

bronchiseptica. It had been established that B. bronchiseptica contains
genes homologous to the B. pertussis ptlA, ptlB and part of ptlC (Arico
and Rappuoli, 1987). Significantly, none of the 56 base pair differences
detected in the sequenced region of the B. bronchiseptica ptl operon result
in the introduction of a stop codon thereby truncating the putative open
reading

frames.

Southern

blot

analysis

demonstrated

that

B.

bronchiseptica also contains sequences homologous to the 3' end of the
ptl operon (ptlH gene). Although the B. bronchiseptica ptl A, B and C open
reading frames so far examined remain essentially intact, and despite the
presence of D N A sequences homologous to ptlH, this study has s h o w n
that B. bronchiseptica is unable to secrete PT. The reason for this has been
traced to the ptl operon in B. pertussis being transcribed from the Fptx
promoter (Kotob et al, 1995; Baker et al, 1995). The Fptx promoters in B.
parapertussis and B. bronchiseptica are inactive.

The lack of PT secretion in B. bronchiseptica in this study confirm the
findings of Kotob et al (1995) and strongly suggest that the ptl genes of B.
bronchiseptica are cryptic. This has since been further confirmed with the
introduction of the B. pertussis Fptx promoter into B. parapertussis and B.
bronchiseptica strains (Hausman et al, 1996). This resulted in the
production and secretion of P T in B. bronchiseptica and in limited
amounts in B. parapertussis. Yields were well below that of B. pertussis,
however it w a s s h o w n that B. bronchiseptica contains all the essential ptl
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genes required for P T secretion (Hausman et al, 1996).

Although this study and others have shown that the ptl genes of B.
bronchiseptica are fundamentally intact, the lack of transcription from the
Fptx promoter of B. bronchiseptica abrogates expression of Ptl proteins in
the strains used in this study. Therefore secretion of P T cannot be
achieved in these strains without further genetic modification. T h e
cloning technique developed in this study w a s utilised to obtain
expression of pertussis toxin in both virulent and avirulent strains of B.
bronchiseptica Furthermore, this in vivo chromosome transfer system
could be used in other transposon-tagged loci of Bordetella spp. to analyse
transposon induced gene mutations across species and genera.

Apart from pertussis toxin, a number of other antigens have recently
been included in vaccine trials, with promising results (Greco et al, 1996;
Gustafsson

et

al,

1996).

These

antigens

include

filamentous

haemagglutinin, serotype specific fimbriae and pertactin. The selected B.
pertussis C S L strains used in this study demonstrate overexpression of
these different proteins, the increased expression postulated to be the
result of mutations within the promoter regions of the different loci. This
investigation w a s aimed at providing evidence of these mutations in an
effort to genetically characterise these B. pertussis strains.

The Australian licensed whole cell whooping cough vaccine,
manufactured by C S L Ltd. is a heat killed preparation of Bordetella
pertussis. Research methods at C S L have not utilised deliberate genetic
modification, but have relied on continuous subculture and selection to
produce vaccine strains expressing high levels of virulence antigens.
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The selected strains, C S L 127S, C S L 137S and C S L 1237S represent excellent
vaccine candidates for either a whole cell vaccine or for the production of
antigens in n e w generation acellular vaccines. It m a y also be possible to
engineer the beneficial mutations contained within

overexpressing

promoter regions into other B. pertussis vaccine strains to improve
antigen yield.

The promoter regions of CSL 137 and CSL 137S exhibited a single genetic
difference. Predictably, this change results from a difference in the
number of cytosine residues within the C stretch of the fim3 promoter of
CSL 137S. This mechanism is employed by B. pertussis populations in
vivo to alter the fimbrial serotype expressed. This fimbrial phase
variation has been shown to be caused by a change in the number of
cytosine residues in the C stretch of the promoter (Willems et al, 1990).
The activation of transcription is proposed to be dependent on the
distance between the putative -10 box and the B v g A binding site. T h e
alteration of the nucleotide number in the C stretch affects this distance,
changing the expression of fimbriae (Willems et al, 1990; Mooi et al,
1990; Riboli et al, 1991).

High level expression of type 3 fimbriae has been found to correlate with
a sequence of 14 nucleotides in the C stretch of the fim3 gene promoter
(Willems et al, 1990; Riboli et al, 1991). The original published sequence
of fim3 w a s taken from the T o h a m a I strain. The promoter of the fim3
gene of this strain contains 13 cytosine residues within the C stretch
(Mooi et al, 1990). However, this strain is considered a serotype 2 strain,
and produces very low levels of type 3 fimbriae. A subsequent study
determined that the Wellcome 28 strain, which produces large amounts
of both serotype specific fimbriae, contains 14 residues within the C
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stretch (Willems et al, 1990). The fim3 promoter sequence from another
strain, B P S A l has also been obtained (Riboli et al, 1991). The C stretch of
this strain contains only 10 cytosine residues. The fim3 promoter of this
strain w a s s h o w n to be only 3 0 % active (as determined by C A T assays)
w h e n compared to the fiml gene promoter. The authors suggest that the
low level fim3 production was likely due to the deletion of 4 residues in
the C stretch region.

Although a difference in the C stretch regions of CSL 137 and CSL 137S
was predicted, the nature of this change was somewhat unexpected. T h e
results of the current study with the non-engineered overexpressing
mutant C S L 137S, are somewhat contrary to previous observations. T h e
strain expressing the highest levels in this study contains a run of 13
cytosine residues in the fimbrial C stretch, equivalent to that of T o h a m a I,
which expresses only low levels of type 3 fimbriae. The parental strain
from which this selected strain w a s obtained contained 14 cytosines, the
number usually reserved for strong fim3 gene promoters.

One possible rationalisation for the difference between the CSL 137 strains
is that the control of expression of fimbrial subunits m a y actually be m o r e
complex than initially proposed. The original sequence of the B. pertussis
fim3 gene was analysed using the T o h a m a I strain (Mooi et al, 1990).
There was found to be 13 cytosines in the fim3 C stretch of this strain,
which does not produce serotype 3 fimbriae. C S L 137S exhibits a 13
residue C stretch, yet expresses high levels of fim3.

Willems et al. (1990) demonstrated that a loss of residues in the C stretch
resulted in fimbrial phase variation, using a B. pertussis mutant strain
deficient in the expression of both fimbrial subunit genes. Into this strain
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(B52) they placed plasmids containing fim3

genes along with the

corresponding promoters. O n e promoter region contained 14 cytosines
within the C stretch and the other contained only 9. The strain with the
larger promoter expressed significantly higher levels of type 3 fimbriae. A
difference of 5 residues might

be expected to significantly alter

transcription from the gene.

The discrepancies observed between previous studies and this current
work m a y suggest that the expression of serotype 3 fimbriae is m o r e
complex than originally postulated. A comparison between C S L 137S and
T o h a m a I fim3 expression suggests that the length of the C stretch m a y
not be the only factor affecting fimbrial serotype. They both contain 13
cytosine residues within the fim3 C stretch yet exhibit markedly differing
fim3 expression profiles. It is postulated here that there m a y be different
requirements for different Bordetella strains. There are a number of
possible mechanisms which could bring about these differences. T h e
transcriptional activator, B v g A m a y be different in different strains due to
accumulated mutations that have altered its binding affinity for fimbrial
promoters. These mutations m a y cause the binding capacity of B v g A to
become stronger or weaker at one particular serotype fimbrial gene
promoter while having no affect at the other. The same argument can
also be m a d e for the R N A polymerase of different strains. Perhaps there is
more than one R N A polymerase (a or a subunit difference) operating
within B. pertussis which initiate transcription at different fimbrial
subunit genes. The inference here is that the R N A polymerase displaying
affinity for the fim3 gene promoter of T o h a m a I is no longer functional,
while in C S L 137S, this protein is fully operational. The R N A polymerase
a subunit interacts with transcription factors and the a subunit is
involved

in promoter recognition, interaction

with

transcriptional
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activators, D N A unwinding and setting u p initiation complex (Ishihama,
1992; Ishihama, 1993; Busby and Ebright, 1994). Mutations in the B.
pertussis R N A polymerase have been s h o w n to effect the transcription of
virulence genes (Stibitz, 1998). Bacteria produce a range of a factors for
separate tasks. Specialised R N A polymerases (aF) are used by a n u m b e r of
species to control

the expression

of flagellar genes (Arnosti

and

Chamberlin, 1989; Arnosti, 1990; Akerley and Miller, 1993; Kapatral et al,
1996). The flagellar-specific a F factor has been implicated in the regulation
of flagellar genes of B. bronchiseptica (Akerley and Miller, 1993). Perhaps
there

is a corresponding

fimbrial-specific a factor controlling

the

expression of fimbriae that m a y recognise and bind certain fimbrial
promoter architectures and not others. Mutations accumulated over time
could cause these specific c factors to become quite strain-specific. Along
the same lines, there is also a possibility that an R N A

polymerase

designed for other tasks, such as the transcriptional control of heat shock
or flagella genes m a y have mutated, allowing it to recognise some, but
not all, fimbrial gene promoters. Again, this rogue R N A

polymerase

could become a strain-specific p h e n o m e n o n after m a n y generations.

Another possible explanation may be the presence of an undiscovered
factor which, possibly via an uncharacterised binding activity, has a
degree of control over the expression of major fimbrial subunit genes. In
their analysis of the fimX pseudogene of B. pertussis, Riboli and associates
(1991) alluded to the "C stretch" and the "fim box" being binding regions
for two separate transcription factors which m a y interact to bring about
fimbrial expression. They isolated a fim3

gene promoter

exhibiting

constitutive expression. The loss of virulence regulation w a s traced to
deletions in the fim box. These results and those of this study point to the
fim box being involved with B v g A binding, while the C stretch m a y be
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involved in the binding of a yet to be elucidated serotype determination
factor and /or R N A polymerase.

Strain CSL 127S overexpresses serotype 2 fimbriae and FHA. There was an
18 fold increase in fim2 production and 47 fold upregulation of F H A
expression exhibited by this strain compared with the parental strain. D u e
to the linkage of the fimbrial and F H A accessory genes {fimA-fimD and
fhaC), it was hypothesised that the overexpression exhibited by this strain
m a y be the result of a mutation in the promoter of the fimbrial/FHA
accessory genes or the fimC

upstream region. This was not the case

however, with no differences detected in either of these regions. The
difference between C S L 127 and C S L 127S was an alteration to the fiml
gene promoter, again located within the C stretch. The promoter of the
parental fiml gene contains a 17 residue C stretch, while the equivalent
region of the overexpressing strain was 16 residues long. The non-fim2
producing serotype 3 C S L 137 strains both contain a 16 residue C stretch.
The strains expressing both fimbrial types, the C S L 1237 series, both
possess a fiml 15 cytosine C stretch and exhibit only approximately 2 0 %
the fim2 expression of C S L 127S. The original published sequence
demonstrated that the Wellcome 28 strain (serotype 2, 3) fiml gene
promoter region contains a 16 residue C stretch (Livey et al, 1987).
Sequence data of the fiml promoter of BPSAl revealed that this strain
also possesses a 16 cytosine C stretch. The agreement of this work with
previous studies m a y be further evidence that 16 residues is the o p t i m u m
number for expression of serotype 2 fimbriae. Once again however, the
number of residues within the C stretch does not seem to be the sole
determinant of fimbrial serotype. The type 3 strains (CSL 137 and CSL
137S), which do not express fim2 at all, contain the same number of
residues as the type 2 overexpressing strain (CSL 127S). A s was discussed
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earlier, it m a y be that different strains have different positioning
requirements for the expression of fimbriae. There m a y be another factor
involved in the expression of the serotype 2 major fimbrial subunit gene.
The precise identity of this factor is u n k n o w n , however it is proposed
here that an R N A

polymerase or an as yet undetermined

serotype

determination factor m a y be the cause of differential fimbrial expression
from similar or identical promoter architectures in different strains.
Whatever the factor involved, a simple mechanism can be employed to
explain differences exhibited by different strains. The "activating factor" of
one strain (CSL 127S) might recognise and bind to a. fiml gene promoter
containing a 16 residue C stretch, thereby initiating transcriptional
machinery. Another strain m a y also possess a. fiml gene promoter with a
16 residue C stretch (CSL 137S), however the activating factor in this
strain, might only recognise promoters containing a 13 cytosine C stretch.
In this case transcription would not be activated at the fiml gene,
however expression of the fim.3 gene would proceed.

The strain exhibiting a minor increase in all virulence factors assayed
except F H A (CSL 1237S) does not contain differences in any of the
promoters analysed. Possible reasoning for the increase in a number of
proteins m a y include an alteration to a m e m b r a n e protein which m a y
have slightly increased the efflux of periplasmic proteins.

The results of this study also suggest that the sensitivity to alterations in
the C stretch differ between the two major fimbrial serotypes. Changes of
one residue either side of the ideal number (16 in W 2 8 strain, B P S A
(Livey et al, 1987; Riboli et al, 1991) and C S L 127S) contained within the C
stretch of the fiml gene promoter can markedly alter expression. A n
addition of a single cytosine in C S L 127 (17 residues) resulted in the
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abolition of fim2 expression entirely. The removal of one residue (CSL
1237 series, 15 residues) caused a reduction of fim2 expression to only 2 0 %
of the original. At the fim3 gene promoter however, a reduction of 2-3
residues still allows for substantial fim3 production. The C S L 1237 series
produce moderate levels of fim3 even though the C stretch contains only
11 residues, which is d o w n on the value of 14 indicative of high
expression levels (Willems et al, 1990; Riboli et al, 1991) and the 13
obtained for the overexpressing strain (CSL 137S) in this work.

The differences among the promoter regions of the B. pertussis strains
studied has once again demonstrated

the intricate nature of the

expression of virulence genes in this highly complex organism. Further
research into the regulation and architecture of the promoter regions of
virulence genes and the roles they play in the pathogenesis of whooping
cough will eventually lead to the development of more suitable vaccines
against this disease.
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General Conclusion

The inherent side effects associated with whole cell whooping cough
immunisation regimes has necessitated the development of new, less
reactogenic recombinant acellular vaccines. Purified pertussis toxoid has
been a major component in all recent vaccine trials. Thus, there is a need
for a safe and efficient system for the high level expression of pertussis
toxin. This work reports that B. bronchiseptica possesses sequences
homologous to the 3' end of the ptl operon {ptlH gene). Also described is
the development of a system designed for the transfer of the pertussis
toxin

expression

locus from

ATCC

10580::Tn/wsPT2 to other

B.

bronchiseptica strains. The transfer w a s successful, with this locus being
mobilised

to derivatives

of virulent

and avirulent

strains of B.

bronchiseptica. N o loss in the expression levels of the toxin w a s observed
after the transfer. The levels of P T secretion in these overexpressing
strains w a s monitored

and it w a s found that neither virulent nor

avirulent B. bronchiseptica exhibited the ability to secrete PT, confirming
that the B. bronchiseptica ptl genes are cryptic. The transfer system
developed here has the potential to be used to clone other types of
selectable transposon-tagged expression systems. Insertion of the entire
ptx/ptl operon into B. bronchiseptica, again under the control of a P Bb like promoter, would allow for the constitutive expression and secretion
of P T in avirulent B. bronchiseptica. This would create an ideal
background for P T production for vaccine preparations.

Increasingly, vaccine manufacturers are including fimbriae and pertactin
in acellular preparations in addition to the P T and F H A used in the
original acellular vaccines. These multivalent pertussis vaccines confer a
greater i m m u n e response and are no more reactogenic than their m o n o -
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and divalent counterparts. Therefore there is a need for the production of
large amounts of these antigens. This study has examined B. pertussis
strains expressing increased levels of these immunogens. These results
suggest that the control of fimbrial expression and phase variation m a y be
more complicated than has been previously understood. Further w o r k
using a greater range of B. pertussis strains m a y confirm this observation.
Increasing our level of understanding of the regulation of fimbrial
expression m a y bring about safer, easier production methods for these
immunologically important antigens, leading to less reactogenic, m o r e
affordable vaccines. Alternatively, the fimbrial production by whole cell
vaccine

strains

could

be

improved

with

the

introduction

of

overexpressing promoter regions, resulting in a net increase in the
immunogenic response elicited.

Whether in B. pertussis or B. bronchiseptica, the development of high
level expression and secretion systems for recombinant

candidate

antigens for use in vaccines against whooping cough, will ensure the
development of safer, more protective vaccines in the future.
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Appendix II Recipes And Buffers

Media
Bordet-Gengou Agar
This agar, used to determine haemolytic ability, consisted of sterilised Bordet Gengou
agar base supplemented with glycerol to 10 g/L. After cooling to approximately 45°C,
sterile defibrinated horse blood to 1 5 % was added.

Z Agar
Z agar was used as the solid nutrient substrate for all Escherichia

coli strains. This

medium contained glucose 1 g/L; NaCl 10 g/L; CaCl2-2H20 0.367 g/L; tryptone 10 g/L;
yeast extract 5 g/L. Agar to 1 5 % was then added to solidify the medium.

Stainer-Scholte Medium
Used as minimal medium for Bordetella

spp., Stainer-Scholte

medium has two

components.

SS-X Base
The contents of this medium consisted of L-glutamate (monosodium salt) 10.72 g/L; Lproline 0.24 g/L; NaCl 2.5 g/L; K H 2 P 0 4 0.5 g/L; KC1 0.2 g/L; MgCl 2 .6H 2 0 0.1 g/L;
CaCl 2 .2H 2 0 0.026 g/L; Tris-Base 6.075 g/L. The p H of this solution was then adjusted to
p H 7.6. After sterilisation, the solution is supplemented with an appropriate amount of
SS-X lOOx salts.

SS-X lOOx Salts
This is a mixture of heat-sensitive components which are essential to the diet of
Bordetella; L-cysteine 0.04 g/L; FeSO4.7H20 0.01 g/L; ascorbic acid 0.02 g/L; nicotinic acid
0.004 g/L; glutathione 0.1 g/L. Components were filter sterilised

X-Gal Medium
X-Gal broth was prepared by adding 2 m L of a 2 % X-gal in D M F solution and 200 uL of a 0.1
M solution of IPTG to 1 L of sterile Z agar.

Urea Agar
The presence of urease enzymes can be detected using this medium. To prepare this,
sterilised urea agar base 25.2 g/L was cooled to 50°C and supplemented with 5 m L of a 4 0 %
filter sterilised urea solution.
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Luria Broth (LB)
L B w a s used as the liquid nutrient medium substrate for all E. coli strains. It consisted of
Tryptone 10 g/L; Yeast extract 5 g/1; N a C l 10 g/L.

LBMgMal
Cells to be transfected by bacteriophage lambda were grown in this medium. It contained
Tryptone 10 g/L; Yeast extract 5 g/1; N a C l 10 g/L; Glucose lg/L; Maltose 4 g/L;
M g C l 2 . 6 H 2 0 1 g/L.

SOC Medium
S O C m e d i u m w a s used in conjunction with the T A Cloning™ Kit. It contained tryptone, 2 % ;
yeast extract, 0.5%; sodium chloride, 10 m M ; potassium chloride, 2.5 m M . A 2 M stock of
M g 2 + , comprised of 1 M M g C l 2 and 1 M MgSC>4 w a s filter sterilised, along with a 2 M
glucose stock. These were added to the sterile m e d i u m just prior to use, and the m e d i u m w a s
then filter sterilised.

Antibiotics
M e d i u m w a s m a d e selective by the addition of antibiotics, to final concentrations as shown
below in the following table:

G

Concentration
(ug/mL)
Antibiotic

for B. bronchiseptica

for E. (
Ampicillin

100

200

Chloramphenicol

50

50

Cephalexin

50

100

Kanamycin

50

50

Nalidixic Acid

50

50

Rifampicin

100

100

Tetracycline

20

20

Trimethoprim

50

50

Agarose Gel Electrophoresis
Agarose Gel
Agarose
IX T A E buffer to

(1%)
2.0 g
200 m L

solution w a s heated to dissolve agarose, cooled to 50°C and poured

TAE Buffer 10X
Tris.Base

48.44 g/L

Sodium acetate

27.22 g/L
7.44 g/L

EDTA

made up to volume with d H 2 0 and adjusted to p H 8.0

DNA Loading Buffer
Ficoll 400
Bromophenol blue

15%
0.25% (w/v)

made up to volume with d H 2 0

Molecular Weight Markers (k HmdIII)
Bacteriophage lambda D N A

50 uL

dH20

120 ul

Restriction buffer lOx

20 uL

Hindlll restriction enzyme

lOuL

This mixture was incubated at 37°C for 60 minutes, followed by 65°C for 10 minutes

DNA Extraction Buffers
TE Buffer (Plasmid D N A )
Tris.HCl

50mM

EDTA

lOmM

made up to volume and adjusted to pH 8.0

TE Buffer (Chromosomal DNA)
Tris.HCl
EDTA

lOOmM
25*^

made up to volume and adjusted to pH 8.0

TES
Tris.HCl

lOOmM

EDTA

25mM

NaCl

150mM

made up to volume and adjusted to p H 8.0

TE Buffered Sucrose
Tris.HCl

50mM

EDTA

50mM

Sucrose

15% (w/v)

made up to volume with d H 2 Q and adjusted to p H 8.5

Triton-X Solution
Triton-X 100

0.1% (v/v)

Tris.HCl

50mM

EDTA

lOmM

made up to volume with d H 2 Q and adjusted to p H 8.5

TE saturated Phenol
200 m L

TE
Phenol (solid)

to 200 m L

8-Hydroxyquinoline

0.1%

Enzyme Incubation Buffers (10X)
Enzymes were supplied with incubation buffer concentrates by manufacturers.

T4 D N A ligase buffer

MgCl 2

660mM
50mM

EDTA

ImM

Dithioerythreitol

lOmM

ATP

lOmM

Tris.HCl

pH7.5

4 Units of ligase was used per reaction.

Southern Blot Buffers
SSC Buffer 20x
NaCl
Sodium citrate

175.3 g/L
88.2 g/L

made up to volume with d H 2 Q and p H adjusted to 7.0

Protein Analysis

PBS
NaCl

137mM

KC1
Na 2 HP0 4

2.7mM
8mM

KH2P04

1.5mM

made up to volume with d H 2 0 and p H checked at 7.4

Cracking Buffer
Tris.HCl
Bromophenol blue

60mM
0.01% (w/v)

Glycerol

10% (v/v)

SDS

1% (w/v)

fi-mercaptoethanol

1% (w/v)

Running Buffer
Tris.Base

15 g/L

Glycine

72 g/L

SDS
5 g/L
made up to volume with d H 2 0 and p H checked at 8.3

Acrylamide Stock Solution (35:0.8)
Acrylamide

87.5 g

Bis

2.0 g

made up to 250 m L with d H 2 0

Resolving Gel (15%)
Acrylamide stock (35: 0.8)4.25 m L
1.5M Tris.HCl (pH 8.8)

2.5 m L

10% SDS
dH20

0.1 m L
3.4 m L

Fresh 10% APS

50 uL

TEMED

50 uL

Stacking Gel (4%)

Acrylamide stock (35: 0.8)1.1 m L
0.5M Tris.HCl (pH 6.8)

2.5 m L

10% SDS

0.1 m L

dH20

6.3 m L

Fresh 10% APS

50 uL

TEMED

50 uL

Coomassie Stain
Coomassie Brilliant Blue R250

1 g/L

Methanol

5 0 % (v/v)

Acetic acid

1 0 % (v/v)

Destain
Methanol

5 % (v/v)

Acetic acid

7.5% (v/v)

Western Buffer
SDS

0.037% (w/v)

Glycine

39mM

Methanol

2 0 % (v/v)

made up to volume with d H 2 0

TBE Buffer
TBE buffer (x 10) for D N A sequencing contained
Tris-base

162 g/1

Boric acid

27.5 g/1

EDTA

9.5 g/1.

The p H of this solution is approximately p H 8 and was not adjusted.

Buffers For Qiagen Plasmid Extraction
Buffer PI
Buffer PI contained RNase A, 100 mg/1; Tris-HCl, 6.06 g/1; EDTA, 3.72 g/1;
p H 8.0, store at 4°C

Buffer P2
Buffer P2 contained N a O H , 8.0 g/1; 2 0 % SDS, 50 ml/1.
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Buffer P3
Buffer P3 contained potassium acetate, 294.45 g/1.

Buffer QBT
Buffer Q B T contained NaCl 43.83 g/1; M O P S , 10.46 g/1; ethanol, 15 ml; Triton X-100,
0.15%; p H 7.0.

Buffer QC
Buffer Q C contained NaCl 1 M , 43.83 g/1; M O P S , 10.46 g/1; ethanol ,15%; p H 7.0.

Buffer QF
Buffer Q F contained NaCl, 73.05 g/1; Tris-HCl, 6.06 g/1; ethanol, 15%; p H 8.5.

Appendix III

Plasmids Used in This Study

These are diagrammatic representations of plasmids used in
that are mentioned, but not pictured within the text.

ptlH fragment
Flori
ColEl ori
Kan r

Ampr

Viae
Bvg Locus

mob
Kan r

180

PT
Subunits

Kan

tnp
mob
Amp r
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